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Background: Opioid use and opioid use disorder (OUD) during pregnancy are significant issues 
in the United States; yet little is known about postpartum contraception use among these women, 
particularly in comparison to women who do not use opioids.  This study examined the relation 
between opioid use during pregnancy and postpartum prescription contraception.       
Methods:  Privately insured women with livebirths from 2011 to 2017 were identified using 
MarketScan, a database of paid health insurance claims.  Provision of prescription contraception 
within 60 days postpartum was assessed among women who maintained continuous health 
insurance coverage through pregnancy and the first 60 days postpartum (n=1,291,352).  A subset 
of women who used opioids during pregnancy were linked with infant records (n=63,897) to 
examine the impact of infant outcomes on contraceptive provision within 60 days postpartum.  
Contraceptive provision within 365 days postpartum was assessed among women with a livebirth 
from 2011 to 2016 and who maintained health insurance coverage through pregnancy and for 
any duration postpartum, up to 365 days (n=1,270,832).  Multivariable logistic and multinomial 
regression models estimated the odds and relative risk ratio (RRR) of contraceptive provision by 
60 days postpartum.  Multivariable Cox Proportional Hazards models assessed the hazard of 
contraceptive provision within 365 days postpartum.   
Results: Women with non-chronic and chronic prescription opioid use were more likely to 
receive postpartum prescription contraception than women with no opioid use; women with 
OUD were less likely to receive contraception.  Women who used opioids had a higher RRR of 
sterilization verses no prescription method compared to women with no opioid use.  Among 
women provided contraception, women with chronic prescription opioid use had the shortest 
time to provision and women with OUD had the longest time to provision.  Increasing infant 
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hospital length of stay was associated with decreased provision of contraception by 60 days 
postpartum among women who used opioids.   
Conclusions:  Opioid use during pregnancy was associated with different levels of contraceptive 
provision overall and by method type across the postpartum period compared to women with no 
opioid use.  This study highlights the need to address disparities in postpartum contraceptive 
provision among women who use opioids, particularly for women with OUD.           
Advisor: Donna Strobino, PhD  
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Over the past 60 years, expanded contraception access and use has contributed to gains in 
women’s health, the health of families, and the social and economic opportunities available to 
women in the United States (US) [1, 2].  Contraception use in the postpartum period, defined as 
the first year following delivery, is an important aspect of women’s health and confers many of 
the same benefits of contraception use generally, with the added advantage of allowing women 
time to recover from pregnancy and childbirth and focus on caring for their newborn.  
Postpartum contraception use in the US has remained steady over the past decade, with increases 
in uptake of highly effective methods, such as the IUD, among women who use postpartum 
contraception [3-5].  
Postpartum contraception use among marginalized groups of women, including women 
who misuse opioids or have opioid use disorder (OUD), is a topic of increasing focus because 
women with OUD represent a growing segment of the population and face additional clinical and 
social risks [6].  While research on postpartum contraceptive use has focused on identifying 
disparities by race/ethnicity, income-level, and among teen mothers, there is more limited work 
about use and potential disparities among women who use opioids during pregnancy [7-10]. 
Understanding the patterns, correlates, and predictors of contraception use among women who 
use opioids during pregnancy is a crucial gap in the literature addressed by this research.           
The misuse of opioids and opioid use disorder among women of reproductive age is a 
significant public health concern. Pooled national survey data from 2005-2014 indicate that 1.4 
million women of reproductive age and over 50,000 pregnant women have misused prescription 
opioids in the past 30 days [11].  The prevalence of maternal opioid abuse at the time of delivery 
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has increased from 1.5 cases per 1,000 hospital deliveries in 1999 to 6.5 in 2014 [12].  The 
growing misuse of opioids among this population has significant implications for maternal and 
infant health.  Between 2007 and 2016, the percentage of pregnancy-related deaths in the US 
involving opioids doubled, increasing from 4% to 10% [13].  Additionally, there is growing 
evidence that opioid use and OUD is a significant contributor to increasing rates of severe 
maternal morbidity [14].  Women who use opioids during pregnancy are more likely to 
experience postpartum hospital readmissions and have a higher obstetric comorbidity index at 
the time of delivery [15].  In tandem with rising rates of opioid use during pregnancy, the 
incidence of neonatal abstinence syndrome (NAS), the most common sequela associated with 
fetal exposure to opioids, increased 300% from 1.5 cases per 1,000 hospitals births in 1999 to 6.0 
in 2013 [16].  Increasing access to and provision of postpartum contraception is one strategy to 
help minimize these adverse outcomes as it may help women who misuse opioids avoid 
unintended pregnancies, delay mistimed births, and focus on their own health.   
Despite being a crucial component of reproductive health, postpartum contraception use 
in women with OUD is not well understood.  With an estimated 85% of pregnancies to women 
with OUD being unintended coupled with an increasing number of pregnancies impacted by 
opioid use in the US, identifying the prevalence and use patterns of postpartum contraception 
among women with OUD is imperative for preventing unintended pregnancies and improving 
reproductive health outcomes in this population [12, 17-19].  Prior research examining 
postpartum contraception use among women who use opioids has largely focused on women 
insured through Medicaid or select groups actively enrolled in drug treatment programs or 
clinical trials [20-26].  To our knowledge, the current research is the first to examine postpartum 
contraception among women who use opioids in a commercially insured population. This 
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dissertation research explored the relation of opioid use during pregnancy with postpartum 
contraceptive provision, comparing women who did and did not use opioids during pregnancy at 
multiple time points during the postpartum period.         
The three specific research aims of this dissertation were to:     
Aim 1: Evaluate the association between opioid use during pregnancy and prescription 
contraception provision by 60 days postpartum, including by contraceptive method type.   
Aim 2: Evaluate the time to first prescription contraception provision during the postpartum 
period for women who did and did not use opioids during pregnancy, including by type of 
opioid.  
Aim 3: Assess if adverse newborn outcomes are associated with provision of prescription 
contraception within 60 days postpartum among women who used opioids during pregnancy.  
These research aims were evaluated using a nationwide database of paid health insurance 
and pharmaceutical claims from privately insured patients in the US from 2010-2017.  This 
database allowed for the identification of opioid use during pregnancy and the analysis of 
postpartum prescription contraception provision for as long women maintained continuous health 
insurance coverage.  Analyses for Aims 1 and 2 were adjusted for maternal age at delivery, year 
of delivery, characteristics of the geographic location in which women resided, health insurance 
plan type, several comorbidities, non-opioid substance use, mode of delivery, and, for Aim 1, 
whether a postpartum health visit occurred within the first 60 days postpartum.  Analyses for 
Aim 3 were adjusted for the same covariates as well as several infant variables.  The measures of 
postpartum contraception used in this research are clinical performance measures recently 
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endorsed by the National Quality Forum, ensuring that results of this research are in accordance 
with nationally recommended measures [27].   
This research addresses a significant gap related to the health of women of reproductive 
age who use opioids. The postpartum period offers a window of opportunity to increase uptake 
of moderately and highly effective forms of contraception among women who desire to use 
postpartum contraception because they are in close contact with the healthcare system and are 
motivated to prevent unintended pregnancy [28-30]. The results of this research help elucidate 
patterns of postpartum contraceptive provision among women who use opioids during pregnancy 
and how these patterns compare to women who do not use opioids among a sample of privately 
insured women who are not often the focus of substance use or contraceptive research.  
Furthermore, this research serves as a valuable resource for clinicians who work with opioid-
using patients, particularly in terms of counseling and educating patients on their contraceptive 
options.  Postpartum contraception plays a crucial role in women’s health and is of particular 
importance among women with OUD, who have very high levels of unintended pregnancy and 
face significant social and clinical challenges. 
1.2 Dissertation Overview 
This dissertation is organized into five chapters.  The first chapter provides an 
introduction to the study and overview of the research aims.  Chapter two presents a 
comprehensive literature review covering the topics of contraception use generally, postpartum 
contraception, opioid use during pregnancy, and reproductive health outcomes among women 
with substance use disorders.  The literature review informs the conceptual framework 
underpinning this research, which also is presented in Chapter two. Chapter three describes in-
depth, the study design, data source, study sample, and analytic methods used in this research.  
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The results of the analysis, including descriptive statistics, univariate, bivariate, and 
multivariable analyses results, along with several sensitivity analyses, are presented in Chapter 
four.  The final chapter, Chapter five, provides a discussion of the study findings, reviews the 
study strengths and limitations, public health implications of the study result, and the study 
conclusion.      
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 This chapter presents a literature review on contraception use, including during the 
postpartum period, opioid use in women and during pregnancy, and contraception use among 
women with substance use disorders or who use substances.  The significance and rationale for 
this study are presented next within the context of limitations of prior research.  The chapter 
concludes with a review of the conceptual framework that served as a guide for this research.  
2.2 Contraception and Women’s Health 
The benefits of contraception for the health and well-being of women are widely 
recognized.  Contraception allows women and their partners to plan, delay, and space 
pregnancies over their reproductive lifespan.  It also helps prevent unintended pregnancies, avert 
maternal deaths, and expand women’s economic, social, and educational opportunities [1, 2].   
Since the introduction of the combined-hormonal contraceptive pill in 1960, the use of 
contraception has become universal in the United States with 99% of women aged 15-44 
reporting any lifetime use of contraception [3].  The prevention of unintended pregnancies and 
birth spacing are two direct benefits of contraception use and expanded contraception use in the 
US has resulted in substantial declines in rates of unintended pregnancy and abortion [4, 5].  This 
decline is important for women’s and infants’ health as unintended pregnancies are associated 
with lower levels of prenatal care, low birth weight, and increased risk of maternal depression or 
depressive symptoms [6-9].  In the US, unintended pregnancies are increasingly concentrated 
among women with low education, low income, and women of color [10].  Contraception also 
reduces pregnancy-related morbidity and mortality by reducing a woman’s exposure to 
pregnancy [1].  The health risks associated with pregnancy, including exacerbation of existing 
illnesses, gestational diabetes, gestational hypertension and preeclampsia, significantly exceed 
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the risks associated with contraception use [11].  There are also non-contraceptive health benefits 
of hormonal contraception use including treatment for menstrual cramps, heavy menstrual 
bleeding, migraines associated with the menstrual cycle, and acne [12].  
The benefits of contraception and family planning extend beyond physical health. 
Contraception allows women to expand their role in society through increased employment 
outside the home, pursuit of higher education, and economic independence.  There is strong 
evidence linking expanded contraception use and associated delayed childbearing to gains in 
female education, particularly at the college level and beyond [13-16].  Similarly, studies have 
demonstrated an empirical link between the introduction of the pill and an increase in female 
participation in the work force [17, 18].  Expanded contraception use has significantly 
contributed to women’s increasing earning capability, and by delaying childbearing, women can 
enter parenthood with more economic stability [13, 19] 
[20-23].  Delayed childbearing has important 
ramifications for the health and well-being of women and 
their offspring.  Entering parenthood as a teenager or as a 
result of an unplanned pregnancy is associated with 
increased depressive symptoms and anxiety among 
mothers and poorer parent-child relationships, which may 
be due in part to the reduced economic stability that is 
often present among teen parents [24-26].    
The extensive evidence supporting the benefits of 
contraception is the reason why in 2011, the Institute of Medicine recommended that all FDA-
approved contraceptive methods be considered preventative health care for women (Table 2.1) 
Table 2.1 FDA Approved 
Contraceptive Methods Covered by 







Oral Contraceptive Pill – combined, progestin-
only, extended use 
Patch 
Vaginal Ring 
Diaphragm with Spermicide 
Sponge with Spermicide 
Female Condom 
Spermicide alone 





Table 2.2 FDA Approved 
Contraceptive Methods Covered by 







[27].  This recommendation is the basis for the Affordable Care Act’s (ACA) “contraceptive 
mandate”, which requires that women have access to the full range of FDA-approved 
contraceptive methods with no cost-sharing or copays from their health insurer [28].  Since the 
introduction of the contraceptive mandate, out-of-pocket costs for contraception for insured 
women have decreased substantially and the percentage of women using long-acting reversable 
contraception, such as the IUD and implant, has increased [28, 29].   
2.3 Postpartum Contraception in the United States 
Postpartum contraception refers to contraception used in the first 12 months following 
pregnancy and includes all available contraceptive methods, ranging from sterilization to the 
lactational amenorrhea method [30].  The use of postpartum contraception helps prevent rapid 
repeat pregnancies, defined as pregnancy within 18 months after a live birth, and unintended 
pregnancies, resulting in better health outcomes for women, their infants, and families [31, 32].  
The result of a recent systematic review in high-resource country settings indicated that 
interpregnancy intervals shorter than six months may be associated with increased risk of 
preterm birth and infant death [33].  The importance of the postpartum period as a window of 
opportunity to counsel and provide women with a contraceptive method of their choice has been 
increasingly recognized as women are motivated to prevent pregnancy and have frequent contact 
with the healthcare system during this period [34].      
Measures of postpartum contraception vary depending on the data source and research 
question, making comparisons difficult across studies and data sources.  In 2016, the US-based 
National Quality Forum (NQF), a non-profit, nonpartisan organization, endorsed two clinical 
performance measures for assessing the quality of postpartum contraceptive care [35].  The first 
measure addresses the receipt of a moderately or most effective contraceptive method by three 
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and 60 days postpartum [35].  Moderately effective contraceptive methods include depot 
medroxyprogesterone injection (DMPA), the pill, patch, ring, or diaphragm and the most 
effective methods are sterilization, the IUD, and implants.  The second measure is focused on 
long-acting reversible methods (LARC), which includes the IUD and implants, measured at three 
and 60 days following delivery [35].   
The timeframes of three and 60 days represent clinically significant time points during 
the postpartum period.  Measuring the provision of contraception within three days of delivery 
corresponds to the immediate postpartum period when many women are still hospitalized 
following delivery.  This time is optimal to provide postpartum contraception, particularly 
LARCs, as it is both safe and convenient to do so then [36].  There are several reasons why 
immediate postpartum contraceptive provision is beneficial.  Foremost, immediate provision 
eliminates the need for an additional visit(s) to a healthcare provider to obtain contraception.  
Research findings demonstrate that women at the highest risk for unintended pregnancy in the 
postpartum period also have low postpartum visit attendance, which includes women with 
substance use disorders (SUD) [37, 38].  Secondly, 40-57% of women report the resumption of 
sexual intercourse prior to their 6-week postpartum visit, putting them at risk for pregnancy [39, 
40].  Finally, randomized trials have demonstrated that immediate postpartum LARC insertion 
results in greater adherence to the method and decreases the risk of pregnancy when compared to 
delayed insertion of postpartum LARC [41].  The 60-day timeframe represents the clinically 
recommended timeframe by which women should receive contraceptive care, typically at the six-
week postpartum care visit [35]. The new NQF evidence-based measures enhance continuity 
across studies and are designed with feasibility and usability in mind.   
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Estimates of the postpartum contraceptive prevalence rate are quite variable in the US.  
National estimates from the Pregnancy Risk Assessment Monitoring System (PRAMS) indicate 
that approximately 80% of women queried postpartum report used some form of contraception in 
the first four months following delivery [42].  Data from the National Survey of Family Growth 
(NSFG) indicate that 72% of women use some form of contraception within three months 
following delivery [43].  The most commonly reported methods were moderately effective 
methods, such as the pill, patch, or ring, and less effective methods including male condoms, 
withdrawal, and the rhythm method [43].  Approximately 25% of women, however, reported 
using no method and this proportion remained consistent throughout the postpartum period [43].  
The results of a study using data from women and families enrolled in the Military Health 
System noted that 36.7% of women did not initiate any prescription form of contraception in the 
first six months following delivery [44].  Among women who did initiate prescription 
contraception, 7.0% relied on tubal ligation or partner vasectomy; 16.9% initiated an IUD or 
implant; 2.5% were prescribed DMPA; and 36.8% were prescribed a pill, patch or contraceptive 
ring [44].   
Estimates of postpartum contraception use are available specifically for the privately 
insured population; however, these estimates are limited to prescription contraceptive methods 
which include female sterilization, the IUD, implant, DMPA, the pill, patch, ring, and diaphragm 
[45].  Law, et al. employed the recently endorsed NQF measures to assess postpartum 
contraception use at three and 60 days postpartum in the MarketScan database, the source of data 
for this research.  Between 2005 and 2014, the percentage of women using a moderately or most 
effective method of contraception within 60 days postpartum increased from 24.1% to 38.6% 
among women 15-20 years old and from 32.5% to 37.7% among women 21-44 years old [45].  
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The pill was the most commonly used form of prescription contraception at 60 days postpartum 
among both age groups and in every year across the study time period [45].  At three days 
postpartum, which serves as an indicator for the immediate postpartum period, the percentage of 
women receiving a moderately or most effective method, however, decreased over the study time 
period.  For 15-20-year-old women the percentage decreased from 6.0% in 2010 to 3.2% in 2014 
and from 10.4% to 8.0% among women aged 21-44 [45].  For both age groups, female 
sterilization was the most common form of contraception in the immediate postpartum period 
and immediate postpartum LARC was rare (<0.2%).  
Several recent studies have examined the circumstances and characteristics associated 
with receipt of postpartum contraception in the US.  The results of a nationwide retrospective 
cohort study examining receipt of immediate postpartum LARC and sterilization prior to 
discharge for a hospital delivery showed that receipt of LARC increased significantly from 1.86 
per 10,000 hospital deliveries in 2008 to 13.5 in 2013, while sterilization rates remained steady 
over the same time period [46].  In adjusted models, women with non-private insurance, which 
includes Medicaid, Medicare, self-pay, or no charge, were five times more likely to receive 
immediate-postpartum LARC than privately insured women (aOR: 5.23, 95% CI: 3.82-7.16).  
Women with non-private insurance were also more likely to be sterilized than privately insured 
women (aOR: 1.90, 95% CI: 1.38-2.63) [46].  Other characteristics significantly associated with 
immediate postpartum LARC receipt included delivering at an urban teaching hospital and in the 
later years of the study period and having a medical comorbidity [46].  Women in the Southern 
region of the US were significantly less likely to receive LARC and significantly more likely to 
be sterilized compared with women in the Western region (reference region) [46].   
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A second, smaller study examined postpartum LARC receipt at 90 days postpartum 
among women delivering at a single urban teaching hospital in Ohio [47].  Receipt of LARC by 
90 days postpartum among women in this sample was significantly associated with adequate 
prenatal care but was not associated with insurance type in adjusted models [47].  A final study 
based on PRAMS data from 2012-2015 explored factors associated with postpartum LARC use 
[48].  The overall prevalence of LARC was 15.3%, with significant variation by state [48].  
Among women using reversible contraception, the prevalence of LARC was highest in Alaska 
(37.6%) and lowest in New Jersey (11.2%), with a general trend of higher LARC prevalence in 
the Western US [48].  Women who reported using LARC were significantly more likely to be 
younger, be publicly insured, report their most recent pregnancy as unintended, and report 
attending a postpartum check-up visit [48].   
Studies have also examined the characteristics and conditions associated with receipt of 
other forms of postpartum contraception.  Cesarean delivery and older age are consistently 
associated with increased likelihood of sterilization [49].  There is also evidence that women 
with public insurance, such as Medicaid, are more likely to undergo postpartum sterilization [50, 
51].  Women delivering in the Southern US have a higher prevalence of sterilization than women 
in other regions [51].  In general, prevalence of postpartum contraception decreases as maternal 
age increases [52].                          
Postpartum contraception has become an increasingly important component of obstetric 
care in the US.  The Healthy People 2020 initiative has set a goal of reducing the percentage of 
pregnancies conceived within 18 months of a previous birth from 33.1% to 29.8%, a 10% overall 
reduction [32, 53].  The latest national birth certificate data indicates that in 2016 approximately 
29% of singleton births to multiparous women were preceded by an estimated birth to pregnancy 
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interval of less than 18 months [54]. Birth to pregnancy intervals shorter than 12 months are 
associated with significantly increased odds of neonatal morbidity [55].  Additionally, birth to 
pregnancy intervals less than 6 months, although quite infrequent, are associated with increased 
odds of preterm birth, low birthweight, small for gestational age, and infant mortality [33].  
Younger women and women with high school or less education are more likely to have short 
birth to pregnancy intervals [43].  Women who use other moderately effective or less-effective 
methods are at significantly higher risk for short birth to pregnancy intervals than women who 
use highly effective forms of postpartum contraception, such as IUDs or implants [43].  
Interconnected with the goal of achieving safe birth to pregnancy intervals, postpartum 
contraception also helps prevent unintended pregnancies.  The postpartum period is particularly 
important because upwards of 70% of pregnancies that occur within the first 12 months 
postpartum are unintended [43].  Recent research findings indicate that as the birth to pregnancy 
interval shortens, the percentage of unintended pregnancies increases, with the highest levels of 
unintended pregnancy occurring among birth to pregnancy intervals of 0-5 months [56]. 
Unintended pregnancies have been linked to poorer maternal and infant health outcomes 
including lower levels of prenatal care, higher odds of preterm birth, higher odds of postpartum 
depressive symptoms, and lower rates of breastfeeding [57, 58].         
There is limited research exploring how maternal comorbidities and infant outcomes 
potentially influence postpartum contraceptive use.  The findings from a 2015 study suggest that 
women experiencing an extremely preterm birth (gestational age of ≤27 weeks) were more likely 
to report using no postpartum contraception than women who did not experience an extremely 
preterm birth [59].  In a second study of the impact of preterm birth, 54.6% of women with 
preterm births were using no method or low-efficacy methods including male condoms and 
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withdrawal, though the majority reported not wanting to get pregnant in the first 12 months 
postpartum [60].  In this sample of women who experienced a preterm birth, the strongest 
predictor of desiring a pregnancy in the first 12 months postpartum was an infant death 
(OR:18.2, 95% CI: 8.9-37.0) [60].  In a study of postpartum women in North Carolina, 
researchers found that women with a recent preterm birth were less likely to receive any 
contraception compared to women with a term birth; they were also less likely to receive a 
highly effective method [61].   
The results of qualitative studies suggest that women with critically ill infants are at risk 
for delayed or inadequate postpartum care, typically because they are focused on the health 
status of their infant [62].  In a study of women with medically complex births, study authors 
reported high interest in highly effective contraceptive methods, but similar rates of subsequent 
unintended pregnancy compared to women with low-risk pregnancies [63].  Although these 
studies are limited in scope, they suggest that women who experience poor birth outcomes such 
as preterm birth or admission of their infant to the neonatal intensive care unit, may be less likely 
to use postpartum contraception.  Very few studies have examined how complications in the 
infant due to fetal drug-exposure, such as neonatal abstinence syndrome (NAS), may impact the 
use of postpartum contraception. The findings from a study from a single, high-risk obstetric 
clinic in North Carolina indicated that NAS was not a significant predictor of postpartum 
contraception use; however, the sample size was quite small (n=96) [64].      
2.4 Opioids and Opioid Use Disorder 
The current opioid epidemic in the United States began in the late 1990s, recognized by a 
steady rise in overdose deaths related to prescription opioids, which continued through the late 
2000s [65].  In 2010, a sharp rise in overdose deaths involving heroin began, coinciding with a 
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plateauing of overdose deaths related to prescription opioids [65].  Beginning in 2013, in 
conjunction with the continued rise in heroin-related deaths, deaths involving synthetic opioids 
such as fentanyl rose precipitously and continued to increase thereafter [65].  In 2017 alone, 
nearly 48,000 Americans died from opioid-involved overdoses, with a rate of 14.9 opioid-
involved overdose deaths per 100,000 population, representing a 12% rate increase from 2016 
[66, 67].  Recent evidence, however, suggests that overdose deaths from opioids are plateauing 
[68].  Between 2017 and 2018, overdose deaths from all opioids decreased 2% (p<0.05), with 
further decreases in deaths due to prescription opioids (14.5% decrease) and heroine (4.1% 
decrease) [68].  Deaths involving synthetic opioids increased 10% (p<0.05) from 2017 to 2018 
[68].   
Opioids encompass a broad array of chemically related substances [69].  All opioids work 
by binding to chemical receptors located in the brain, central nervous system, and 
gastrointestinal tract.  While the mechanism of action is similar for all opioids, there are distinct 
classes of the drug with important implications for potency and use.  The first class of opioids are 
endogenous opioids produced by the human body such as endorphins [70].  Natural opioids, the 
second class, are exclusively derived from the poppy plant and include morphine and opium 
[70].  Semisynthetic opioids are derivatives of natural opioids, including heroin, oxycodone, and 
buprenorphine [70].  Finally, fully synthetic opioids are completely human-made and include 
methadone and fentanyl [70].  The classes of opioids are further distinguished by varying 
pharmacological characteristics such as their half-life, lipid solubility, and pharmacodynamic 
strength.  In clinical settings, opioids are commonly used for pain control ranging from acute 
pain management following surgery to more long-term pain associated with malignancy.  Along 
with pain control and sedation, opioids are known to induce feelings of euphoria which is often 
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the motivation for misuse and abuse.  Other effects of opioids include respiratory depression and 
constipation [70].   
Opioid use disorder (OUD) is defined by the DSM-5 as a “problematic pattern of opioid 
use leading to clinically significant impairment or distress” [71].  Within psychiatry, OUD is 
clinically identified using a scale that includes eleven behaviors and patterns associated with 
OUD [72].  Some behaviors include taking opioids in increasing amounts, experiencing cravings 
for opioids, and making substantial lifestyle changes to accommodate opioid use [71]. A patient 
is described as having OUD if they exhibit at least two of the eleven behaviors within a 12-
month period, with six or more behaviors classified as severe OUD [72].  OUD, along with other 
types of SUD, is associated with mental health conditions such as depression and post-traumatic 
stress disorder, as well as with an increased risk for serious co-morbidities such as HIV, 
Hepatitis B and C, and endocarditis [73-75].  National surveys estimate that 11.5 million US 
adults are currently misusing opioids and an additional 1.9 million are currently addicted to 
opioids [76].  The number of adults with a clinical diagnosis of OUD is significantly smaller, 
with 1.5 million people having a formal diagnosis of OUD [76].   
The demand for OUD treatment in the US has grown substantially over the past decade 
or so.  Between 2005 and 2015, the proportion of substance abuse treatment admissions for 
opiates increased from 18% to 34% of all admissions [77].  However, the proportion of 
individuals with OUD who receive any form of substance abuse treatment was low with just 
19.7% receiving treatment in 2018 [78].  Increasing access to health insurance that covers 
substance abuse treatment is one way the federal government has sought to address the opioid 
epidemic.  The Affordable Care Act helped to decrease the proportion of adults with a SUD 
without health insurance from 25% to 20% in 2014, with the majority of the decrease due to the 
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expansion of Medicaid in participating states [79].  In 2011, close to 60% of adults aged 26 years 
and older who sought substance abuse treatment were uninsured, and 20% were insured by 
Medicaid [80].  Women who entered treatment were less likely to be uninsured compared with 
men, but the percentage without insurance is high across both groups, 51% of women and 64% 
of men.  Of the remaining adults who entered treatment, nearly 30% of women were covered by 
Medicaid compared to 17% of men and approximately 10% of both men and women were 
covered through private health insurance [80].            
2.5 Opioid Epidemic and Women 
Recognizing the role of sex is crucial for addressing the on-going opioid epidemic.  The 
risk factors for substance use, biophysical pathways of addiction, and response to treatment are 
significantly different for women than men, but there are similarities in the demographic risk 
factors for substance use in men and women.  Effective research and policy aimed at curbing the 
opioid epidemic must recognize and address both the biological and social needs and 
circumstances of women. 
The demographic risk factors for substance use among women, particularly opioids, are 
like those for men.  Deaths from opioids among women are highly concentrated among non-
Hispanic Whites between ages 25-54 [81].  In fact, opioid-related deaths have become so 
widespread among this demographic group that these deaths have resulted in a decrease in life 
expectancy for middle-aged non-Hispanic White men and women in the United States [82].  
There are important geographic “hotspots” for opioid deaths, with certain states such as West 
Virginia, Maryland, and New Hampshire incurring deaths rates from opioids of 30 deaths per 
100,000 population, twice as high as the national average of 14.6 [68].  Other demographic risk 
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factors related to OUD and overdose include low income, unemployment, and low education 
levels [83]. 
Although men misuse and overdose from opioids in greater numbers, women have 
experienced higher rates of increase in opioid misuse and deaths for some classes of opioids.  
From 1999 to 2016, prescription opioid deaths among women rose 583% compared with 404% 
among men [66].  During a similar timeframe, deaths from synthetic opioids increased 850% 
among women [66].  National survey estimates indicate that between 2007 and 2014, heroin use 
among men increased at an average rate of 8 per 1,000 persons whereas the rate of increase 
among women was nearly double at 15 per 1,000 persons [84].   The result of a study of 
overdose deaths among women aged 30-64 showed an increase in overall overdose deaths from 
6.7 deaths per 100,000 population in 1999 to 24.3 deaths in 2017 [85].  The rate of overdose 
deaths involving opioids increased 492% over the same time period, with the largest increases 
observed among women in older age brackets [85].  Men are more likely to misuse all forms of 
opioids, but the gender gap has narrowed over the past 15 years [84, 86].  Between 2017 and 
2018, deaths from all opioids decreased 4.3% among women, with a smaller decrease of 1.5% 
observed among men [68].   
The rapid increase in opioid misuse and overdose in women can in part be traced to how 
women experience and report pain, develop drug dependency, and prescribing patterns among 
physicians. Research highlights the different pathways by which women are introduced to 
opioids and develop drug dependence.  Population-based studies have shown that women are 
more likely to experience pain, including chronic pain, and are more likely to be prescribed 
opioids to treat their pain than men [87-89].  A recent study using nationally representative data 
confirmed that women are significantly more likely to receive prescription opioid analgesics 
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compared to men [90].   The authors also reported that the difference in prescribing incidence is 
largely attributable to women experiencing lower socioeconomic status, more adverse health 
events, and having greater healthcare utilization compared to men [90].  However, trends in 
prescribing patterns indicate that physicians have begun to decrease both the frequency and 
dosage of prescription opioids, with opioid prescriptions rates falling nearly 37% between 2012 
and 2018, from 81.3 opioids per 100 persons in 2012 to 51.4 in 2018 [91-93].  The underlying 
mechanisms for the sex differences in both prevalence and intensity of pain, however, are not 
well understood and are an area in need of further research [89, 94].       
Women have also been found to use prescription opioids in higher doses and for longer 
periods of time than men [95].  There is evidence that women progress to opioid dependence 
more quickly than men and experience stronger cravings once dependent [96].  The “telescoping 
effect”, seen in alcohol abuse, suggests that women progress more quickly to substance 
dependence because of physiological differences in body composition, hormonal concentrations, 
and metabolic rates [97].  While the telescoping effect has been observed in women in relation to 
opioids, the research is limited and has primarily focused on alcohol use [97, 98]; even with 
alcohol use, findings are not supported by strong empirical evidence.  
Beyond sex-based physiologic differences, there are important social risk factors that 
distinguish the development and persistence of opioid dependence among women from that in 
men.  Substance use in women is often associated with current or past trauma and violence, 
where substance use may be a coping mechanism to help women deal with negative emotions 
and experiences [96].  For example, findings from a large study examining intimate partner 
violence and substance use indicated that OUD was significantly associated with being a victim 
of intimate partner violence (IPV) (aOR: 3.27, 95% CI: 2.61-4.09) [99].  Qualitative studies have 
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also noted that women cope with IPV through substance use and that both physical and 
emotional abuse can interfere with women’s recovery efforts [100].  Substance use in women is 
also strongly associated with a history of childhood abuse, both sexual and physical, and reported 
levels of trauma among women with SUD are significantly higher than both the general 
population and men with SUD [101].  The findings of a recent study of obstetric outcomes 
among pregnant women with OUD showed a very high prevalence of sexual (56.6%) and 
physical abuse (65.5%) among the study participants [102].  
Mental illness among women with SUD also is an important factor in OUD.  In general, 
women are more likely to experience a diagnosable mental illness with a past-year prevalence of 
22.3% in women compared with 15.1% in men in 2017 [103].  A recent study examining data 
from the National Survey on Drug Use and Health from 2015-2017 reported that among adults 
with OUD, men were significantly less likely to experience any co-occurring mental illness 
(aOR = 0.39, 95% CI:0.26–0.57) including serious mental illness (aOR = 0.47, 95% CI:0.32–
0.69) compared with women [104].  Results from a randomized controlled trial of adults with 
OUD indicated similar results with women participating in the trial being 1.6 times more likely 
to have a co-occurring psychiatric disorder than men [105].  In a large randomized trial of OUD 
patients, 45% of women reported ever experiencing psychiatric problems compared with 24% of 
men [96].  Similar to the hypothesis surrounding trauma and drug use, many of these psychiatric 
problems precede a woman’s drug use and drugs may be used as a form of self-medication [96].  
It is difficult, however, to separate the cause and effect in this association.              
The unique needs and circumstances of women with SUD extend to treatment and 
rehabilitation.  With the dramatic rise in opioid use over the past two decades, there is a well-
documented disparity between rates of opioid dependence and the availability of treatment [106, 
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107].  The shortage of treatment is even more acute among women because less than half of 
treatment programs offer specialized programs for women and only 23% provide treatment for 
pregnant or postpartum women [108].  Historically, drug treatment programs have been designed 
to address the clinical profile and needs of men with SUD; yet, women who present for 
substance abuse treatment often have more severe medical, psychological, and social problems 
than men [109].  Women with SUD also face increased social stigma and discrimination 
compared with men [110].   
Services often do not address the specific needs of women with SUD.  In 2018 only 26% 
of substance abuse programs provided targeted services for victims of sexual abuse and intimate 
partner violence, both of which occur at high levels among women with SUD [108].  Among 
women who enter substance abuse treatment, 70% have children and yet very few rehabilitation 
programs allow for children to accompany their parents while receiving treatment [111].  The 
lack of treatment options designed to accommodate women, both in their life circumstances and 
their clinical profile, may help explain why women report significantly lower utilization of 
treatment than men [112-114].    In general, the findings of research evaluating the effectiveness 
of gender-specific treatment programs verse standard treatment are inconsistent; however, 
substance abuse programs designed to address co-occurring problems more common in women, 
such as concomitant psychiatric disorders or experiences of abuse, demonstrate higher 
effectiveness among these sub-populations [113]. 
The risk of relapse is an important component of understanding the opioid epidemic and 
its impact on women, particularly within the context of pregnancy.  There is growing consensus 
among medical professionals that OUD and other SUD are chronic brain diseases, with relapse 
rates of approximately 40-60%, rates similar to those of other chronic disease such as asthma and 
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hypertension [115, 116]. Research findings suggest that women are more likely to relapse than 
men and may relapse at more frequent intervals [117].  The reasons for the increased risk of 
relapse in women are complex and may be due to both the tendency for women to report more 
severe withdrawal symptoms while trying to quit and a lack of social support; men who are in 
the process of recovery are more likely to receive social support at home, at their places of 
employment, and from their partners [117-120].   
The postpartum period is an especially vulnerable time for women with SUD and is 
considered a period when they are at high-risk for relapse.  Findings from a 2015 randomized 
trial among pregnant women who reported using alcohol or illicit substances indicated that 80% 
of women who were drug-abstinent in the last month of pregnancy relapsed to at least one 
substance over the postpartum period [121].  In a recent study examining rates of opioid 
overdose in the year prior to delivery and the first year postpartum, women with OUD were at 
the highest risk for overdose in the first 7-12 months postpartum [122].  This finding highlights 
the importance of providing access to contraception throughout the recovery process, especially 
during the postpartum period when both stress and risk of relapse are elevated.                
2.6 Opioid Use During Pregnancy 
Opioid use during pregnancy and pregnancy-related deaths involving opioids have 
increased in tandem with the opioid epidemic in the United States.  This rise in OUD at the time 
of delivery and during pregnancy has been documented using various data sources, including 
insurance claims databases, national surveys, and admissions to drug rehabilitation facilities.  
Taken together, there is clear evidence that opioid use during pregnancy is a growing and 
significant problem in the US.   
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There is a spectrum of opioid use during pregnancy ranging from women who use illicit 
forms of opiates or use prescription opioids for nonmedical purposes during pregnancy, women 
who are in treatment and using opioid maintenance therapy drugs such as methadone and 
buprenorphine, and those who obtain medically legitimate prescription opioids from their 
clinician.  While any opioid use during pregnancy carries risk, it is important to distinguish 
between these groups for the purposes of discussing the prevalence of opioid use during 
pregnancy, the risk factors associated with each type of opioid use, and for the development of 
effective interventions. 
One of the first studies to examine how the opioid epidemic has impacted maternal 
mortality at a national level is a recent analysis of national vital statistics data between 2007-
2016 [123]. The study findings indicate that pregnancy-associated mortality ratio involving 
opioids increased from 1.3 to 4.2 pregnancy-associated deaths per 100,000 live births [123].  
Gemmill and colleagues also found that the percentage of all pregnancy-associated deaths 
involving opioids increased from 4% to 10% [123].  Evidence from Utah supports the trends 
observed by Gemmill and colleagues at the national level.  From 2005 to 2014, drug-related 
deaths were the leading cause of pregnancy-associated mortality in Utah, with 77% of drug-
related deaths attributable to opioids [124].  Over the same time period, the drug-related 
pregnancy-associated mortality ratio increased 200%, along with a 76% increase in the overall 
pregnancy-associated mortality ratio [124].  Drug-related pregnancy-associated deaths were 
significantly more likely to occur in the postpartum period compared to deaths due to other 
pregnancy-associated causes, underscoring the vulnerability to relapse during to the postpartum 
period [124].   
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Emerging research results indicate that the opioid epidemic also is a significant 
contributor to rising maternal morbidity rates in the US [125].  The findings of a recent study 
using the National Readmissions Database showed that women who used opioids during 
pregnancy had nearly a three times higher odds of having a postpartum hospital readmission than 
women who did not use drugs (aOR: 2.86, 95% CI: 2.49-3.29) [126].  The study authors also 
noted that women who used opioids had a significantly higher obstetric comorbidity index at the 
time of delivery [126].  The authors of a study of a state-wide inpatient database in North 
Carolina reported similar increases in maternal morbidity among women who used opioids 
during pregnancy [127].  Women who used opioids were more likely to experience early onset of 
delivery, threatened preterm labor, premature rupture of membranes, and had significantly longer 
hospital stays compared to women who did not use opioids [127].  A recent study of birth 
outcomes among women with prescription opioid exposure during pregnancy reported that 
women who used prescription opioids had higher obstetric risk scores and more comorbid 
conditions than women who did not use prescription opioids [128].  However, the directionality 
of the relationship between opioid use during pregnancy and maternal morbidity is difficult to 
ascertain.        
The authors of a study based on data from the National Inpatient Sample (NIS) noted a 
significant increase in the prevalence of opioid use disorder at the time of delivery, rising from 
1.5 to 6.5 cases per 1,000 delivery hospitalizations between 1999 and 2014 [129].  A second 
study, also using the NIS, examined OUD diagnoses in antepartum and delivery hospitalizations, 
and postpartum hospital readmissions from 1998 to 2014 [130].  The proportion of 
hospitalizations with an OUD diagnosis increased significantly for all three types of admissions; 
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antepartum and delivery hospitalizations with an OUD diagnosis were associated with 
significantly higher risk for severe maternal morbidity [130].   
Several prevalence studies of opioid exposure during pregnancy have been conducted 
among pregnant Medicaid populations [131-133].  All have observed an increasing prevalence of 
opioid prescriptions among pregnant women.  In a national Medicaid sample, codeine and 
hydrocodone were among the top 10 most commonly prescribed medications for pregnant 
women from 2000 to 2007 [133].  Over this same time period, the proportion of pregnancies with 
a prescription for hydrocodone doubled from just below 6% in 2000 to nearly 12% in 2007 
[133].  In a second study focused exclusively on opioid prescriptions, the authors reported that 
21.6% of pregnant women enrolled in Medicaid filled at least one prescription for an opioid 
during their pregnancy [131].  A smaller proportion of pregnant women, 2.5%, were chronically 
exposed to prescription opioids, defined as having an available supply of prescription opioids for 
30 days or more during pregnancy [131].  Prescribing patterns varied substantially by state with 
the lowest prescription rate at 9.5% in New York and the highest at 41.6% in Utah [131].  Over 
the study time period, opioid prescriptions during pregnancy increased from 18.5% in 2000 to 
22.8% in 2007 (p for trend <0.001) [131].  In a second study, restricted to Tennessee Medicaid 
patients, 29% of pregnant women filled an opioid prescription at some point during pregnancy 
[132].  Within the study cohort, any opioid use during pregnancy increased 90% between 1999 
and 2009 [132]. 
Prevalence estimates are also available for commercially insured pregnant women.  In a 
national sample from i3 InVisionTM for Data Mart, 14.4% of women were prescribed an opioid at 
some point during pregnancy and 6% of pregnant women received prescription opioids during all 
three trimesters of pregnancy [134].  The percentage of pregnant women prescribed an opioid 
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during decreased over the study period from 14.9% in 2005 to 12.9% in 2011, which may reflect 
larger changes in opioid-prescribing patterns of physicians during this time period [134].  Again, 
stark geographic differences emerged with women living in the Northeast having the lowest 
prevalence of opioid exposure while women in the Southern states, including Arkansas, 
Mississippi, and Alabama had the highest prevalence.  There was a two-fold difference in the 
average prescribing rates of the states in the lowest (10%) vs the highest (20%) prescribing 
quartile [134].   
Other studies have sought to estimate changes in opioid use during pregnancy using data 
sources other than health insurance claims.  The results of a small study from the Mayo Clinic 
indicated that chronic narcotic pain medication use increased significantly among pregnant 
women delivering at the hospital from 1998 to 2009 [135].  Over the study time period, the rate 
of narcotic pain medication use increased from 2.2 cases per 1,000 deliveries to 12 cases per 
1,000 [135].  State-level data from Maine revealed a significant increase in OUD at the time of 
delivery, increasing from 22.7 cases per 1,000 livebirths in 2009 to 34.9 cases in 2018 [136].  
Women with OUD at the time of delivery were also more likely to have hepatitis C, concomitant 
substance use disorders, and depression [136].  In a novel approach to measuring drug use during 
pregnancy, Martin et al. explored trends in drug treatment admissions among pregnant women 
for prescription opioid abuse [137].  The percentage of pregnant women admitted to drug 
treatment facilities as a proportion of all female admissions was stable at 4% nationally from 
1999 to 2012 [137].  The proportion of pregnant admissions with prescription opioid abuse, 
however, increased from 2% to 28% [137].  The authors also found that among admissions 
during pregnancy, the proportion referred by the criminal justice system increased from 11% to 
17% [137].    
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The National Survey on Drug Use and Health (NSDUH) provides one of few 
opportunities to estimate nonmedical and illicit use of opioids during pregnancy among a 
nationally representative sample [138].  Between 2005-2014, 5% of pregnant survey participants 
reported nonmedical prescription opioid use in the past 12 months and 1% reported nonmedical 
use in the past 30 days [138].  The 2012 NSDUH found that among pregnant survey participants, 
5.9% reported current illicit drug use including heroin, fentanyl, and other street drugs compared 
with 11.4% among non-pregnant women aged 15-44 years [139].  Beyond these national survey 
estimates, there is little national data on the frequency of illicit drug use during pregnancy.  The 
prevalence of Hepatitis C virus (HCV) at the time of delivery has mirrored the trends of opioid 
use and OUD during pregnancy.  From 2000-2015, the rate of HCV infection among all hospital 
deliveries in the US increased from 0.8 to 4.1 cases per 1,000 deliveries [140].  Among deliveries 
to women with OUD, the prevalence of HCV infection increased from 87.4 in 2000 to 216.9 
cases per 1,000 deliveries in 2015 [140].  This surge in HCV infections among pregnant women, 
and particularly those with OUD, are a significant consequence of the opioid epidemic, 
particularly as it relates to the health impact on women and infants.        
The risk factors and correlates of opioid use during pregnancy are complex and diverse.  
This diversity is in part due to the heterogeneous population that falls under the broad umbrella 
of opioid use during pregnancy.  Pregnant women with nonmedical prescription opioid use and 
who use illicit opioids, such are heroin, have the greatest risk burden.  Pregnant women with 
OUD often have lower levels of prenatal care than women without OUD during pregnancy 
[141].  Demographically, pregnant women with OUD are more likely to be non-Hispanic White, 
younger, unmarried, low income, have not completed high school, and to be publicly insured or 
uninsured [138].  Pregnant women with OUD are also more likely to experience numerous 
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significant comorbidities.  Psychiatric comorbidities including depression and anxiety are highly 
prevalent in this population as are non-opioid substance use disorders [142].   Pregnant women 
with nonmedical prescription opioid use in the past year have significantly higher prevalence of 
anxiety and depression diagnoses, and more frequently report alcohol, tobacco, and marijuana 
use based on data from the NSDUH from 2005-2014 [138].  This same study reported that the 
strongest predictors of nonmedical prescription opioid use in pregnant women were depression 
or anxiety diagnosis within the past year (aOR: 2.15, 95% CI: 1.52-3.04) and marijuana use 
within the past year (aOR: 3.44, 95% CI: 2.47-4.81) [138]. 
The recommended treatment for women diagnosed with OUD during pregnancy is a 
combination of pharmacotherapy and behavioral counseling [143].  In fact, both ACOG and 
SAMHSA strongly advise against opioid abstinence and medically assisted withdrawal because 
of the high risk of relapse and obstetric complications [143, 144]. Pharmacotherapy, also known 
as medication assisted therapy (MAT), is an important component of treating pregnant women 
with OUD because it helps prevent symptoms of opioid withdrawal which in turn decreases the 
risk of relapse to illicit opioids, increases adherence to prenatal care, and decreases the risk of 
obstetric complications [144, 145].  A meta-analysis found that women undergoing medically 
supervised detoxification during pregnancy have a 1.91 (95% CI: 1.14, 3.21) times higher risk of 
relapse compared with women on MAT [146].   
There are two primary drugs used to treat OUD during pregnancy; methadone and 
buprenorphine, both of which act as full or partial opioid agonists [143, 147].  Opioid agonists 
act on the same receptors as other forms of opioids but are dispensed in highly controlled, 
therapeutic doses designed to limit withdrawal symptoms [143].  Buprenorphine may be favored 
over methadone because of its limited potential for overdose, and lower observed rates of NAS; 
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buprenorphine also does not require daily, supervised administration like methadone [143].  Both 
drugs can cause NAS in infants; however, evidence indicates that buprenorphine results in less 
clinically significant NAS in infants compared with methadone [143, 148, 149]. Naltrexone, an 
opioid antagonist which blocks the euphoric effects of opioids, is a third FDA-approved 
pharmacological OUD treatment option.  Unlike methadone and buprenorphine, naltrexone 
requires full detoxification from opioids before it can be used.  For this reason, naltrexone is not 
recommended for use during pregnancy, but has been used to successfully treat OUD in 
nonpregnant persons [143, 150].   
There is growing evidence that Naltrexone may be a safe and viable treatment option for 
pregnant women with OUD, including significant decreases in NAS diagnoses, decreased infant 
hospital length of stay, and reduced opioid misuse during pregnancy [151, 152].  A recent study 
examined pregnancy outcomes among pregnant women receiving MAT, comparing naltrexone 
with methadone/buprenorphine [152].  The study authors reported significantly lower levels of 
NAS among infants born to women using naltrexone than among infants born to mothers using 
methadone/buprenorphine (8.4% vs 75.2%, p<0.0001). While postpartum relapse rates were not 
captured, there were no relapses during the mandatory detoxification period for women using 
naltrexone [153].       
2.7 Neonatal Abstinence Syndrome 
Fetal exposure to opioids has garnered significant public attention as one of the most 
troubling consequences of the opioid epidemic.  The evidence is inconsistent, however, 
regarding the risk of preterm birth and low birth weight among infants with prenatal opioid 
exposure [154]. The results of a recent study from the Boston Birth Cohort indicated that opioid-
exposed births had significantly higher odds of fetal growth restriction (OR: 1.87, 95% CI: 1.41-
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2.47) and preterm birth (OR: 1.49, 95% CI: 1.19-1.86) [155]; however, caution must be 
exercised in interpreting these results because 60 percent of the opioid exposed births had a 
diagnosis of NAS and some important covariates were not adjusted for such as use of other 
substances during pregnancy.  There is some evidence that these infants may be at increased risk 
for some congenital anomalies and fetal death [143, 154, 156].   
The most commonly cited sequalae of fetal opioid exposure is neonatal abstinence 
syndrome (NAS) which results from the sudden interruption of fetal substance exposure at the 
time of delivery.  While NAS is most often associated with fetal exposure to opioids, several 
antipsychotic drugs, methamphetamines, and inhalants are also associated with NAS [157].  
Terminology more specific to fetal opioid exposure is becoming increasingly common including 
Neonatal Opioid Withdrawal Syndrome (NOWS); however, NAS diagnosis is still used for the 
purposes of administrative coding.  NAS is characterized by a constellation of symptoms 
including gastrointestinal issues, irritability, high-pitched cry, poor sleep, difficulty feeding, 
tremors, and in rare cases, seizures [158].    
Among women who use opioids during pregnancy, the observed frequency of NAS has 
ranged from 5% to 94%, with the highest observed levels among women using methadone and 
heroin [157].  Since 2000, the incidence of NAS among US births has increased substantially, 
with notable geographic variation.  Two recent studies examined this increasing incidence: the 
results of one study showed that between 2009 and 2012, NAS increased from 3.4 cases per 
1,000 hospital births to 5.8 cases [159]; in a second study among 28 states, NAS incidence rose 
from 1.5 cases to 6.0 cases per 1,000 hospital births between 1999-2013 [160].  The steep 
increase in NAS cases corresponds to national trends indicating increased use of opioids during 
pregnancy [129].  Beyond the increase in frequency, the severity of NAS cases is also a concern.  
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The proportion of NICU admissions attributable to NAS has increased from 7 cases per 1,000 
NICU admissions in 2004 to 27 cases per 1,000 NICU admission in 2013 [161].  Once admitted 
to the NICU, the median length of stay for these infants increased from 13 days to 19 days over 
the same time period [161].  There also been a rise in the proportion of NAS infants receiving 
pharmacological support, often an indication of heightened severity [161].   
NAS is associated with all classes of opioids including opioid maintenance drugs such as 
methadone and buprenorphine.  The onset, duration, and severity of NAS is influenced by 
several factors including the time of last substance exposure, duration of fetal exposure, and total 
aggregate exposure.  Factors beyond exposure to opioids can also influence NAS outcomes such 
as maternal smoking and poly-substance use, both of which are common among women who use 
opioids during pregnancy [157] [162, 163].  Because opioids can accumulate in fatty tissue, 
infants born full-term or infants with a birth weight of 2,500 grams or higher are more likely to 
experience severe and prolonged NAS symptoms [157].   
Although there are several methods used to assess NAS, the most commonly used clinical 
tool in the US is the modified Finnegan scoring system [164].  In conjunction with the scoring 
system, toxicological tests of infant urine or meconium can confirm recent substance exposure.  
Management of NAS is often a dual approach using pharmacological and nonpharmacological 
interventions.  In all cases, nonpharmacological treatments are used including gentle handling, 
on-demand feedings, swaddling, and low-stimulation environments, all of which have been 
shown to improve NAS symptoms [164].  In more severe cases, pharmacological support is 
necessary, with morphine the most commonly used medication to support infants when needed 
[161].             
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Evidence of the long-term impact of fetal exposure to opioids on child development is 
inconclusive.  There is some evidence that fetal exposure to opioids may be linked to 
hyperactivity and attention issues in toddlers [158].  Evidence from the Boston Birth Cohort 
suggests that children with in-utero opioid exposure have higher odds of conduct disorder (OR: 
2.13, 95% CI: 1.20-3.77) and attention-deficit/hyperactivity disorder (OR: 2.55, 95% CI: 1.42-
4.57), but this study relied on a select follow up sample of infants receiving care at a specific 
medical center, therefore, results must be interpreted with caution [155]. The result of studies on 
long term cognition and academic achievement among exposed children are inconsistent and 
many do not adequately control for confounders [158].  A recent study of Pennsylvania Medicaid 
claims found that 5-years after birth, children with in-utero opioid exposure were no more likely 
to be diagnosed with a complex chronic condition than children without in-utero exposure [165].  
Isolating the impact of opioid exposure is exceedingly difficult for multiple reasons.  Women 
who use opioids during pregnancy are often polysubstance users, making it difficult for 
researchers to isolate the impact of opioids on infant and child development.  Furthermore, 
women who abuse substances often experience concomitant risk factors such as poverty, low 
levels of prenatal care, and stressful home environments all of which influence infant and child 
development outcomes [166].         
2.8 Contraceptive Use and Unintended Pregnancy among Women with 
Substance Use Disorders 
Postpartum contraception is an important consideration for all women, but it is of special 
importance for women with SUD. Women with SUD experience the same benefits from 
postpartum contraception, and contraception use generally, as other women of reproductive age.  
Yet, because women with SUD face additional risks such as substance use relapse, concomitant 
morbidities, and social disparities, postpartum contraception use can confer additional benefits 
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by allowing women to focus on caring for themselves, their newborn, and receiving help for on-
going issues associated with substance use.                 
There is a growing body of literature dedicated to describing and understanding 
contraception use and unintended pregnancy among women with substance use disorders (SUD).  
Overall, women with SUD have been found to have exceptionally high rates of unintended 
pregnancy and tend to use less-effective methods of contraception, such as male condoms, 
compared with the general population [167, 168] [169-171] [172].  Given the US opioid 
epidemic, research focused on the reproductive, sexual, and obstetric health needs of this 
population is critical.  
Understanding contraception use and contraceptive method choice is a crucial component 
for improving reproductive health outcomes in women with SUD. A systematic review examined 
the literature concerning contraception use and unplanned pregnancy among women with SUD 
[172].  The authors found a median contraceptive prevalence of 55% among women with SUD, 
with a range of 6%-77% across studies [172].  In the US, the NSFG, a nationally representative 
survey, reports that 65% of women aged 15-49 are currently using contraception [173].  The 
systematic review also reported that women with SUD more frequently relied on less effective 
methods.  Male condoms were the most common primary contraceptive method among women 
with SUD (62%) whereas just 9.4% of the general US population report using condoms as their 
primary contraceptive method [172, 173].  In a study among low-income women in 
Massachusetts, women with SUD were significantly less likely to use any form of prescription 
contraception compared with women without SUD (aOR: 0.79, p<0.001) [170].  Among those 
who did use prescription contraception, women with SUD were significantly less likely to use 
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the most effective forms of prescription contraception, such as the IUD or implant, than women 
without a SUD (aOR: 0.83, p<0.05) [170].   
A recent study examined contraceptive health insurance claims among privately insured, 
non-pregnant women of reproductive age who were identified as filling chronic opioid 
prescriptions [174].  The authors reported that among the 16,074 women aged 15-44 who were 
identified as filling chronic opioid prescriptions, 23.4% had a contraceptive claim in the 270 days 
before or after the initial opioid prescription [174].  The study authors concluded that the 
relatively low contraceptive prevalence may indicate unmet need in this population: however, the 
study is subject to significant limitations because the 9-month study timeframe reduced the 
accurate identification of long-acting forms of contraception such as the IUD and implant [174].  
A study among women receiving care at two MAT clinics in Tennessee reported that 53% of 
women had experienced an unintended pregnancy; although 90% of women reported wanting to 
avoid pregnancy, only 59% were regularly using contraception [175].       
Studies in high-resource settings outside of the US indicate large disparities in 
contraceptive use among women with SUD.  In a British cohort of women receiving MAT, the 
overall contraceptive prevalence was 30% compared with the national U.K. average of 75% 
[169].  Women receiving MAT also had significantly lower usage of prescription contraceptives 
compared to the national U.K. average (24% vs 50%, p<0.001) [169].  Among women attending 
public opioid treatment programs in Australia, 54.7% reported use of any contraception with the 
most popular methods being male condoms followed by the pill [168].  The literature has 
consistently shown that women with SUD tend to use contraception at lower levels than the 
general population and when they do so, male condoms are often the primary method.          
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Women with SUD have consistently higher rates of unintended pregnancy, abortions, and 
stillbirth compared with the general population [127, 167, 170].  A 2016 systematic review 
indicated that the unintended pregnancy rate among women with SUD ranged from 80%-85% 
compared with 45% in the general US population [4, 167]. In a study involving opioid abusing 
pregnant women in the US, the study authors reported that 86% of pregnancies were unintended 
[171].  The results of a study in Connecticut involving pregnant women with SUD revealed 
similar levels of unintended pregnancy with 80% of women indicating their pregnancy was 
unintended at study entry [176].  A medical record review of women with OUD and two 
consecutive deliveries at a medical center in Vermont, reported that 84% of the pregnancies were 
unplanned [177]. Among a sample of Australian women attending an opioid treatment program, 
study authors reported a lifetime average of 4.6 pregnancies per woman [168].  Among women 
who experienced a pregnancy within the last 12 months, 75.5% of these pregnancies were 
classified as unplanned [168].  A cohort of British women receiving treatment for opioid 
addiction were observed to have substantially higher rates of pregnancy terminations when 
compared with the national average (0.46 abortions per study participant vs 0.025 abortions per 
aged match woman nationally) [169].  
There is evidence that women with SUD have higher rates of miscarriages and stillbirths 
compared with the general population [127, 167].  Australian women in the sample attending an 
opioid treatment program had higher rates of miscarriage, stillbirth, and abortion than a national 
sample of Australian women [167].  A recent study of inpatient hospitalizations among women 
who used opioids during pregnancy in North Carolina found that opioid use was associated with 
50% increased odds of stillbirth (aOR: 1.5, 95% CI: 1.8-2.3), along with several other serious 
maternal and fetal complications [127].   
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The observed rates of unintended pregnancy among women with SUD suggest there may 
be substantial unmet need for contraception among this group, defined as the proportion of 
women at risk for unintended pregnancy who are not using contraception.  Preliminary data from 
a substance abuse treatment center in Michigan indicates that only 37% of women at risk for 
unintended pregnancy were using any form of contraception and only 37% of that group were 
using a highly effective form such as an IUD, implant, or sterilization [178].  More research is 
needed to understand the extent of unmet contraceptive need among women with SUD and the 
barriers that prevent women with SUD from accessing or consistently using contraception. 
Relatively little is known about postpartum contraception use among women with SUD.  
Measurement of postpartum contraception use often varies in terms of follow up time and ability 
to measure the full range of contraceptive methods.  Studies that rely on insurance claims data 
are restricted to examining prescription methods of postpartum contraception and cannot capture 
condom use or other non-prescription contraceptive methods.  The few studies focused on 
postpartum contraception among women with SUD have reported varying prevalence levels.   
Among PRAMS respondents in Tennessee, women who used drugs were less likely to 
report using any postpartum contraception (79.6% vs 88.1%, p-value<0.05) and had significantly 
lower odds of postpartum contraception use than women who did not use drugs (aOR: 0.54, 95% 
CI: 0.29-0.99) [179].  In a recent study using Pennsylvania Medicaid claims data, 74.5% of 
postpartum women with OUD were not using prescription contraception, which included female 
sterilization, IUD, implant, DMPA, the pill, patch, or ring, within the first 3 months postpartum 
[180].  Overall, 7.4% of women with OUD were using a highly effective method, defined as 
female sterilization, IUD, or implant, within the first 3 months postpartum [180] in contrast to a 
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study of a general population of Medicaid-enrolled postpartum women, in which 16.4% were 
using a highly effective form of postpartum contraception [181].   
In a separate study also based on Pennsylvania Medicaid claims for women with OUD at 
the time of delivery, the authors examined whether Medicaid expansion impacted postpartum 
health care utilization by measuring changes in postpartum visit attendance and receipt of 
postpartum contraception [38].  The Pennsylvania Medicaid expansion included a provision 
extending health insurance coverage for postpartum mothers from 60 days to 300 days 
postpartum.  Despite an increase in length of coverage, there was no change in the percentage of 
women attending a postpartum care visit within 60 days (15% pre-expansion; 16.4% post-
expansion) [38].  Similarly, the authors did not observe a change in the percentage of women 
using postpartum contraception at either 60 days (23.5% pre-expansion; 21.0% post-expansion) 
or 300 days postpartum (39.3% pre-expansion; 37.5% post-expansion) [38].  In both the pre- and 
post-expansion periods, postpartum visit attendance and postpartum contraception use were 
exceptionally low in this population of postpartum women with OUD.    
A recent study examined receipt of LARC among women with OUD who are currently 
using MAT [182].  Among women with an intention to use postpartum LARC, 18% received a 
LARC method by eight weeks postpartum [182].  In adjusted models, prenatal contraceptive 
counseling was significantly associated with prenatal LARC intent (aOR: 6.67, 95% CI: 3.21-
13.89) whereas receipt of prenatal care from a private practice provider was associated with a 
significant reduction in prenatal LARC intent (aOR: 0.48, 95% CI: 0.32-0.72) [182].  The 
authors also noted low postpartum visit attendance among the cohort, with 30% of women 
attending a postpartum care visit within the first eight weeks postpartum.  In comparison, 
approximately 50% of Medicaid-insured women without OUD attended a postpartum visit [181].  
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Prior research indicates that postpartum visit attendance is strongly associated with postpartum 
contraception use, particularly LARC [183].   
Krans and colleagues also examined repeat pregnancies in their sample of Medicaid-
enrolled postpartum women with OUD.  They found no significant difference in time to the next 
pregnancy comparing women using no prescription contraceptive method and those using a user-
dependent prescription method (e.g. pill, patch, ring, DMPA injection); women using a highly 
effective method, however, had a significantly lower hazard of subsequent pregnancy [180].  The 
findings of a second study involving postpartum women with SUD indicated that approximately 
30% of women reported no contraceptive use over the course of a 24-month follow up [176].  
Among women who reported using postpartum contraception, DMPA injections were the most 
popular followed by condoms and the pill [176].  The results of a study from Vermont among 
women with OUD revealed that 56% of study participants had a birth to pregnancy interval less 
than 18 months and 50% of women did not receive any contraceptive method during the 
postpartum period [177].  Finally, a 2014 study examined the effectiveness of contraceptive 
counseling for postpartum women on MAT [64].  Study authors reported that upon hospital 
discharge, 40% of women were using contraception and another 45.7% had a documented plan 
for postpartum contraception [64].  
2.9 Study Rationale 
Prior research focused on postpartum contraception provision among women who use 
opioids during pregnancy is limited in quantity and scope.  Previous literature has generally 
focused on women insured by Medicaid, women with OUD, or women enrolled in substance use 
treatment programs and research trials [38, 64, 176, 177, 180, 182, 184].  Furthermore, much of 
this research lacks a comparison group of women who did not use opioids during pregnancy, 
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limiting generalizability and failing to provide a broader understanding of contraception use 
among women who use opioids compared to the general population.  This study addressed 
several of these limitations.  Foremost, the current research examined a large sample of privately 
insured women who are often omitted from substance use research.  The study included a 
comparison group of women with no evidence of opioid use during pregnancy, providing context 
for how contraceptive provision among women who use opioids compares to the broader, 
privately insured population.   
This study also disaggregated by type of opioid used during pregnancy in relation to 
postpartum contraceptive use.  Three categories of opioid use were examined: non-chronic 
prescription opioid use, chronic prescription opioid use, and formal diagnoses of opioid use 
disorder or buprenorphine prescriptions.  Women in each opioid use category has a distinct 
clinical and demographic profile, highlighting the need to disaggregate by type of opioid use.  
These strengths addressed a current gap in the literature and provide nuance in understanding 
how demographic, clinical, and behavioral characteristics differ across categories of opioid use 
as well as how they relate to postpartum contraceptive provision.   
In addition to expanding the scope compared to prior research, this study capitalized on 
the longitudinal nature of the data source to include variables from the pre-, peri-, and postnatal 
periods.  Previous research reliant on inpatient hospitalization records or other cross-sectional 
data sources did not examine diagnoses during the prenatal period or outpatient pharmaceutical 
claims to identify women who use opioids during pregnancy [127].  While the current study did 
not include the full-array of demographic characteristics typically included in contraceptive 
research, the data source allowed for inclusion of a wide-variety of prenatal clinical variables.  
Clinical outcomes in the infant were also considered in the current study.  There are very few 
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studies that include infant outcomes as covariates in models examining postpartum 
contraception, although there is research that indicates infant outcomes, particularly adverse 
outcomes, play a role in postpartum maternal health-seeking behavior [62, 64, 185-187].   
The opioid epidemic, while no longer growing at the pace of the mid-2000’s, remains a 
substantial and critical public health crisis [65].  Early state-level reports indicate that the current 
COVID-19 pandemic may be reversing much of the progress made in recent years in combating 
opioid-related overdose deaths [188, 189].  Research consistently highlights the pressing need to 
expand efforts to address the sexual, reproductive, and maternal health needs of women who use 
opioids [143, 150, 190, 191].  Over the past decade, research on the opioid epidemic has greatly 
expanded our understanding of how this crisis has impacted women across the US.  Despite the 
heightened research interest, gaps remain in the literature.  This research addressed several of 
these gaps by examining an under-studied population, disaggregating by type of opioid use, 
leveraging a longitudinal data source to include variables for all stages of pregnancy and 
postpartum, and analyzed contraceptive provision over the full postpartum period through one 
year.  Each of these strengths improves our understanding of how opioid use during pregnancy 
impacts postpartum contraceptive provision, a vital component of maternal healthcare.         
2.10 Conceptual Framework 
The conceptual framework for this research is based on the concepts and elements that 
are generally thought to influence a woman’s decision to use postpartum contraception while 
also incorporating factors that are unique to women with substance use disorders.  The 
framework presents three, hierarchical layers each containing various factors that influence 
postpartum contraception use as well as additional factors associated with the complications 
posed by opioid use during pregnancy.   
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Factors at the individual level are divided into three broad categories: demographic, 
psychosocial, and clinical.  Demographic factors cover characteristics typically included in 
contraceptive research in the US such as maternal age, race/ethnicity, parity, income, and 
relationship status.  Frequency of sexual activity is also included within the demographic factors 
as this may influence or encourage postpartum contraception use.  Clinical factors focus 
primarily on concerns that arise from opioid use during pregnancy and opioid use disorder 
generally but also include universal clinical considerations such as mode of delivery and 
common comorbidities.  These comorbidities include chronic and gestational hypertension, pre-
existing and gestational diabetes, autoimmune disorders, and pain conditions. Pain conditions are 
an important consideration as they are associated with prescription opioid use.  This research 
also explored if postpartum complications of opioid use during pregnancy, such as an NAS 
diagnosis in the infant, NICU admission, and infant hospital length of stay, influence postpartum 
contraceptive provision. Finally, psychosocial factors include conditions and events typically 
associated with substance use such as unstable life circumstances and experience of abuse as 
well as factors that are widely generalizable to most contraceptive decision making.  Several 
partner-level psychosocial factors, such as experiences of intimate partner violence (IPV) and 
partner substance use, are included as these factors are known to influence substance use in 
women and, particularly in the case of IPV, may influence contraception use [99, 192, 193].  
Data about these psychosocial factors, however, were not available for the current study.       
A limited number of healthcare system factors were assessed in this research including 
antenatal and postpartum care visits.  Other aspects of the healthcare system are important for 
contraceptive decision making including the quality of healthcare interactions, affordability and 
accessibility of contraceptive methods, and past encounters with the healthcare system; these 
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factors could not be measured in the current study.  Evidence suggests that high quality 
contraceptive counseling in the antenatal period can increase postpartum contraceptive use [34].  
However, if a woman has persistently poor or limited interactions with the healthcare system, she 
may be less inclined to engage with providers about her postpartum contraceptive options.  The 
quality of healthcare interactions as well as past experiences within the healthcare system are 
particularly important in the case of women who use opioids during pregnancy as they may be 
subject to stigma from a variety of sources.  The quality of healthcare interactions could not be 
measured in this study, but receipt of antenatal care and a postpartum care visit were included in 
the analysis.   
Finally, social and cultural factors that influence postpartum contraception use are broad 
measures of how society views women who use drugs during pregnancy.  The laws and policies 
directed towards women who use illicit drugs during pregnancy can act as significant barriers to 
care-seeking as research indicates that women may delay or avoid the healthcare system when 
punitive laws are in place [194-197].  Furthermore, punitive laws do not decrease the incidence 
of NAS or maternal substance use which are often the stated goals of these laws and policies 
[197].  Beyond explicit laws and policies, the shame and stigma attached to drug use during 
pregnancy may be enough to delay or deter women from seeking care [196, 198, 199].  Women 
report fear of child protective services, potential criminal justice involvement, and past negative 
interactions with healthcare workers as barriers to seeking care [196].  
Access to contraception is also impacted by laws and policies such as the Affordable 
Care Act, which has significantly decreased out-of-pocket costs for all reversible prescription 
contraceptive methods and may be a contributing factor to increased LARC uptake in the US 
[200].  However, consistent availability of LARC devices and delays in contraceptive placement 
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continue to impede women’s ability to access contraception.  Insurance reimbursement policies 
that support immediate postpartum LARC insertion also play an important role and have been 
shown to decrease unintended pregnancy and reduce short birth-to-pregnancy intervals [201].  
Unlike numerous state-based Medicaid programs, few private insurance companies cover 
immediate postpartum LARC insertion, making it difficult for privately insured women to obtain 
LARCs during their hospital stay for delivery [46].   
While the conceptual framework presented in Figure 2.1 is comprehensive, the data 
source for this research was limited in the ability to capture demographic and psychosocial 
variables but contains extensive clinical measures including varying types of opioid use, a 
strength of this research.  An attempt was made, however, to create state-level variables (race, 
education and poverty) as proxy measures for the important missing demographic variables. The 
variables available for inclusion in the current research are presented in bold in the framework. 
This research is the first to examine the relationship between opioid use during pregnancy, 
disaggregating by type of opioid use, and postpartum contraception use among a privately 
insured patients in the US based on a very large sample.  Future research should focus on 
including a broader range of sociodemographic and clinical variables, including parity, maternal 
relationship status, income, methadone usage, and expanded measures of contraception to 
include methods that do not require a prescription.  The use of alternative data sources, such as 
linked medical records and insurance claims, may help expand the information available for 
analysis while retaining the longitudinal scope of the data.  This research serves as the initial 
foundation for understanding the relationship between opioid use during pregnancy and 
postpartum contraceptive provision among privately insured women.     
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This chapter describes the data source and study methods used to address the three study 
aims related to provision of prescription contraception during the postpartum period among 
women who did and did not use opioids during pregnancy.  It begins with an overview of the 
specific aims, followed by a description of the study design, data source, and study cohort for 
each study aim. The dependent and independent variables for each study aim are then defined 
and described.  Finally, the analytic plan, including statistical models, are presented for each aim.  
3.2 Study Aims 
The three study aims were evaluated in a population of privately insured women in the 
United States (US) with a live birth between January 2011 and November 2017; they were to:     
Aim 1: Evaluate the association between opioid use during pregnancy and prescription 
contraception provision by 60 days postpartum, including by contraceptive method type.   
Aim 2: Evaluate the time to first prescription contraception provision during the postpartum 
period for women who did and did not use opioids during pregnancy, including by type of 
opioid.  
Aim 3: Assess if adverse newborn outcomes are associated with provision of prescription 
contraception within 60 days postpartum among women who used opioids during pregnancy.  
3.3 Study Design 
This study was a retrospective cohort study using health insurance claims data for 
privately insured women in the US who experienced a live birth between January 2011 and 
November 2017.  The initial cohort included all women with a live birth captured in the data 
source, hereafter referred to as the MarketScan database.  Pregnancies that did not end in a live 
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birth, including ectopic pregnancies, molar pregnancies, stillbirths, and spontaneous abortions 
prior to 20 weeks gestation were excluded.  Several additional exclusion criteria, including 
length of continuous health and pharmaceutical insurance coverage, were applied to identify the 
analytic sample for each study aim but the initial cohort of women with a delivery was retained 
to conduct sensitivity analyses throughout the analysis. 
3.4 Data Source 
The data source for this study was the MarketScan database which contains paid 
insurance claims for privately insured patients in the US from 2010 to 2017.  The data was 
collected and compiled by Truven Analytics and later IMB into the MarketScan database.  It is 
comprised of seven separate but linked categories of claims and enrollment data.  The database 
contains paid claims data from 350 payers including commercial insurance companies and third-
party administrators, with an estimated total of 100 million individual enrollees.  According to 
the US Census, approximately 67% of American’s are insured through private health insurance 
plans [1].   
The Marketscan database is structured by claim and information type which fall into 
seven categories.  These categories include four categories capturing inpatient and outpatient 
services, one category documenting outpatient pharmaceutical claims, and two categories with 
demographic and enrollment data for each individual enrollee (Table 3.1).  Inpatient 
pharmaceutical claims are not captured in the Marketscan database.  The seven data categories 
are linked using a unique enrollment ID (“enrolid”) for each individual with insurance coverage.  
This enrollment ID is used to link paid claims across categories within the database and allows 
researchers to follow patients over time.  It links claims for individuals for as long as they have 
continuous enrollment in a specific health insurance plan, but not across different plans.  If, for 
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instance, an individual receives health insurance through their employer, switches to a new job, 
and regains health insurance through a new employer, the individual will re-enter the 
MarketScan Database with a new enrollment ID.  
 Beyond the individual enrollment ID, there is also a family ID which links claims within 
a family or group of related people who are receiving health insurance through the same plan.  In 
other words, health insurance claims for the child of a person receiving health insurance through 
their employer will be linked to the primary beneficiary through the family ID (“efamid”).  This 
family ID was used to link the records of women and their live-born infant during the inpatient 
admission for delivery for Aim 3.  This linkage was important for this research as infant 
outcomes, including neonatal abstinence syndrome (NAS) diagnosis, admission to the neonatal 
intensive care unit (NICU), and infant hospital length of stay were included as predictor 
variables for postpartum contraceptive provision.  A final linkage within the database is a unique 
case ID, which links all inpatient claims associated with a single inpatient admission, such as a 
hospital admission for a delivery.  This case id was used to link NICU admissions for the infant 
with their overall inpatient admission record at the time of delivery.     
Diagnoses and procedures captured within the MarketScan database are coded using 
standard clinical coding systems.  Primary and secondary diagnoses are captured using 
International Classification of Disease (ICD) codes.  Version 9 of the ICD coding system (ICD-
9-CM) was used until September 30th, 2015; a switch to ICD-10-CM was made beginning on 
October 1st, 2015.  Procedures are captured and classified using the Current Procedural 
Terminology, 4th Edition (CPT-4) coding system or the Healthcare Common Procedural Coding 
System (HCPCS).  Prescription drug types are identified using the National Drug Codes (NDC).  
A comprehensive list of all diagnostic, procedure, and contraceptive drug codes used in this 
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research can be found in Appendix A.  The drug codes used to identify opioids prescription can 
be found at the Centers for Disease Control website: 
https://www.cdc.gov/drugoverdose/resources/data.html.   
Table 3.1 outlines and describes the seven categories of data contained within the 
MarketScan Database and how each category was used in the current research.  The inpatient 
admissions data includes a single line for every inpatient admission, including demographic 
information associated with the patient and up to fifteen separate diagnosis and procedure codes.  
The inpatient admission records were used to identify several critical variables for this research 
including the livebirth, all maternal comorbidities, immediate postpartum contraceptive 
provision, and select infant variables.  The inpatient services data is closely related to the 
inpatient admissions data as the inpatient services data contains individual lines for each 
diagnostic and/or procedure codes associated with the overall inpatient admission.  The inpatient 
services data is linked to the inpatient admission using the unique case ID assigned to each 
inpatient admission.  The inpatient services data was used to ascertain infant NICU admission. 
The outpatient services claims data contains diagnoses and procedures associated with 
outpatient encounters and was used to identify several variables including postpartum 
contraceptive provision, maternal comorbidities, and both antenatal and postpartum care visits.  
The outpatient pharmaceutical data contains records for all paid outpatient pharmaceutical 
claims.  This data was used to determine postpartum contraceptive provision and prescription 
opioid use during pregnancy.  Finally, the annual enrollment data provides month-by-month 
information on individual health and pharmaceutical insurance enrollment.  The enrollment data 
was used to determine periods of continuous enrollment for the analytic cohorts in Aims 1-3.  
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Neither the facility header data nor the enrollment detail data were used in this analysis.  Table 
3.1 summarizes the data categories.         
Table 3.1. Summary of MarketScan Data Categories 




All encounters and 
claims linked with a 
hospital admission 
 
Contains the principle 
diagnosis and 
procedure code and up 
to 14 other diagnostic 
and procedure codes 
Cases and services link to 
inpatient services claims; 




Linked to all other data 
categories through 
enrollment id (ENROLID) 
Identify deliveries, all 
delivery-related variables 
(maternal age, year, region, 









OUD diagnosis, non-opioid 






Infant hospital length of stay; 
Infant NAS diagnosis 
Inpatient 
Services (S) 
Individual facility and 
professional services 
comprised in the 
inpatient admissions 
record 




Linked to all other data 
categories through 
enrollment id (ENROLID) 
Infant NICU admission 
Outpatient 
Services (O) 
Encounters and claims 
for services obtained in 
a doctor’s office, 
hospital outpatient 
facility, emergency 
room, or other 
outpatient facility 
Linked to all other data 
categories through 
enrollment id (ENROLID) 




including female sterilization 
 
OUD diagnosis, non-opioid 





Data Category Category Description  Linkage Variable Application in Current 
Research 










obtained outside of an 
inpatient setting 
Linked to medical/surgical 
data (ENROLID) 
Opioid prescriptions during 
pregnancy 
 




Monthly arrays of 
enrollment indicators 
with a single record 
per-person, per-year 
Linked to all other data 
categories through 
enrollment id (ENROLID) 
Length of continuous 
enrollment 
 
Length of continuous 
prescription drug coverage 
Enrollment 
Detail (T) 
One record per person 




Linked to all other data 
categories through 




information for facility 
claims 
Linked to the inpatient 




Linked to all other data 
categories through 
enrollment id (ENROLID) 
N/A 
N/A= Not applicable; indicates a data category not used in the analysis 
3.4.1 Strengths and Limitations of the MarketScan Database 
 
The MarketScan database has notable strengths as well as several limitations.  Foremost, 
the MarketScan database is large, providing data on an estimated 100 million privately insured 
persons in the US.  The size and scope of the database allows researchers to examine otherwise 
rare subpopulations, events, and clinical outcomes.  In the case of this research, although opioid 
use during pregnancy is a rare event in the general population and even more so in the privately 
insured population, the size of the Marketscan database allowed for an adequately powered 
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analysis not only of opioid use during pregnancy but also the sub-types of opioid use.  
Furthermore, the longitudinal nature of the database allows researchers to follow participants 
over time so long as they maintain continuous health insurance coverage. In the current research, 
women were followed for the duration of their pregnancy, delivery of a livebirth, and into the 
postpartum period. Finally, the MarketScan data has limited missingness and extensive data 
checks are performed prior to the release of the data.         
Despite these strengths, there are some important limitations.  The sample derived from 
the MarketScan database is a convenience sample, and while the database contains claims 
information for millions of individuals, the results of any analysis based on the database are not 
generalizable to other populations.  Similarly, the employers and health plans that provide paid 
claims data to MarketScan are typically large employers, with medium and small employers 
underrepresented in the data.  Data contained within the MarketScan database was not collected 
for epidemiological research but rather for financial purposes; therefore, diagnosis codes and 
dates may be poorly captured and subject to error.  Finally, beginning in 2015 and continuing 
through 2017, there was a notable decrease in the number of individuals captured in the database.  
Researchers speculate that this decrease is due to more individuals obtaining health insurance via 
the health insurance marketplace, established by the Patient Protection and Affordable Care Act, 
and away from employee-sponsored health insurance.  Although these limitations reduce 
generalizability, the population captured in the MarketScan database represents a significant 
portion of the privately insured population in the US and provides an opportunity to examine rare 





3.5 Study Population 
 Aim I Analytic Cohort 
The Aim 1 analytic cohort included women with a livebirth between January 1st, 2011 
and November 1st, 2017 who maintained continuous health and pharmaceutical insurance 
coverage for the duration of pregnancy and through the first 60 days postpartum.  The 60-day 
timeframe coincides with the ACOG recommended guidance for the time by which women 
should receive contraceptive care and is in accordance with the National Quality Forum (NQF) 
postpartum contraceptive care performance measures [2, 3].  Length of continuous health 
insurance enrollment was determined after identifying the initial cohort of women with a live 
birth.  The method for assigning the start of pregnancy was developed specifically for use with 
administrative databases in prior literature [4-6].  Women were eligible for inclusion in the Aim 
1 analytic cohort if they maintained continuous health and pharmaceutical insurance coverage for 
the duration of pregnancy, defined as the 273 days prior to delivery, and for at least 60 day 
postpartum.  The timeframe for deliveries was restricted to January 2011 through November 1st, 
2017.  Due to the requirement that women maintain continuous health and pharmaceutical 
coverage for the first 60 days postpartum, women who delivered after November 1, 2017 were 
not eligible for Aim 1 because they could not be observed for the first 60 days postpartum based 
on the available MarketScan data. 
The continuous enrollment inclusion criterion was designed to increase the capture of 
relevant pre-existing conditions, maternal morbidities, and was crucial for identifying women 
who use opioids during pregnancy.  Pharmaceutical claims data was used not only to identify 
women who used opioids during pregnancy but also identify postpartum prescription 
contraception that was otherwise not captured in outpatient or inpatient claims data.  The 
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criterion that women have continuous enrollment for the first 60 days postpartum was designed 
to identify postpartum contraception use, the primary outcome of interest, without excluding an 
unnecessarily large number of women.  This approach is particularly important because women 
who use opioids during pregnancy may have shorter continuous enrollment periods; therefore, 
the continuous enrollment criteria were designed to maximize both the sample size and capture 
of postpartum contraception while minimizing potential bias.  Data that go beyond the first 60 
days postpartum were included in the analysis for research Aim 2.  Figure 3.1 shows the process 
of identifying the analytic sample for Aim 1.     
An initial cohort of 2,366,863 women with a livebirth between January 2011 and 
December 2017 was identified.  Women who delivered after November 1st, 2017 were excluded 
(n=32,182) followed by women who did not maintain continuous health and pharmaceutical 
coverage for the duration of pregnancy (n=944,568).  Finally, 98,761 women who did not 
maintain continuous health and pharmaceutical coverage for the first 60 days postpartum were 
excluded, resulting in a final sample of 1,291,352 women for inclusion in the Aim 1 analysis 
(Figure 3.1).  Once all Aim 1 inclusion criteria were satisfied; inpatient, outpatient, and 
outpatient pharmaceutical claims occurring in the 273 days prior to the day of delivery and for 
the first 60 days postpartum were included in the analytic data.  The inclusion criteria were 
applied to the first (index) delivery for women with more than one delivery captured in the data.     
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Figure 3.1. Aim 1 Analytic Sample Identification 
 
Aim 2 Analytic Cohort 
The analytic cohort for Aim 2 included all women with a livebirth between January 2011 
and December 2016 who maintained continuous health and pharmaceutical coverage for the 
duration of pregnancy and for some duration during the postpartum period, up to 365 days after 
delivery.  No requirements were placed on length of continuous coverage during the postpartum 
period because Aim 2 was a time-to-event analysis, with the unit of measurement being days 
since delivery.  However, women whose continuous coverage ended on the day of delivery were 
excluded (n=170) as there was no measurable time-at-risk.  All data from the day of delivery 
onward was included in the Aim 2 analysis up until the participant experienced the event of 
interest (provision of prescription contraception), lost continuous coverage, or was 
administratively censored at 365 days postpartum.  Women who delivered after December 2016 
74 
 
were excluded from the Aim 2 analysis in order to minimize bias due to differential follow up 
periods as they could not be followed for 365 days after delivery.  As with Aim 1, all criteria 
were applied to the first live birth during the study period for each woman; higher order births to 
the same woman were excluded.   
 The Aim 2 cohort began with the identification of 2,366,863 women with a livebirth between 
January 2011 and December 2017.  All women delivering after December 2016 were 
immediately excluded (n=204,837).  A further 878,922 women were excluded because they did 
not maintain continuous health and pharmaceutical coverage for the duration of pregnancy.  
Finally, women who did not maintain continuous pharmaceutical coverage for the duration of 
their continuous postpartum health insurance enrollment were excluded (n=12,102), along with 
the 170 women whose continuous coverage ended on the day of delivery.  The final Aim 2 
analytic sample included 1,270,832 women with a livebirth between January 2011 and December 
2016, who maintained continuous health and pharmaceutical insurance coverage for the duration 
of pregnancy and for any duration during the postpartum period, up to 365 days postpartum (see 
Figure 3.2).  Once all Aim 2 inclusion criteria were satisfied, inpatient, outpatient, and outpatient 
pharmaceutical claims occurring in the 273 days prior to the day of delivery and through the first 
365 days postpartum or until loss of continuous postpartum coverage, were included in the 
analytic data.  
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Figure 3.2. Aim 2 Analytic Sample Identification 
       
Aim 3 Analytic Cohort 
The inclusion criteria for the Aim 3 analytic cohort were the same as those for Aim 1, 
with the additional criteria of limiting the sample to women with evidence of opioid use during 
pregnancy who were matched with a liveborn infant.  The Aim 3 cohort began with all women 
included in the Aim 1 analysis (n=1,291,352).  Women with no evidence of opioid use during 
pregnancy were excluded (n=1,167,228) leaving 124,124 women with evidence of opioid use 
during pregnancy who also maintained health and pharmaceutical insurance coverage for the 
duration of pregnancy and for at least the first 60 days postpartum.  Among the women with 
evidence of opioid use during pregnancy, 51.5% were successfully linked with a liveborn infant 
for a total sample of 63,897 women included in the Aim 3 analysis (see Figure 3.3). 
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Figure 3.3. Aim 3 Analytic Sample Identification 
 
3.6 Key Measures and Variables 
Obstetric Deliveries 
Women were identified for inclusion in the study sample based on a delivery of a live 
born infant between January 2011 and December 2017 using inpatient admissions claims.  For 
purposes of this research, the index delivery was defined as the first delivery captured during the 
study period; if a woman had multiple deliveries during the study time period, the exclusion 
criteria were only applied to the first delivery and higher order births to the same woman were 
excluded in order to avoid potential selection bias.     
Inclusion criteria were only applied to the first livebirth because randomly selecting 
which livebirth to apply the inclusion criteria may have biased the sample towards women with 
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longer periods of continuous insurance coverage or older women as parity and age are highly 
correlated.  The alternative approach of including multiple births to the same woman in the 
analytic cohort presented similar issues related to bias.  The likelihood of capturing a second or 
higher order livebirth increases as the length of continuous insurance coverage increases.  
Therefore, if multiple births per woman were included in the analytic cohort, this approach 
would favor women with longer periods of continuous coverage and would not accurately reflect 
the birthing patterns within the cohort.  Furthermore, women with longer periods of continuous 
coverage may be substantively different than women who have shorter periods of continuous 
health insurance coverage across demographic and clinical characteristics.  This source of 
potential bias was eliminated by including only the first livebirth per woman captured during the 
study period.    
The identification of index deliveries was done using validated methodology designed for 
insurance claims data and originally proposed by Kuklina et al. [7].  This method employs a 
hierarchical design for identifying deliveries using the following algorithm: (1) outcome of 
delivery (ICD-9-CM code = V27; ICD-10-CM code = Z370), (2) normal delivery (ICD-9-CM 
code = 650; ICD-10-CM Code = O80), (3) diagnosis-related group (DRG) delivery codes, and 4) 
ICD-9-PCS/ICD-10-PCS procedure codes for selected delivery-related procedures (see Table 3.2 
for full listing of ICD-9/10 codes).   
This hierarchical method was designed under the hypothesis that previous methods, 
which typically rely solely on the ICD-9-CM code for outcome of delivery (“V27”), did not fully 
capture births with acute complications.  The authors applied the revised methodology to the 
Nationwide Inpatient Sample and demonstrated that the enhanced method captured 3.4% more 
obstetric deliveries than the standard methodology [7].  Importantly, the authors noted that 
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deliveries with acute complications such as major puerperal infections, sepsis, and respiratory 
distress syndrome had significantly greater odds of being missed by the standard methodology 
[7].  This omission is significant for this research because women who use opioids during 
pregnancy may experience more obstetric and fetal complications than women who do not use 
opioids during pregnancy, and accordingly, may be missed by using a single delivery code [8].  
Furthermore, experiencing a high-risk or medically complex pregnancy may influence 
postpartum contraceptive method type either because of contraindications for specific methods 
or a strong preference to avoid a rapid repeat pregnancy [9, 10].     
The Kuklina et al. algorithm was applied to the inpatient admissions data.  After the 
initial application of the algorithm, 2,652,781 records were identified between January 2011 and 
December 2017 as obstetric deliveries.  Records with missing enrollment IDs (n=1,232) and 
records to women outside of the age range of 14-55 (n=2,720) were excluded.  Several 
approaches were employed to correctly identify the index delivery record when two or more 
delivery records were identified for the same woman.  If two delivery records for the same 
woman were more than 300 days, only the first record was retained as the first record was 
assumed to be the first live birth captured the database (n=264,872).   
The hierarchical nature of the Kuklina et al algorithm was leveraged to parse delivery 
records to the same woman that were less than 300 days apart.  Deliveries identified by the level 
I code (e.g. outcome of delivery as identified by ICD- 9 code V27/ICD-10 code Z37.0), were 
given priority over a separate delivery claim to the same women identified by the presence of a 
level II-IV code.  Overall, when multiple delivery records were found for a woman with less than 
300 days between admissions, priority was given to the delivery record identified with the 
highest-level code, with level I codes being the highest.  In total, 16,879 delivery records were 
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eliminated using this approach.  Finally, any remaining unresolved delivery claim conflicts were 
examined on a case-by-case basis by the author, which occurred in <0.01% of identified delivery 
records (430 total records reviewed; 215 records dropped).  The final initial cohort of deliveries 
included 2,366,863 women with livebirths, prior to the application of any exclusion criteria.      
Table 3.2. Index Delivery Identification Algorithm from Kuklina et al. 
Description Code Type Codes 
Level I 










Complicated Cesarean Section DRG 765 
Uncomplicated Cesarean Section DRG 766 
Complicated Vaginal Delivery DRG 774 
Uncomplicated Vaginal Delivery DRG 775 
Uncomplicated vaginal delivery with 
sterilization and/or dilatation & curettage 
DRG 767 
Vaginal delivery with operation room 
procedure except sterilization and/or 
dilatation & curettage 
DRG 768 
Level IV: Selected Delivery-Related Procedures 
Forceps ICD-9-PCS 
ICD-10-PCS 
720, 721, 7221, 7229, 7231, 
7239, 724, 726 
10D07Z3, 0W8NXZZ, 10D07Z4, 
10D07Z5, 10S07ZZ 
Breech Extraction ICD-9-PCS 
ICD-10-PCS 
7251, 7252, 7253, 7254 
10D07Z3, 10D07Z4, 10D07Z5, 
10D07Z6 
























Description Code Type Codes 
Cesarean Section ICD-9-PCS 
ICD-10-PCS 
740, 741, 742, 744, 7499 
10D00Z0, 10D00Z1, 10D00Z2 
Exclusionary Diagnosis and Procedure Codes 




Abnormal Products of Conception ICD-9-CM 
ICD-10-CM 
631 
O02*, O07* O08*  
Ectopic Pregnancy ICD-9-CM 
ICD-10-CM 
633 
O00*, O03*, O08*  
Abortion ICD-9-CM 
ICD-10-CM 
632, 634, 635, 636, 637, 638, 
639, 6901, 6951, 7491, 750 
Z332, O04*, O07*, 10A07ZZ, 




V271, V274, V277 
Z371, Z374, Z377 
 
Postpartum Prescription Contraceptive Provision 
The primary dependent variable for Aims 1-3 was provision of postpartum prescription 
contraception, defined and identified using NQF recommended measures and associated clinical 
codes [3].  The provision of postpartum prescription contraception was defined two ways, the 
first as a binary measure of any evidence of postpartum prescription contraception provision 
compared with no evidence of provision.  The second measure was a categorical variable defined 
as no evidence of provision, moderately effective methods (MEM), long-acting reversible 
contraceptive methods (LARCs), and female sterilization.  As proposed by the NQF measures, 
moderately effective contraceptive methods include the pill, patch, ring, DMPA injection, and 
the diaphragm.  LARCs include the IUD and contraceptive implants.   
Evidence of postpartum prescription contraception provision was identified using 
national drug codes (NDC), International Classification of Disease 9th and 10th Edition codes 
(ICD-9, ICD-10), Current Procedural Terminology (CPT) codes, and the Healthcare Common 
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Procedure Coding System (HCPCS) codes (See Table 3.3 for full list of contraceptive codes).  
These codes were identified and compiled by the CDC and included in the NQF recommended 
measure [3].  Using the codes included in the NQF recommended measure, prescription forms of 
contraception were identified by searching for contraceptive codes in outpatient pharmaceutical 
claims, inpatient admissions claims, and outpatient services claims from the date of delivery and 
for the duration of the postpartum period.  The MarketScan database does not capture inpatient 
pharmaceutical claims data, therefore, contraception prescribed on an inpatient basis was not 
captured.  
Beginning with outpatient pharmaceutical claims for the years 2011 through 2017, 
National Drug Codes were used to identify pharmaceutical claims associated with IUDs, 
contraceptive implants, DMPA injections, contraceptive pills, patch, ring, or diaphragms at any 
time on or after the date of delivery.  Once all contraceptive claims were identified, claims with 
an improbable days’ supply were excluded (days’ supply ≤0 or >365).  Of the 4,636,085 
contraceptive claim records from 2011 through 2017, 8,509 (0.18%) had a days’ supply ≤0; 28 
records had a days’ supply exceeding 365 days.  Identification of contraceptive claims in 
inpatient admissions and outpatient services relied on ICD-9 and ICD-10, CPT, and HCPCS 
codes and included codes for female sterilization.  If claims with a shared service date and 
method type for the same woman were identified across all three claim types, only the first of 
these duplicate records were retained.  Among inpatient admissions claims for contraception, 
98.0% of originally identified claims were associated with female sterilization, with very few 
instances of multiple claims to the same woman; therefore, no adjustments were made prior to 
combining these claims with other two claim types.   
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Once contraceptive claims were identified across all three claim types, they were 
combined into a single file in order to identify the postpartum contraceptive claim most 
proximate to the date of delivery as well as to cross-reference claims in the event that a woman 
had conflicting methods claims (e.g. an inpatient admissions claim for female sterilization 
followed by an outpatient services claim for an IUD).  Several systematic methods were 
employed to identify the first instance of contraceptive provision following delivery.  When the 
first contraceptive claim following delivery (or at the time of delivery) contained both a 
diagnosis and procedure code for sterilization or LARC, they were retained as the first 
postpartum provision of contraception.  If all contraceptive records for a woman were outpatient 
prescription claims for the pill, patch, or ring, the first prescription claim was retained as the first 
postpartum provision of contraception.  Finally, if a woman had a claim for both a LARC and 
moderately effective method (pill, patch, ring, DMPA, diaphragm) on the same day, the LARC 
method was retained.    
For Aim 1, the binary and categorical measures of postpartum prescription contraceptive 
provision were calculated at three and 60 days postpartum, consistent with the recommended 
NQF measures and in alignment with clinically significant time points in the postpartum period.  
In Aim 3, a similar approach was taken but because of the smaller sample size, only postpartum 
contraceptive provision at 60 days was examined.  A survival analysis approach was used in Aim 
2 to examine differences in time to first contraceptive uptake, with provision of any postpartum 
prescription contraceptive method considered an “event”.        
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Clinical Codes Data Source 
Female 
Sterilization 





ICD-10: Z30.2, Z98.51, 0UL.74ZZ, 0UL.78ZZ, 0U5.74ZZ, 
0U5.78ZZ, 0UL.74DZ, 0UL.78DZ, 0UL.74CZ, 0UL.70ZZ, 
0UL.73ZZ 0UL.77ZZ, 0UL.70CZ, 0UL.70DZ, 0UL.73CZ, 
0UL.73DZ, 0UL.77DZ,  0UL.78DZ 
CPT: 58600, 58605, 58615, 58611, 58670, 58671, 58565 
HCPCS: A4264 





ICD-10: Z30.430, Z30.433, Z30.431, Z97.5, T83.39XA, 
0UH.97HZ, 0UH.98HZ, 0UH.C7HZ, 0UH.C8HZ  
CPT: 58300 
HCPCS: J7300, J7301, J7302, S4989, Q0090, S4981 










ICD-10: Z30.49, Z30.18 
CPT: 11981, 11983 
HCPCS: J7306, J7307  










NDC: 54569370100, 54569490400, 54569552700, 
54569561600, 54569621900, 54868361300, 54868410000, 
54868410001, 54868525700, 55045350501, 59762453701, 









ICD-10: Z30.011, Z30.41  
HCPCS: S4993 
NDC: 00008111720, 00008111730, 00008251402, 
00008253505, 00008253601, 00008253605, 00052026106, 
00052028306, 00062125100, 00062125115, 00062125120, 








Clinical Codes Data Source 
00062171415, 00062176100, 00062176115, 00062178100, 
00062178115, 00062179600, 00062179615, 00062190120, 
00062190320, 000190700, 00062190715, 00062191000, 
00062191015, 00247052028, 00247069028, 00247069128, 
00247069228, 00247139828, 00247151328, 00247151628, 
00247151728, 00247176404, 00247176421, 00247176521, 
00247198621, 00247198628, 00247200828, 00247201004, 
00247201008, 00247201028, 00247201228, 00247201328, 
00247214728, 00247216928, 00247217028, 00247223028, 
00247223528, 00247226028, 00247226828, 00378655053, 
00378727253, 00378729253, 00430042014, 00430048214, 
00430053014, 00430053550, 00430057014, 00430057045, 
00430058014, 00430058045, 00430058114, 00430058514, 
00430058545, 00555034458, 00555071558, 00555900867, 
00555900942, 00555901058, 00555901258, 00555901467, 
00555901658, 00555901858, 00555902058, 00555902542, 
00555902557, 00555902658, 00555902742, 00555902757, 
00555902858, 00555903270, 00555903458, 00555904358, 
00555904558, 00555904758, 00555904958, 00555905058, 
00555905158, 00555905167, 00555906458, 00555906467, 
00555906558, 00555906658, 00555906667, 00555912366, 
00555913167, 00555913179, 00603359017, 00603359049, 
00603752117, 00603752149, 00603752517, 00603752549, 
00603754017, 00603754049, 00603760615, 00603760648, 
00603760715, 00603760748, 00603760817, 00603760917, 
00603762517, 00603762549, 00603763417, 00603763449, 
00603764017, 00603764217, 00603766317, 00603766517, 
23490765301, 23490767001, 23490769901, 24090080184, 
24090096184, 35356001468, 35356001568, 35356002168, 
35356025528, 35356037028, 43386062030, 45802084054, 
50419040201, 50419040203, 50419040303, 50419040503, 
50419040701, 50419040703, 50419041112, 50419041128, 
50419043306, 50419043312, 50452025115, 50458017115, 
50458017615, 50458017815, 50458019115, 50458019411, 
50458019416, 50458019615, 50458019715, 50458025115, 
51285005866, 51285007997, 51285008070, 51285008198, 
51285008297, 51285008370, 51285008498, 51285008787, 
51285009158, 51285009287, 51285011458, 51285043165, 
51285054628, 51285076993, 51285094288, 51285094388, 
52544014331, 52544017572, 52544020431, 52544021028, 
52544021928, 52544022829, 52544023528, 52544023531, 
52544024531, 52544024728, 52544024828, 52544025428, 
52544025928, 52544025988, 52544026528, 52544026531, 





Clinical Codes Data Source 
52544027536, 52544027928, 52544028754, 52544029128, 
52544029231, 52544029241, 52544029528, 52544038328, 
52544038428, 52544047536, 52544055028, 52544055228, 
52544055428, 52544062928, 52544063028, 52544063128, 
52544084728, 52544084828, 52544089228, 52544093628, 
52544094028, 52544094928, 52544095021, 52544095121, 
52544095328, 52544095428, 52544095931, 52544096691, 
52544096728, 52544098131, 52544098231, 52959045002, 
54569067900, 54569068500, 54569068501, 54569068900, 
54569068901, 54569143900, 54569384400, 54569422200, 
54569422201, 54569426900, 54569427301, 54569481700, 
54569487800, 54569487801, 54569489000, 54569498400, 
54569499700, 54569499800, 54569516100, 54569534300, 
54569534900, 54569549300, 54569549302, 54569579600, 
54569579700, 54569579800, 54569581600, 54569582600, 
54569603200, 54569612800, 54569614400, 54569614500, 
54569627200, 54569628000, 54569628100, 54868042800, 
54868044300, 54868050200, 54868050700, 54868050801, 
54868050901, 54868051600, 54868151200, 54868156400, 
54868231600, 54868260600, 54868270100, 54868377200, 
54868386300, 54868394800, 54868409300, 54868423900, 
54868436900, 54868453800, 54868459000, 54868460700, 
54868473000, 54868473100, 54868474200, 54868474500, 
54868475400, 54868477600, 54868481400, 54868482800, 
54868485100, 54868486000, 54868491100, 54868502800, 
54868528600, 54868532600, 54868535600, 54868582600, 
54868582800, 54868594200, 55045283902, 55045348506, 
55045349701, 55045349801, 55045378106, 55045378206, 
55045378302, 55289024708, 55289088704, 55887005228, 
55887028628, 58016474701, 58016482701, 66993061128, 
66993061528, 68180084313, 68180084413, 68180084613, 
68180084813, 68180085413, 68180087611, 68180087613, 
68180089713, 68180089813, 68180090213, 68462030329, 
68462030529, 68462030929, 68462031629, 68462031829, 
68462038829, 68462039429, 68462055629, 68462056529 





NDC: 00062192001, 00062192015, 00062192024, 








Clinical Codes Data Source 

















NDC: 00027013160, 00027013180, 00062330100, 
00062330200, 00062330300, 00062330400, 00062330500, 
00062330600, 00062330700, 00062330800, 00062330900, 
00062331000, 00062331100, 00062331200, 00062331300, 
00062334100, 00062334200, 00062334300, 00062334400, 
00062334500, 00062334600, 00062334700, 00062334800, 
00062334900, 00062335000, 00062335100, 00062335200, 
00062338100, 00062338200, 00062338300, 00062338400, 
00062338500, 00062338600, 00062338700, 00062338800, 
00062338900, 00062364103, 00062364300, 00234005100, 
00234013100, 00234013150, 00234013155, 00234013160, 
00234013165, 00234013170, 00234013175, 00234013180, 
00234013185, 00234013190, 00234013195, 00234013600, 
00234013660, 00234013665, 00234013670, 00234013675, 
00234013680, 00234013685, 00234013690, 00234013695, 





Primary Independent Variable: Opioid Use During Pregnancy 
The primary independent variable of opioid use during pregnancy was examined as a 
categorical variable with four mutually exclusive categories: no opioid use during pregnancy, 
non-chronic prescription opioid use, chronic prescription opioid use, and OUD diagnosis or 
Buprenorphine prescription during pregnancy (OUD/Buprenorphine category).  Women with 
multiple forms of opioid use during pregnancy were assigned to the highest degree of opioid use 
indicated (from lowest to highest degree of use: non-chronic opioid use, chronic opioid use, 
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OUD/Buprenorphine).  For instance, if a woman had an OUD diagnosis during pregnancy as 
well as a claim for prescription opioids (chronic or non-chronic use), she was assigned to the 
OUD/Buprenorphine category.                
Women who used opioids during pregnancy were identified using a multipronged 
methodology. This approach accounts for the many forms opioid use during pregnancy can take 
as well as the variable time points during pregnancy and delivery when opioid use may be 
identified.  Women were classified as having used opioids during pregnancy if any of the 
following diagnostic, procedure, or prescription codes were present over the course of their 
pregnancy: diagnosis of OUD, prescription for medication assisted therapy (MAT) (i.e. 
buprenorphine, excluding transdermal buprenorphine, or naltrexone), chronic prescription opioid 
use based on definitions used in prior literature, or non-chronic prescription opioid use [6, 11, 
12].  A diagnosis of OUD was identified using ICD-9/ICD-10 codes present during any 
outpatient or inpatient encounter during pregnancy or at the time of delivery.  The codes are 
consistent with prior literature as well as ACOG recommended coding for substance use during 
pregnancy and the postpartum period [13-16].   
Women being treated for OUD with MAT were identified using outpatient 
pharmaceutical claims containing prescriptions for buprenorphine and naltrexone.  However, 
because naltrexone is not approved for use in pregnant women, it is not commonly provided as a 
first line treatment for OUD in pregnant women [17].  Both buprenorphine and naltrexone 
prescriptions were identified using National Drug Codes (NDC).  These codes, along with the 
NCD’s for other prescription opiates, were obtained from a publicly available list of all opioids 
and opioid replacement therapy drugs currently available on the market [18] compiled by the 
CDC and National Center for Injury Prevention and Control.  Although methadone is also 
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commonly used to treat OUD during pregnancy, ongoing restrictions involving the 
administration and prescribing of methadone to treat OUD meant it is not captured in private 
claims data.   
Prior studies indicate that approximately 50-60% of pregnant women with OUD receive 
MAT in the form of methadone or buprenorphine; however, these studies are largely confined to 
Medicaid populations or women enrolled in clinical trials [19-21].  The results of a study 
evaluating MAT use among pregnant women diagnosed with OUD based on Pennsylvania 
Medicaid claims from 2009-2015 indicated that 27.1% of women received buprenorphine and 
28.8% received methadone.  Over the study period, buprenorphine use increased significantly 
from 15.8% in 2009 to 30.9% in 2015, with a concurrent, but smaller decline in methadone [20].  
While there is no published data regarding the type of medication or trends in MAT among the 
privately insured pregnant population, the trend towards increased use of Buprenorphine since 
2009 observed in Medicaid populations is likely reflected in the privately insured population as 
well.           
Several studies have identified chronic or persistent opioid use during pregnancy using 
insurance claims data [6, 11, 22-24].  Using these studies as a guide, chronic prescription opioid 
use during pregnancy was defined as 30 or more days of cumulative prescription opioid 
availability during pregnancy by summing across all filled prescriptions, under the assumption 
that multiple prescriptions filled on the same date were taken concurrently [6, 11].  Opioid 
prescriptions, except those for buprenorphine or naltrexone, that occurred on the day of delivery 
were excluded as these are likely associated with cesarean delivery or other postpartum pain 
control and would not be considered opioid use during pregnancy.  The following prescription 
opioids were considered when identifying chronic prescription opioid use during pregnancy: 
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hydrocodone, codeine, dihydrocodeine, levorphanol, nalbuphine, opioid alkaloids, oxycodone, 
propoxyphene, tramadol, meperidine, hydromorphone, morphine, fentanyl, butorphanol, 
methadone, pentazocine, tapentadol, and oxymorphone [23, 25].   
The NDC’s used to identify each type of opioid were obtained from the CDC and 
National Center for Injury Prevention and Control [18]. Methadone, for the treatment of OUD, is 
rarely captured in pharmaceutical insurance claims, but it is occasionally prescribed as an 
analgesic in patients who do not have OUD; therefore, prescription claims for methadone were 
used for identifying women with non-chronic and chronic prescription opioid use [25].  Non-
chronic prescription opioid users during pregnancy were defined as women who filled an opioid 
prescription during pregnancy but did not meet the duration criteria for chronic opioid use.  
Prescription records with an improbable number of pills dispensed (>1,000) or days of supply 
(>180 days or ≤0 days) were excluded as they are likely in error; this approach is consistent with 
previous studies [23, 26].  In total, 1,221 prescription opioid claims records (0.4%) were dropped 
because of improbable days’ supply.     
 Co-Morbidities During Pregnancy  
Based on prior research, several morbidities were identified for inclusion in this research 
[5, 6, 13, 27-29].  These morbidities include pain-related conditions as well as common pre-
existing and pregnancy-associated conditions.  These comorbidities were selected to adjust for 
the a priori hypothesis that women with chronic and non-chronic prescription opioid use during 
pregnancy are also more likely to experience co-morbidities during pregnancy, particularly co-
morbidities associated with pain.  Furthermore, experiencing comorbidities during pregnancy is 
also related to postpartum contraception, particularly method type.  Therefore, the inclusion of 
these co-morbidities strengthens the results and conclusions drawn from this analysis by 
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adjusting for the potential confounding effects of these co-morbidities on the association between 
opioid use during pregnancy and provision of postpartum prescription contraception.       
Pain-related conditions included lower back pain, headache, fibromyalgia, arthritis, and 
neuropathic pain.  These pain conditions and the associated diagnostic codes were identified by a 
group of researchers and clinicians at the Johns Hopkins School of Public Health who specialize 
in chronic pain and opioid prescribing [30].  Inclusion of these conditions is consistent with 
findings from the literature documenting the most common maternal conditions for which 
opioids may be prescribed during pregnancy [5, 6, 28, 29].  Both inpatient admissions and 
outpatient services claims were searched for the ICD-9-CM and ICD-10-CM codes associated 
with each pain-condition.  A woman was considered to have a pain-related condition if two or 
more outpatient diagnosis codes or one or more inpatient diagnosis codes for any included 
condition was present during her pregnancy or at the time of delivery. 
The other significant pre-existing and pregnancy-associated conditions included in the 
analysis were chronic hypertension, gestational hypertension, including pre-eclampsia and 
eclampsia, diabetes mellitus, gestational diabetes, asthma, and autoimmune disorders.  Each 
condition was included in the models as a binary variable.  Women were considered to have a 
pre-existing or pregnancy-associated condition if one of the associated ICD-9-CM or ICD-10-
CM diagnostic codes was observed in an outpatient or inpatient record during pregnancy or at 
the time of delivery. These conditions are some of the most common co-morbidities among 
pregnant women in the US and have been included in prior research examining similar 
populations [13, 27].  The presence of co-morbidities during pregnancy can influence both 
opioid prescribing and postpartum contraception, particularly method type.  Prior studies 
demonstrate that women with comorbidities such as chronic hypertension, diabetes, and pain 
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conditions are more likely to use opioids during pregnancy [6, 31].  Study results have also found 
that women with medically complex or high-risk pregnancies are more likely to choose 
sterilization or LARC for postpartum contraception than women with low-risk pregnancies [10].  
There are also important contraindications for some methods of contraception in the postpartum 
period.  Women with hypertension or those at high risk for venous thromboembolism should not 
use combined hormonal contraception in the postpartum period [9].  Hepatitis C was also 
included in descriptive tables as women who use opioid during pregnancy are known to 
experience significantly higher rates of hepatitis C infection during pregnancy [32].      
Maternal Psychiatric Diagnosis 
Maternal psychiatric conditions are an important covariable as psychiatric disorders and 
substance use in women are highly correlated [29, 33, 34].  Pre-existing psychiatric conditions 
are also associated with contraceptive method type, with women with psychiatric conditions 
more likely to use highly effective forms of contraception such as LARCs or sterilization [33, 
35].  For this research, psychiatric conditions included major depressive disorder, bipolar 
disorder, schizophrenia, post-traumatic stress disorder, and generalized anxiety disorder.  Based 
on prior literature, a woman was considered to have a psychiatric condition if two or more 
outpatient diagnosis codes or one or more inpatient diagnosis codes for any psychiatric condition 
was present during her pregnancy or at the time of delivery [14, 33, 36].  The full list of ICD-9 
and ICD-10 diagnostic codes can be found in Appendix A.           
Non-Opioid Substance Use Disorder 
Non-opioid substance use disorders (SUDs) during pregnancy or at the time of delivery 
included diagnoses related to cocaine, cannabis, amphetamine, hallucinogen, alcohol, and other 
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substance dependence or use.  Non-opioid SUDs were identified using outpatient services and 
inpatient admissions claims data.  A woman was considered to have a non-opioid SUD if any 
non-opioid SUD diagnostic codes was present on an outpatient services or inpatient admissions 
claim during pregnancy or at the time of delivery.  The full range of ICD-9 and ICD-10 
diagnostic codes used to identify non-opioid SUDs during pregnancy are noted in Appendix A.     
Antenatal Care 
An antenatal care (ANC) visit indicator was defined as any professional claim taking 
place between the LMP date and the delivery date at a medical office or outpatient hospital 
location (place of service =11 or 22) with one of the following specialists: obstetrics & 
gynecology, certified nurse midwife, gynecologist, family practice, family practice OB/Gyn, 
certified nurse midwife, maternal and fetal medicine, nurse practitioner, or perinatology [37].  
These specialists were identified using a provider type code in the MarketScan database.  The 
ANC variable was a binary measure of any ANC verses no indication of ANC.  This binary 
definition, rather than the timing of a first visit, was necessary because a common timeframe for 
pregnancy was applied to each woman.  By applying a standard length of pregnancy (273 days), 
a more nuanced measure of ANC, such as measuring ANC by the trimester of initiation, would 
be inaccurate and correlated with preterm birth because women who delivered preterm would 
appear to have initiated ANC later in pregnancy.  
Postpartum Care Visit 
The variable indicating whether a woman had a postpartum care visit within the first 60 
day postpartum was identified using methods previously established in the literature [14, 37].  
Prior research indicates that when a woman has a routine postpartum care visit, her odds of using 
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a prescription form of postpartum contraception increases by 50% [38].  For this research, a 
woman was considered to have a postpartum care visit if she had an outpatient services claim 
within 60 days of delivery and if the visit took place in a medical office or outpatient hospital 
location (place of service code “11” or “22”) and either included a postpartum care diagnosis 
code (ICD-9 codes: V24.1, V24.2/ICD-10 codes: Z39.1, Z.39.2) or the service provider was a 
specialist in one of the following: obstetrics & gynecology, certified nurse midwife, 
gynecologist, family practice, family practice OB/Gyn, certified nurse midwife, maternal and 
fetal medicine, nurse practitioner, or perinatology [37].   
Infant Variables 
Infant related variables, including NICU admission, NAS diagnosis, and hospital length 
of stay, were extracted from the inpatient admissions and inpatient services claims data 
associated with the infant delivery.  These variables were used for the Aim 3 analysis. The 
revenue codes “0174” and “0175” in the inpatient services claims data were used to identify 
infants admitted to the NICU and a binary, yes/no variable was created based on the presence or 
absence of the codes.  NAS diagnosis in the infant was identify using select ICD-9/ICD-10 
diagnosis codes previously validated in the literature [19, 39].  A 2019 study examined the 
positive predictive value (PPV) of the following ICD-9/ICD-10 codes in administrative data for 
identifying clinically confirmed NAS cases: 779.5, 760.72 (ICD-9), P96.1, P04.49 (ICD-10) and 
reported a positive predictive value of 91% and 98% for the associated ICD-9 and ICD-10 codes, 
respectively [39].   
 Once an infant was identified with a diagnosis of NAS, further refinement was done by 
eliminating infants with probable iatrogenic NAS.  Iatrogenically-induced NAS is fundamentally 
different from NAS caused by antenatal exposure to opioids because iatrogenic NAS is induced 
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by opioid analgesics provided to the infant while under clinical management during an inpatient 
admission; therefore, it was crucial to correctly categorize type of NAS diagnosis.  Because 
iatrogenically-induced NAS does not have a unique diagnosis code, previously identified clinical 
diagnosis codes associated with iatrogenically-induced NAS were used to identify probable 
cases, as in prior research [40].  Infants were considered to have iatrogenic NAS if they also had 
a diagnosis of very low birthweight (IDC-9/ICD-10 codes V21.31, V21.32/P07.00, P07.02, 
P07.01, P07.03), intraventricular hemorrhage (ICD 9/ICD-10 codes 772.10, 772.12, 772.14, 
772.11, 772.13/P52.3, P52.1, P52.22, P52.0, P52.21), periventricular leukomalacia (ICD 9/ICD-
10 codes 779.7/P91.2), necrotizing enterocolitis (ICD 9/ICD-10 codes 777.51, 777.52, 777.53, 
777.50/P77.9, P77.3, P77.2, P77.1), spontaneous intestinal perforation (ICD 9/ICD-10 codes 
777.6/P78.0), or bronchopulmonary dysplasia (ICD 9/ICD-10 codes 770.7/P27.0, P27.1, P27.8) 
[40].   Of the initial 860 NAS diagnoses, only 8 (>0.1%) were classified as probable iatrogenic 
NAS.  The remaining 852 cases were considered to have NAS due to antenatal opioid exposure.  
NAS diagnosis in the infant was a binary variable in the Aim 3 analyses and was used to explore 
whether opioid-related sequalae in the infant affected postpartum contraception provision among 
women who use opioids during pregnancy.    
The final infant variable in the Aim 3 analysis was length of hospital stay, as measured in 
days.  This variable was taken directly from the inpatient admission records associated with the 
infant’s birth.  It was measured as both a continuous variable and a binary measure of a length of 
stay of seven days or longer. In order to retain the maximum amount of detail concerning the 
impact of hospital length of stay on postpartum prescription contraception, the continuous 




All remaining covariates including demographic and clinical variables were extracted 
from the delivery record.  The mode of delivery was coded as a binary variable, whether a 
woman delivered vaginally or via cesarean-section.  It was identified using ICD-9/10 diagnosis 
and procedure codes, used previously in the literature, that were present in the inpatient 
admission claims data at the time of delivery (See Appendix A) [41, 42].   
Several other variables were obtained from the delivery record, including maternal age at 
delivery, insurance plan type, year of delivery, and state of delivery.  Maternal age at delivery 
was coded as a categorical variable, with categories for <20, 20-24, 25-29, 30-34, 35-40, and 40 
years or older.  Insurance plan type was defined based on the health insurance plan type at the 
time of delivery.  The categories included: comprehensive, preferred provider organization 
(PPO), HMO and EPO, Point-of-Service (including capitation), consumer-driven health plan 
(CDHP), and high deductible health plans (HDHP).  Type of insurance plan was included based 
on the hypothesis that women with more health needs, including those with substance use 
disorders or other chronic conditions, may choose more expansive insurance coverage, such as 
comprehensive plans.  Furthermore, insurance plans with more comprehensive coverage may 
increase contraceptive uptake if woman face fewer financial and administrative obstacles to 
obtaining postpartum contraception.  Insurance plan type had a low level of missingness (~3.0% 
in Aims 1-3).  Rather than exclude these observations, a sixth category for “unknown insurance 
plan type” was included in the plan type variable.   Indicator variables were included for the year 
of delivery (2011-2017) in order to account for secular trends in opioid use and medical practice, 
such as increasing postpartum LARC provision over the study period.  Finally, the state in which 




The MarketScan data includes limited demographic variables except for those noted 
above; accordingly, state of delivery was used to create additional measures to characterize the 
study cohort.  A region variable, modeled on the ten regions designated by the Health Resources 
and Services Administration (HRSA), was created based on the state in which the delivery took 
place (see Figure 3.4).  The states grouped into each region share demographic and clinical 
characteristics, particularly in relation to provision and access to medical care.  Prior literature 
has documented significant regional differences in opioid use during pregnancy, contraceptive 
provision overall and by method type, maternal demographic characteristics, and obstetric 
practices, making these geographic groupings an important adjustment variable [43-49].  A small 
percentage of observations (~3.0%) were missing state-level information and were placed in an 
“unknown” category but still included in all analyses.  The MarketScan database also includes a 
region variable based on one of five Census regions: Northeast, North Central, South, West, and 
Unknown.  This variable was explored in conjunction with the HRSA region variable as the 
HRSA regions provide more detail, but the Census regions allow for a more parsimonious 
model.   
Beyond the HRSA and Census regional variables, demographic information including 
measures related to the racial composition, female educational attainment, and household income 
for the state in which the delivery took place were also included in the model.  Indicator 
variables were defined as “1” if a state had the characteristic of interest and a “0”, otherwise.  
The state-level characteristics were: 20% or more of the population identified as Hispanic; 20% 
or more of the population identified as Black; 15% or more of the population lived below the 
poverty threshold as defined by the US Census Bureau [50]; and 35% or more of females aged 
18 and older have a college degree or higher (Table 3.4).  For example, for a delivery taking 
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place in Mississippi, the state-level indicator variable for Black race and high poverty, take a 
value of “1” within the model.  All state-level demographic data estimates were obtained from 
the 2013-2017 American Community Survey 5-Year Estimates [51].       
Figure 3.4 Map of HRSA Regions 
 
Source: Health Resources and Services Administration.  
Table 3.4 States Included in State-Level Demographics Indicator Variables 
Indicator Variable States Meeting Indicator Variable Criteria 
States in which 20% or more of the 
population identifies as Hispanic 
Arizona, California, Colorado, Florida, 
Nevada, New Jersey, New Mexico, Puerto 
Rico, Texas 
States in which 20% or more of the 
population identifies as Black 
Alabama, Delaware, District of Columbia 
(D.C.), Georgia, Louisiana, Maryland, 
Mississippi, North Carolina, South Carolina 
States in which 15% or more of the 
population lives at or below the poverty 
threshold 
Alabama, Arkansas, District of Columbia 
(D.C.), Kentucky, Louisiana, Mississippi, 
New Mexico, Oklahoma, Puerto Rico, South 
Carolina, Tennessee, West Virginia 
States in which 35% or more of women, aged 
18 and older, have college degrees or higher 
District of Columbia (D.C.), Massachusetts, 
Maryland, Colorado, Vermont, Connecticut, 




3.7 Cohort Creation & Analytic Sample 
Once the index delivery records were identified, date of delivery was assumed to be the 
date of admission for delivery plus one day.  From there, the start date of the last menstrual 
period (LMP) was estimated as 273 days prior to the date of delivery.  For the postpartum period, 
the immediate postpartum timeframe was calculated by adding three days to the date of delivery, 
and the second postpartum period by adding 60 days to the date of delivery.  These timeframes 
(LMP to delivery, delivery through the postpartum period) established the time period for which 
continuous enrollment was required for Aims 1 and 3 and served as the timeframe for restricting 
the relevant claims data.  The relevant time period for Aim 2 extended to a maximum of 365 
days postpartum.  The inpatient admissions claim associated with the index delivery and the 
calculated pregnancy and postpartum dates were retained in a single, master file referred to as the 
“index delivery file”.  The index delivery file was used as the building block for the creation of 
the analytic cohorts.    
With the relevant timeframe for each index delivery established, the next step in creating 
the cohort involved running all appropriate diagnostic, procedure, and drug codes associated with 
each described variable in the respective claims data (see Table 3.1 for more detail).  Claims that 
occurred prior to the start of pregnancy or after the specified postpartum period were excluded.  
After identifying all the relevant claims during the appropriate time period, an indicator variable 
or an otherwise simplified value for each variable was merged back into the master index 
delivery file, signifying whether a woman experienced the variable of interest during pregnancy, 
delivery, or in the postpartum period, respectively.   
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Information regarding postpartum contraception was integrated into the data for the 
cohort using several variables.  First, simple indicators of any evidence of contraceptive 
provision during the 3-day postpartum period, 60-day postpartum period, and 365-day 
postpartum period were integrated.  Secondly, variables reflecting the type of contraception were 
included.  The date of the first instance of contraceptive provision within the first 365 days 
postpartum was included as this variable was necessary for the Aim 2 analysis.  In the Aim 3 
analysis, infant variables were merged into the analytic cohort file for women who were 
successfully linked with an infant and had evidence of opioid use during pregnancy.  The final 
variable merged into the index delivery file was annual enrollment information.  All index 
deliveries, regardless of meeting the continuous enrollment criteria were retained for sensitivity 
analyses.  Indicator variables were used to denote women who maintained continuous coverage 
for the duration of pregnancy and for at least the first 60-days postpartum.  Table 3.5 provides a 
listing of all covariates for Aims 1-3, as well as their associated coding.  All variables reaching 
statistical significance of p≤0.05 in the bivariate analyses or those thought to be confounders or 
important predictors of postpartum contraception were included in the adjusted models.    
Table 3.5 Covariates and Coding by Research Aim 
Aim Variable Values 
1, 3 Any postpartum prescription contraceptive 
Provision within 60 days postpartum (outcome) 
No provision (ref.) 
Provision 
1 Any postpartum prescription contraceptive 
Provision within 60 days postpartum, by method 
type (outcome) 




2 Any postpartum prescription contraceptive 
Provision within 365 days postpartum (outcome) 
No provision (ref.) 
Provision 
1, 2 Opioid use during pregnancy No Use (ref.) 
Non-chronic prescription use 




Aim Variable Values 
3 Opioid use during pregnancy Non-chronic prescription use 
(ref.) 
Chronic prescription use 
OUD/Buprenorphine 






1, 2, 3 Mode of delivery Vaginal (ref.) 
Cesarean  
1, 3 Year of delivery Indicator variable for 2011-
2017 
2 Year of delivery Indicator variable for 2011-
2016 
1, 2, 3 HRSA Region 10 Region categories 
Region 3 (ref.) 
1, 2, 3 State of delivery: 20% or more Hispanic No (ref.) 
Gave birth in state meeting 
criteria 
1, 2, 3 State of delivery: 20% or more Black No (ref.) 
Gave birth in state meeting 
criteria 
1, 2, 3 State of delivery: 15% or more living in poverty No (ref.) 
Gave birth in state meeting 
criteria 
1, 2, 3 State of delivery: 35% or more of females with 
college or higher education 
No (ref.) 
Gave birth in state meeting 
criteria 







1, 2, 3 Non-Opioid Substance Use Disorder No (ref.)  
Yes 
1, 2, 3 Psychiatric Conditions No (ref.)  
Yes 
1, 2, 3 Pain Conditions No (ref.)  
Yes 




Aim Variable Values 
1, 2, 3 Gestational Hypertension No (ref.)  
Yes 
1, 2, 3 Diabetes Mellitus No (ref.)  
Yes 
1, 2, 3 Gestational Diabetes No (ref.)  
Yes 
1, 2, 3 Asthma No (ref.)  
Yes 
1, 2, 3 Autoimmune Disorder No (ref.)  
Yes 
1, 2, 3 Hepatitis C No (ref.) 
Yes 
1, 2, 3 Any ANC No 
Yes (ref.) 
1, 3 Postpartum clinical visit within 60 days  No visit (ref.) 
Visit 
3 Infant NAS diagnosis No (ref.) 
Yes 
3 Infant NICU admission No (ref.) 
Yes 
3 Infant hospital length of stay Continuous measure (days) 
   
3.8 Data Analysis 
Aim 1: Methods for Data Analysis 
Aim 1 evaluated the association between type of opioid use during pregnancy and 
postpartum prescription contraceptive provision, both overall and by contraceptive method-type 
at 60 days postpartum.  The Aim 1 cohort included women with a livebirth with continuous health 
and pharmaceutical insurance coverage for the duration of pregnancy and through the first 60 days 
postpartum.  Descriptive analyses were conducted to summarize the distribution of characteristics 
in the study cohort, both overall and stratified by opioid use and type as well an contraceptive 
method.  Next, unadjusted and adjusted multivariable and multinomial logistic regression models 
were used to assess the relationship between opioid use during pregnancy and prescription 
contraception provision at 60 days postpartum.   
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Analysis began by examining the distribution of all variables in the Aim 1 cohort,  
including the distribution of maternal age at delivery, year of delivery, HRSA region, state-level 
demographic characteristics, insurance plan type, mode of delivery, type of opioid use during 
pregnancy, psychiatric conditions, non-opioid substance use disorders, pain conditions, chronic 
hypertension, gestational hypertension, diabetes mellitus, gestational diabetes, asthma, 
autoimmune disorders, hepatitis C, any ANC, and postpartum clinical visit within 60 days 
postpartum.  The descriptive analyses also included examining the Aim 1 cohort by provision of 
contraception at 60 days postpartum, at three days postpartum, stratified by opioid use status 
during pregnancy and the covariates.  These descriptive analyses helped illuminate important 
differences within the cohort by type of contraceptive method and by type of opioid use during 
pregnancy.  Significant changes in trends over time for the number of livebirths and provision of 
prescription contraception were assessed using the “nptrend” command in Stata, which performs 
a nonparametric test for trend across ordered groups.  In this instance, the ordered groups are the 
years included in the study period (2011-2017). 
Next, bivariate logistic regression analyses were conducted to evaluate the unadjusted 
relationship between contraception provision and select covariates.  The variables included in the 
bivariate analyses were: maternal age at delivery, year of delivery, HRSA region, state-level 
demographic characteristics, insurance plan type, mode of delivery, type of opioid use during 
pregnancy, psychiatric conditions, non-opioid substance use disorders, pain conditions, chronic 
hypertension, gestational hypertension, diabetes mellitus, gestational diabetes, asthma, 
autoimmune disorders, hepatitis C, any ANC, and postpartum clinical visit within 60 days 
postpartum (Table 3.5).   
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Based on the results of the bivariate analyses and a priori hypotheses, a multivariable 
logistic model was fit to evaluate the adjusted odds ratios and 95% confidence intervals for the 
association between opioid use during pregnancy and postpartum contraceptive provision.  An 
example is shown below of the multivariable model and interpretations of each component:     




A similar analysis, using a multinomial logistic regression model, was conducted for 
evaluating differences in the relative risk ratio (RRR) of provision of each type of contraceptive 
method relative to no provision.  This analysis examined differences in the RRR of sterilization, 
LARC, or MEM, relative to no provision of a prescription contraceptive method.  Contraceptive 
method-type grouping was based on the NQF recommended measures with moderately effective 
methods consisting of the pill, patch, ring, DMPA, and diaphragm and LARCs consisting of the 
IUD, and implant [3].  The base category for the multinomial model outcome was “no provision 
of a prescription method”.  The equations used to estimate the multinomial model are shown 
below, with each equation evaluating the RRR of a given contraceptive method relative to no 
provision of prescription contraception:  
𝐿𝑜𝑔𝑂𝑑𝑑𝑠(𝑌𝑖)= log odds of provision of any postpartum prescription contraception within 60 days 
following delivery for the ith woman 
β0= log odds of postpartum contraceptive provision for a woman with all covariates set to 0  
X1i = type of opioid use during pregnancy for the ith woman 
β1= change in log odds of provision of postpartum contraception use within 60 days following delivery 
given her category of opioid use during pregnancy for the ith woman 
X2i…Xki = value of covariates for the ith woman 
β2…βk = change in log odds of the provision of postpartum contraception within 60 days following 

















) =  𝛽30 + 𝛽31𝑋31𝑖 + 𝛽32𝑋32𝑖 + ⋯ + 𝛽3𝐾𝑋3𝑘𝑖 
Where:  
 
 For both the multivariable logistic regression models and multinomial logistic regression 
models, model fit was assessed using AIC and BIC, with preference given to models with the 
lowest AIC and BIC [52]. All analyses were performed in Stata/MP-16 [53].      
Aim 2: Methods for Data Analysis 
The Aim 2 analysis examined time to first contraceptive provision within the first 365 
days postpartum comparing women who did and did not use opioids during pregnancy.  The 
analytic sample included women with a livebirth who maintained continuous health and 




)= relative risk ratio of sterilization within 60 days following 
delivery relative to no provision of prescription contraception the ith woman 
Β10= relative risk ratio of sterilization relative to no prescription contraception method within 
60 days following delivery for a woman with all covariates set to 0  
X11i = category of opioid use during pregnancy for the i
th woman  
β11= change in relative risk ratio of sterilization relative to using no prescription contraception 
within three days following delivery given maternal opioid use during pregnancy for the ith 
woman 
X12i…X1ki = value of covariates for the i
th woman 
β12…β1k = change in relative risk ratio of sterilization relative to using no prescription 




postpartum, up to 365 days.  Aim 2 involved a survival analysis, using Kaplan-Meier curves and 
Cox Proportional Hazards models.   
Exploratory analyses for Aim 2 were conducted to understand the distribution of 
variables by contraceptive provision, including by method type, and by type of opioid use during 
pregnancy.  Sensitivity analyses compared women included in the Aim 2 analysis with those 
who did not meet the inclusion criteria to identify any potential differences between the groups.  
Next, mean days to contraceptive provision and 95% confidence intervals were calculated for 
each covariate among women who received contraception within 365 days postpartum.  This 
analysis provided a crude estimate of the mean days to contraceptive provision by type of opioid 
use and all other covariates.  A fully adjusted analysis of mean days to contraceptive provision 
was also conducted by estimating the marginal means from an adjusted linear regression model.  
The linear regression model was adjusted for maternal age, HRSA region, state-level 
characteristics, insurance plan type, year of delivery, delivery mode, opioid use category, and 
chronic conditions.  The adjusted means days to contraceptive provision and accompanying 95% 
confidence intervals were reported by type of opioid use.  
The survival analysis began by generating Kaplan-Meier curves, including log rank tests, 
and log-log plots for each covariate of interest.  The Kaplan-Meier curves provide a visualization 
of the survival function for each categorical covariate and indicate whether the groups are 
proportional over the study period.  The log rank test, based on the Kaplan-Meier curve, is a non-
parametric test of the hypothesis that the survival curves among the covariate categories are 
equal, with a p-value<0.05 indicating that the survival across groups is different.  Log-log plots 
offer a similar visualization to the Kaplan-Meier curves; they are a natural log transformation of 
the estimated survival curve.   
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Bivariate Cox models were run for each covariate to assess the relationship between the 
covariate and risk of contraceptive provision.  Covariates reaching a significance of p<0.05 in the 
univariate models or those thought to be confounders or important predictors of postpartum 
contraception were included in the full Cox model.  Ties (e.g. two events occurring 
simultaneously in the data) in continuous time-to-event analyses can be problematic, therefore, 
Efron’s approximation was used to account for possible ties in the multivariable Cox model [54].  
After the full Cox model was run, the proportional hazards assumption was tested for each 
individual covariate based on the Schoenfeld residuals.  A global test of the proportional hazards 
assumption was also performed.  An example of the fully adjusted, Cox proportional hazards 
model and interpretations of each component is:    
𝜆(𝑡|𝑋) = 𝜆0(𝑡)𝑒
(𝛽1𝑋1+ 𝛽2𝑋2+⋯+𝛽𝑝𝑋𝑝)  
Where:  
 
An extensive sensitivity analysis was performed to assess the degree to which certain 
variables violated the proportional hazards assumption.   The sensitivity analysis involved 
running three fully adjusted cox models across three different postpartum time periods.  The first 
model covered the full postpartum period, delivery through 365 days postpartum and was 
equivalent to the full cox model presented for the final results.  The second model was restricted 
to the date of delivery through the first 60 days postpartum and assessed the risk of failure (e.g. 
provision of contraception) over the first 60 days.   The third model covered the timeframe of 61 
𝜆(𝑡|𝑋) = hazard of postpartum contraceptive provision at time t for a woman with a particular 
set of covariate values X 
𝜆0(𝑡) = baseline hazard of postpartum contraceptive provision at time t for a woman with all 
covariates equal to zero 
eβ1 = hazard ratio of postpartum contraceptive provision comparing women who use opioids 




days postpartum through 365 days postpartum and included women who had not experienced the 
outcome by 61 days postpartum and maintained continuous coverage up until that time.  The 
severity of the violation of proportional hazards was assessed by comparing the adjusted hazard 
ratios across all three models.  This analysis also highlighted important changes over time in the 
hazard of contraceptive provision over the first year postpartum.        
A competing-risk model was considered for the Aim 2 analysis to account for the 
competing risk of a pregnancy during the postpartum period.  Competing-risk in survival 
analysis is defined as an event that either impedes or modifies the chances of observing the event 
of interest, in this case, postpartum contraception provision.  Experiencing a pregnancy during 
the postpartum period is a competing risk for postpartum contraception use as the need for 
contraception is eliminated if a pregnancy occurs.  Only 1.15% (n=14,571) of the Aim 2 cohort 
had evidence of a subsequent pregnancy during the postpartum follow up period, as defined by 
the presence of an ANC visit.  Based on the low proportion of women with evidence of a 
pregnancy during the postpartum period, a competing-risk model was not necessary.                       
Aim 3: Methods for Data Analysis 
Aim 3 assessed the relationship between infant outcomes and postpartum prescription 
contraception provision among women with evidence of opioid use during pregnancy. The Aim 
3 sample was based on women included in the Aim 1 analysis with the additional inclusion 
criteria of opioid use during pregnancy and successful linkage with an infant record.  It was 
restricted to women with evidence of opioid use during pregnancy who were successfully linked 
with an infant record and maintained continuous health and pharmaceutical insurance coverage 
for the duration of pregnancy and through the first 60 days postpartum. Initial exploratory 
analysis was conducted comparing the distribution of characteristics between the women 
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successfully linked with an infant record, those who were not linked, and the full cohort of 
women with evidence of opioid use during pregnancy from Aim 1.  This analysis served as both 
a sensitivity analysis and an exploration of potential differences between the two groups.  Further 
sensitivity analysis was performed to better understand potential selection bias in the Aim 3 
cohort; this analysis is explained in detail at the end of this section.    
Descriptive statistics were performed for the Aim 3 cohort, including characterizing 
provision of contraception within 60 days postpartum by the covariates.  Several exploratory 
analyses focused on the infant-related variables including examining type of opioid use during 
pregnancy by NAS status in the infant; contraceptive method provision by NAS status in the 
infant and by NICU admission; and average infant hospital length of stay by type of 
contraceptive provision.  Each infant-focused descriptive analysis provided insight into how 
infant outcomes may relate to postpartum contraceptive provision.    
Bivariate associations of the infant-related variables and covariates with contraceptive 
provision within 60 days postpartum were conducted using logistic regression.  A fully adjusted 
logistic regression model was fit including all independent variables that reached a significance 
level of p<0.05 in the bivariate models and variables with a theoretical or established relationship 
with postpartum contraception.  Model fit and selection was based on both AIC and BIC, with 
preference given to models with the lowest AIC and BIC [52].  An example of the fully adjusted, 
multivariable model and interpretations of each component is shown here:     




    
Further exploration of potential selection bias was warranted for the Aim 3 cohort 
because of significant differences between the women successfully linked to an infant record 
compared to those who were not.  This analysis involved calculating the relative odds ratio 
(ROR), a method used to quantify the magnitude and direction of selection bias in cohort studies 
[55-57]. The ROR is calculated by dividing the crude odds ratios from the subpopulation by the 
crude odds ratio in the source population.  In this sensitivity analysis, women who used opioids 
during pregnancy in the Aim 1 cohort served as the source population and women included in the 
Aim 3 analysis were the subpopulation.  The crude odds ratio used for the ROR analysis was the 
odds of contraceptive provision among women with OUD/Bup compared to the odds of 
provision among women with non-chronic prescription opioid use, as women with non-chronic 
prescription opioid use were the reference group in the Aim 3 analysis.  An ROR equal to 1 
indicates there is no differential selection bias because the ORs from the source and 
subpopulation are equivalent; however, an ROR>1 indicates an overestimation of the true 
association between the exposure and outcome of interest in the subpopulation; an ROR<1 
indicates an underestimation.    
Figure 3.5 Method for Calculating Relative Odds Ratio for Aim 3 Sensitivity Analysis 
Opioid Use Category Provided Contraception Not Contraceptive Provision 
𝐿𝑜𝑔𝑂𝑑𝑑𝑠(𝑌𝑖)= log odds of provision of any postpartum prescription contraception within 60 
days following delivery for the ith woman 
β0= log odds of postpartum contraceptive provision for a woman with all covariates set to 0  
X1i = type of opioid use during pregnancy for the i
th woman 
β1= change in log odds of provision of postpartum contraception use within 60 days following 
delivery given her category of opioid use during pregnancy for the ith woman 
X2i…Xki = value of covariates for the i
th woman 
β2…βk = change in log odds of the provision of postpartum contraception within 60 days 
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(𝑎 ∗ 𝑑)/(𝑏 ∗ 𝑐)
(𝐴 ∗ 𝐷)/(𝐵 ∗ 𝐶)⁄  = 
𝑂𝑅𝑎𝑖𝑚3
𝑂𝑅𝑎𝑖𝑚1
 = ROR 
3.9 Ethical Considerations 
This study was exempted by the Institutional Review Board at the Johns Hopkins 
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This chapter describes the findings for the three study aims: Aim 1) Evaluate the 
association between opioid use during pregnancy and prescription contraception provision by 60 
days postpartum, including by contraceptive method type; Aim 2) Evaluate the time to first 
prescription contraception provision during the postpartum period for women who did and did 
not use opioids during pregnancy, including by type of opioid; and Aim 3) Assess if adverse 
newborn outcomes are associated with provision of prescription contraception within 60 days 
postpartum among women who used opioids during pregnancy.  
This chapter opens with a description of the analytic cohorts for Aims 1 and 2.  Next, the 
aim-specific results are presented beginning with descriptive statistics specific to opioid use 
during pregnancy followed by descriptive statistics for contraceptive provision.  Bivariate and 
main multivariable model results are then presented, including any sensitivity analyses.  The 
Aim 3 results, including a description of the analytic cohort are presented at the end of the 
chapter, because the Aim 3 cohort was substantively different from Aims 1 and 2.  The chapter 
closes with a brief summary of the study results.        
4.2 Study Sample Characteristics 
Table 4.1 shows the descriptive characteristics of the analytic cohorts for Aims 1 and 2.  
Across both Aims, the majority of live births were to women ages 30-34 and who lived in HRSA 
Region’s 4 and 5 which primarily include states in the South and Midwest.  Approximately 3.0% 
of livebirths were to women with unknown geographic region.  Most women were insured 
through a PPO plan type.  Clinically, 65% of women had a vaginal delivery and the most 
common comorbidity experienced during pregnancy was gestational diabetes.  As anticipated, 
the cohorts for Aims 1 and 2 were very similar in size and distribution of covariates.   
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The average age of delivery was the same for Aims 1 and 2, as was the age distribution.  
The largest percentage of births was in Region 4, consisting of states in the South, and the 
overall distribution of births across HRSA region was similar for both Aims.  The prevalence of 
comorbidities was nearly identical for Aims 1 and 2, except for pain conditions which had a 
slightly higher prevalence in the Aim 1 cohort (8.3% vs 7.7%).  Finally, postpartum 
contraception provision in the Aim 2 sample was higher overall compared to Aim 1 because of 
the longer postpartum time period examined in Aim 2.       
Table 4.1 Descriptive Characteristics of Aims 1 and 2, Column Totals 
 Aim 1 Cohort Aim 2 Cohort 
Total N 1,291,352 1,270,832 
Opioid Use During Pregnancy   
No Opioid Use 90.4% (1,167,228) 89.9% (1,142,590) 
Non-Chronic Prescription Use 8.5% (109,622) 8.9% (113,273) 
Chronic Prescription Use 0.7% (9,347) 0.8% (9,838) 
OUD Diagnosis/Bup Prescription 0.4% (5,155) 0.4% (5,127) 
Contraceptive provision within 60 
Days Postpartum 
 N/A 
No Provision 62.4% (806,103)  
Evidence of Provision 37.6% (485,249)  
Sterilization 6.1% (79,130)  
LARC 7.0% (90,391)  
Moderately Effective Methods 24.5% (315,728)  
Any contraceptive provision within 
365 days of delivery 
N/A  
No Provision  49.8% (632,814) 
Evidence of Provision  50.2% (638,018) 
Sterilization  6.6% (84,450) 
LARC  11.9% (150,776) 
Moderately Effective Methods  31.7% (402,792) 
Age, mean years (SD) 30.3 (5.5) 30.2 (5.5) 
Age, Categorical   
<20 2.9% (36,882) 2.9% (37,089) 
20-24 12.3% (159,196) 12.4% (158,131) 
25-29 27.6% (356,299) 27.9% (354,483) 
30-34 35.3% (455,415) 35.1% (445,584) 
35-39 17.6% (227,946) 17.4% (221,526) 
40+ 4.3% (55,614) 4.2% (54,019) 
HRSA Region   
Region 1 4.3% (55,782) 4.3% (55,254) 
Region 2 7.5% (97,282) 7.3% (93,385) 
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 Aim 1 Cohort Aim 2 Cohort 
Region 3 8.6% (111,514) 8.8% (111,322) 
Region 4 21.7% (280,470) 20.9% (265,460) 
Region 5 18.3% (236,920) 18.6% (236,731) 
Region 6 13.2% (170,845) 13.3% (169,643) 
Region 7 4.1% (52,726) 4.0% (51,232) 
Region 8 3.2% (41,104) 3.2% (40,969) 
Region 9 12.0% (155,183) 12.2% (154,906) 
Region 10 4.0% (51,831) 3.9% (50,210) 
Unknown 2.9% (37,695) 3.3% (41,720) 
Delivery in State with ≥20% Hispanic 
Population 
29.4% (380,268) 29.5% (374,670) 
Delivery in State with ≥20% Black 
Population 
16.6% (214,766) 15.9% (202,221) 
Delivery in State with ≥15% 
Population in Poverty 
13.5% (174,548) 13.1% (167,013) 
Delivery in State with ≥35% Women 
with College Degree or More 
10.1% (130,623) 10.0% (127,759) 
Insurance Plan Type   
PPO 59.4% (767,515) 60.2% (764,813) 
Comprehensive 1.0% (13,122) 0.9% (11,523) 
HMO/EPO 14.7% (189,842) 14.9% (189,815) 
POS/POS+Capitation 7.3% (94,444) 7.2% (92,110) 
CDHP 8.2% (105,445) 7.5% (95,381) 
HDHP 6.1% (78,302) 5.6% (71,385) 
Unknown 3.3% (42,682) 3.6% (45,805) 
Year of Delivery   
2011 20.9% (270,505) 22.2% (282,670) 
2012 20.1% (260,183) 22.3% (283,552) 
2013 15.0% (194,041) 16.2% (205,679) 
2014 14.1% (182,215) 15.8% (201,057) 
2015 11.2% (144,467) 11.9% (151,938) 
2016 10.6% (136,978) 11.5% (145,936) 
2017 8.0% (102,963) N/A 
Delivery Mode   
Vaginal 64.5% (832,323) 64.5% (819,145) 
Cesarean 35.5% (459,029) 35.5% (451,687) 
Non-Opioid Substance Use Disorder 1.4% (17,584) 1.3% (17,044) 
Any Psychiatric Diagnoses 5.5% (71,707) 5.5% (70,309) 
Chronic Hypertension 8.4% (108,503) 8.3% (105,662) 
Gestational Hypertension 12.1% (156,217) 12.1% (153,854) 
Diabetes Mellitus 4.2% (54,023) 4.2% (53,843) 
Gestational Diabetes 14.4% (186,290) 14.7% (187,131) 
Asthma 4.9% (62,718) 4.8% (60,791) 
Autoimmune Disease 1.9% (24,769) 1.9% (23,925) 
Pain Condition 8.3% (107,444) 7.7% (97,478) 
Hepatitis C 0.07% (948) 0.07% (870) 
Any ANC 96.8% (1,249,770) 96.6% (1,227,456) 
Postpartum Care Visit within 60 
Days 
45.1% (582,078) N/A 
N/A= Not applicable; indicates a variable that was not included in the research aim 
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The number of livebirths that met the inclusion criteria for Aims 1 and 2 decreased 
steadily over the study period.  The number decreased by 49% from 2011 to 2016, the last full 
year of births, from a high of 270,505 livebirths in 2011 to 136,978 in 2016 for the Aim 1 sample 
(p for trend<<0.001) (Figure 4.1).  A similar downward trend in the number of livebirths was 
observed for Aim 2.  Although researchers have not empirically confirmed the reason for the 
decrease, it is thought that the decline in the overall capture of the MarketScan database 
beginning in 2015 is due to an increasing number of people moving to the insurance exchange 
marketplace and away from employer-sponsored health insurance plans.  The MarketScan 
database only includes claims to people enrolled in employer-sponsored health insurance plans.  
The decline in livebirths may also be explained, in part, by the ongoing decline in US fertility 
rates beginning in 2015 [1].   
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 4.3 Aim 1 Results  
The primary independent variable in the Aim 1 analysis was opioid use during 
pregnancy.  Overall, 90.4% of women in the Aim 1 cohort had no evidence of opioid use during 
pregnancy.  Just over 8% of women had evidence of non-chronic prescription opioid use; 0.7% 
evidence of chronic prescription opioid use; and 0.4% had an OUD diagnosis or buprenorphine 
prescription (OUD/Bup) during pregnancy or at the time of delivery.  Opioid use during 
pregnancy, in any form, was highest in 2011 and steadily decreased each year thereafter (p for 
trend<<0.001) (Figure 4.2).   
Figure 4.2 Trends in Opioid Use During Pregnancy, Overall and By Opioid Type in Aim 1 
Cohort 
 
There were substantial differences in the characteristics of women by category of opioid 
use during pregnancy (Table 4.2).  The mean age of women in the OUD/Bup group was younger 
compared with other categories of use, including non-use.  Women in the oldest age group had 
the highest prevalence of chronic prescription opioid use; 1.2% of women aged 40 and older had 
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regions 4 and 6, comprised of states in the South and Southwest, had the highest overall levels of 
opioid use during pregnancy, largely due to high levels of non-chronic opioid use (>10.0%).  
Region 2, including New York, New Jersey, and Puerto Rico, had the lowest levels of opioid 
use, with just 5.6% of women having evidence of opioid use during pregnancy.  Women who 
delivered in states where 35% or more of the female population had at least a college degree had 
lower levels of opioid use than the overall Aim 1 cohort (7.8% vs. 9.6%).  There was little 
variation in opioid use during pregnancy across health insurance plan types.   
Women with a cesarean delivery were somewhat more likely to use opioids during 
pregnancy (11.8%) than women with a vaginal birth (8.4%).  Women with a non-opioid 
substance use disorder (SUD) were substantially more likely to use opioids across all categories 
of use, with a pronounced increase for chronic prescription and OUD/Bup use.  Women with a 
psychiatric diagnosis also had higher levels of opioid use across all categories than women who 
did not have a diagnosis.  Levels of non-chronic and chronic prescription opioid use were higher 
for women with all other comorbidities compared to women with no use; OUD/Bup was higher 
for women with pain conditions, hepatitis C, asthma, and autoimmune disorders, but similar for 
women with and without all other comorbidities.  Women with pain-related conditions had 
noticeably higher levels of non-chronic prescription opioid use (15.8%) and chronic prescription 
opioid use (3.0%) than women without pain conditions.  Women who attended a postpartum care 
visit within 60 days of delivery had slightly higher levels of opioid use during pregnancy 
compared with those with no postpartum care visit (10.8% vs. 8.7%).  
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Table 4.2 Characteristics of Aim 1 Cohort by Type of Opioid Use During Pregnancy, Row 
Totals 













Total N (%) 1,167,228 (90.4%) 109,622 (8.5%) 9,347 (0.7%) 5,155 (0.4%) 
Age, mean years (SD) 30.3 (5.4) 30.0 (5.7) 31.4 (5.6) 26.5 (5.9) 
Age, Categorical     
<20 88.8% (32,748) 9.7% (3,578) 0.3% (112) 1.2% (444) 
20-24 88.0% (140,106) 10.1% (16,130) 0.6% (967) 1.2% (1,993) 
25-29 90.6% (322,841) 8.4% (30,012) 0.7% (2,335) 0.3% (1,111) 
30-34 91.2% (415,424) 7.8% (35,752) 0.7% (3,251) 0.2% (988) 
35-39 90.5% (206,260) 8.4% (19,160) 0.9% (2,018) 0.2% (508) 
40+ 89.6% (49,849) 9.0% (4,990) 1.2% (664) 0.2% (111) 
HRSA Region     
Region 1 92.9% (51,806) 6.2% (3,475) 0.4% (247) 0.5% (254) 
Region 2 94.4% (92,223) 4.7% (4,584) 0.4% (416) 0.5% (479) 
Region 3 91.5% (102,007) 7.3% (8,123) 0.7% (790) 0.5% (594) 
Region 4 88.7% (248,858) 10.1% (28,322) 0.8% (2,165) 0.4% (1,125) 
Region 5 91.1% (215,754) 7.7% (18,373) 0.7% (1,711) 0.5% (1,082) 
Region 6 88.6% (151,386) 10.3% (17,550) 0.8% (1,410) 0.3% (499) 
Region 7 89.9% (47,424) 9.0% (4,766) 0.8% (400) 0.3% (136) 
Region 8 90.1% (37,027) 8.8% (3,624) 0.8% (312) 0.3% (141) 
Region 9 90.5% (140,390) 8.5% (13,187) 0.8% (1,188) 0.3% (418) 
Region 10 90.7% (47,014) 8.0% (4,139) 0.7% (382) 0.6% (294) 
Unknown Region 89.4% (33,339) 9.3% (3,479) 0.9% (324) 0.4% (133) 
Delivery in State with ≥20% Hispanic Population 
Yes 90.0% (342,091) 9.0% (34,311) 0.7% (2,793) 0.3% (1,073) 
No 90.6% (825,137) 8.3% (75,311) 0.7% (6,554) 0.4% (4,082) 
Delivery in State with ≥20% Black Population 
Yes 88.8% (190,742) 10.0% (21,574) 0.8% (1,692) 0.3% (758) 
No 90.7% (976,486) 8.2% (88,048) 0.7% (7,655) 0.4% (4,397) 
Delivery in State with ≥15% Population in Poverty 
Yes 88.7% (154,804) 9.9% (17,322) 0.9% (1,511) 0.5% (911) 
No 90.6% (1,012,424) 8.3% (92,300) 0.7% (7,836) 0.4% (4,244) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 92.2% (120,379) 6.9% (9,055) 0.5% (700) 0.4% (489) 
No 90.2% (1,046,849) 8.7% (100,567) 0.7% (8,647) 0.4% (4,666) 
Insurance Plan Type     
PPO 90.3% (692,755) 8.6% (65,730) 0.8% (5,904) 0.4% (3,126) 
Comprehensive 88.9% (11,669) 8.8% (1,152) 1.2% (156) 1.1% (145) 
HMO/EPO 89.8% (170,517) 9.1% (17,371) 0.7% (1,306) 0.3% (648) 
POS/POS+Capitation 90.1% (85,070) 8.8% (8,319) 0.7% (648) 0.4% (407) 
CDHP 91.0% (95,985) 8.0% (8,414) 0.6% (640) 0.4% (406) 
HDHP 92.4% (72,385) 6.7% (5,289) 0.5% (393) 0.3% (235) 
Unknown 91.0% (38,847) 7.8% (3,347) 0.7% (300) 0.4% (188) 
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Year of Delivery     
2011 88.8% (240,190) 10.1% (27,341) 0.8% (2,215) 0.3% (759) 
2012 89.3% (232,369) 9.5% (24,760) 0.8% (2,117) 0.4% (937) 
2013 89.7% (173,988) 9.1% (17,681) 0.8% (1,520) 0.4% (852) 
2014 90.3% (164,520) 8.4% (15,378) 0.8% (1,446) 0.5% (871) 
2015 91.2% (131,758) 7.6% (11,014) 0.7% (1,007) 0.5% (688) 
2016 92.0% (125,996) 7.0% (9,555) 0.6% (802) 0.5% (625) 
2017 95.6% (98,407) 3.8% (3,893) 0.2% (240) 0.4% (423) 
Delivery Mode     
Vaginal 91.6% (762,463) 7.4% (61,598) 0.6% (5,005) 0.4% (3,257) 
Cesarean 88.2% (404,765) 10.5% (48,024) 0.9% (4,342) 0.4% (1,898) 
Non-Opioid Substance Use Disorder 
Yes 64.3% (11,299) 11.0% (1,935) 3.8% (668) 20.9% (3,682) 
No 90.7% (1,155,929) 8.4% (107,687) 0.7% (8,679) 0.1% (1,473) 
Psychiatric Disorder, Any 
Yes 81.9% (58,724) 13.3% (9,553) 2.5% (1,802) 2.3% (1,628) 
No 90.9% (1,108,504) 8.2% (100,069) 0.6% (7,545) 0.3% (3,527) 
Chronic Hypertension     
Yes 86.3% (93,620) 11.7% (12,715) 1.5% (1,647) 0.5% (521) 
No 90.8% (1,073,608) 8.2% (96,907) 0.6% (7,700) 0.4% (4,634) 
Gestation 
Hypertension 
    
Yes 87.3% (136,318) 11.1% (17,378) 1.2% (1,852) 0.4% (669) 
No 90.8% (1,030,910) 8.1% (92,244) 0.7% (7,495) 0.4% (4,486) 
Diabetes Mellitus     
Yes 87.2% (47,117) 11.1% (5,985) 1.3% (697) 0.4% (224) 
No 90.5% (1,120,111) 8.4% (103,637) 0.7% (8,650) 0.4% (4,931) 
Gestational Diabetes     
Yes 89.1% (165,947) 9.7% (18,097) 0.9% (1,704) 0.3% (542) 
No 90.6% (1,001,281) 8.3% (91,525) 0.7% (7,643) 0.4% (4,613) 
Asthma      
Yes 85.6% (53,701) 12.3% (7,745) 1.4% (861) 0.7% (411) 
No 90.6% (1,113,527) 8.3% (101,877) 0.7% (8,486) 0.4% (4,744) 
Autoimmune Disorder     
Yes 84.6% (20,952) 11.7% (2,899) 3.0% (739) 0.7% (179) 
No 90.5% (1,146,276) 8.4% (106,723) 0.7% (8,608) 0.4% (4,976) 
Hepatitis C     
Yes 58.6% (556) 8.9% (84) 1.2% (11) 31.3% (297) 
No 90.4% (1,166,672) 8.5% (109,538) 0.7% (9,336) 0.4% (4,858) 
Pain-Related 
Conditions 
    
Yes 80.3% (86,239) 15.8% (16,948) 3.0% (3,242) 0.9% (1,015) 
No 91.3% (1,080,989) 7.8% (92,674) 0.5% (6,105) 0.3% (4,140) 
Any ANC     
Yes 90.3% (1,128,888) 8.5% (106,787) 0.7% (9,090) 0.4% (5,005) 
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No 92.2% (38,340) 6.8% (2,835) 0.6% (257) 0.4% (150) 
Postpartum Care Visit within 60 Days of Delivery 
Yes 89.2% (519,289) 9.4% (54,955) 0.9% (5,227) 0.5% (2,607) 
No 91.3% (647,939) 7.7% (54,667) 0.6% (4,120) 0.4% (2,548) 
Postpartum Contraception Use within Three days 
No evidence of 
provision 
90.7% (1,93,024) 8.2% (98,661) 0.7% (7,979) 0.4% (4,741) 
Evidence of provision 85.3% (74,204) 12.6% (10,961) 1.6% (1,368) 0.5% (414) 
Female Sterilization 84.5% (61,306) 13.3% (9,691) 1.7% (1,263) 0.4% (322) 
LARC 88.9% (1,184) 8.3% (111) 1.0% (14) 1.7% (22) 
Moderately Effective 
Methods 
   0.5% (70) 
Provided Postpartum Contraception within 60 days Postpartum 
No Evidence of 
Provision 
91.1% (734,766) 7.8% (62,763) 0.6% (5,188) 0.4% (3,386) 
Evidence of Provision  89.1% (432,462) 9.7% (46,859) 0.9% (4,159) 0.4% (1,769) 
Female Sterilization 84.3% (66,706) 13.5% (10,661) 1.8% (1,408) 0.5% (355) 
LARC 89.0% (80,473) 9.8% (8,822) 0.7% (682) 0.5% (409) 
Moderately Effective 
Methods 
90.4% (285,278) 8.7% (27,376) 0.7% (2,069) 0.3% (1,005) 
 
Dependent Variable: Postpartum Prescription Contraceptive Provision 
The dependent variable in Aim 1 was provision of prescription contraception within 60 
days postpartum, both overall provision and by contraceptive method type.  Descriptive statistics 
are provided for contraceptive provision within three days postpartum and 60 days postpartum in 
Table 4.3 for the Aim 1 cohort.  Because the overall prevalence was low, only descriptive 
statistics are provided for provision within three days postpartum.   
Contraceptive provision within three days postpartum was low, with just 6.7% of women 
receiving any prescription contraception in the immediate postpartum period (Table 4.3).  
Provision within three days decreased over the study period from a high of 7.5% in 2011 to 5.8% 
in 2017 (p for trend<0.00), with declines largely attributable to decreases in immediate 
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postpartum sterilization (Figure 4.3).  Provision of LARC methods within three days increased 
over the study period but remained low, reaching a high of only 0.2% in 2017.  Provision of 
MEM was also low, but it remained steady over the study period ranging from 1.1% in 2011 to 
0.9% in 2017.  Female sterilization was the most common method provided within three days 
postpartum, but it decreased from 6.4% in 2011 to 4.7% in 2017.  Figure 4.3 shows the trends for 
each method over the study period.  A full descriptive analysis of the provision of prescription 
contraception within three days postpartum can be found in Appendix B.   




































Figure 4.3 Trends for Provision of Prescription Contraception within 3-Days Postpartum, 
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Overall, 37.6% of women in the Aim 1 cohort were provided prescription contraception 
within 60 days postpartum (Table 4.3), with the majority receiving a MEM.  Female sterilization 
rates declined over the study period from 6.9% in 2011 to 5.2% in 2017 (p for tend<0.00) while 
LARC provision increased from 5.8% to 8.8% (p for trend <0.00) (Figure 4.4).  The provision of 
MEM was variable, ranging from a high of 26.2% in 2013 to a low of 19.9% in 2017.  It is 
unclear why it decreased from 23.4% in 2016 to 19.9% in 2017.   
Figure 4.4 Trends for Provision of Prescription Contraception within 60-Days Postpartum, 
Overall and by Method Type, Aim 1 Cohort 
 
 
Provision of prescription contraception within 60 days postpartum as well as method type 
varied by several covariates (Table 4.4).  There were marked differences among the various 
types of opioid use during pregnancy.  Overall, women with chronic prescription opioid use had 
the highest levels of contraceptive provision and women with OUD/Bup, the lowest.  Levels of 
sterilization were higher for each category of opioid use than for women who did not use opioids 
during pregnancy, with a substantially higher sterilization prevalence among women with 
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chronic prescription opioid use.  LARC provision was also higher for all categories of opioid use 
compared with women who did not use opioids during pregnancy, whereas MEM provision was 
lower for women with chronic prescription opioid use and OUD/Bup.  These same trends were 
reflected in the 3-day contraceptive provision measure (see Appendix B).  
Women undergoing female sterilization had the highest average age (33.1 years), while 
women receiving LARC were the youngest (28.1 years).  Women in the oldest age group (40+ 
years) had the lowest overall levels of contraceptive provision while women in their 20’s had the 
highest levels.  The prevalence of sterilization increased with age, whereas the provision of 
LARC was highest in the youngest age categories.  Provision of contraception varied across 
HRSA regions from a low of 25.8% in Region 2 (NY, NJ, PR) to a high of 42.6% in Region 8 
(MT, ND, SD, WY, UT, CO).  Female sterilization was highest in the southern US (Regions 4 
and 6), and LARC provision was highest in the west (Regions 8 and 10).  MEM provision was 
consistent across regions, except for lower rates in Region 2.        
Women with comorbidities had higher levels of contraceptive provision except those 
with autoimmune disorders and hepatitis C, as did women with cesarean deliveries, who 
experienced higher levels of contraceptive provision, specifically sterilization.  Women who 
attended a postpartum care visit within 60 days postpartum had significantly higher levels of 
contraception provision, with a pronounced increase in levels of LARC provision. 
Table 4.4 Characteristics of Aim 1 Cohort by Postpartum Contraceptive Method Provision 
Within 60 Days of Delivery, Row Totals 
 
 








LARC  Moderately 
Effective 
Methods  
Total N (%) 806,103 (62.4%) 485,249 (37.6%) 79,130 (6.1%) 90,391 (7.0%)  315,728 (24.4%) 













LARC  Moderately 
Effective 
Methods  
No Opioid Use 
During Pregnancy 




57.2% (62,763) 42.7% (46,859) 9.7% (10,661) 8.0% (8,822) 25.0% (27,376) 
Chronic Prescription 
Opioid Use 




65.7% (3,386) 34.3% (1,769) 6.9% (355) 7.9% (409) 19.5% (1,005) 
Age, mean years 
(SD) 
30.2 (5.5) 29.7 (5.4) 33.1 (4.9) 28.1 (5.4) 29.2 (5.0) 
Age, Categorical      
<20 60.2% (22,219) 39.8% (14,663) 0.03% (12) 13.6% (5,066) 26.1% (9,645) 
20-24 59.5% (94,695) 40.5% (64,501) 1.7% (2,775) 11.4% (18,232) 27.3% (43,494) 
25-29 59.3% (211,435) 40.7% (144,864) 3.8% (13,584) 8.0% (28,602) 28.8% (102,678) 
30-34 63.2% (287,640) 36.8% (167,775) 6.3% (28,674) 5.9% (27,052) 24.6% (112,049) 
35-39 66.2% (150,929) 33.8% (77,017) 11.3% (25,758) 4.4% (9,952) 18.1% (41,307) 
40+ 70.5% (39,185) 29.5% (16,429) 15.0% (8,327) 2.8% (1,547) 11.8% (6,555) 
HRSA Region      
Region 1 66.5% (37,093) 33.5% (18,689) 3.8% (2,121) 6.6% (3,705) 23.1% (12,863) 
Region 2 74.2% (72,184) 25.8% (25,098) 4.0% (3,938) 2.7% (2,652) 19.0% (18,508) 
Region 3 65.3% (72,797) 34.7% (38,717) 5.8% (6,44) 4.7% (5,240) 24.2% (27,033) 
Region 4 58.2% (163,141) 41.8% (117,329) 8.1% (22,704) 7.8% (21,972) 25.9% (72,653) 
Region 5 63.3% (149,905) 36.7% (87,015) 4.9% (11,741) 6.2% (14,639) 25.6% (60,635) 
Region 6 58.4% (99,720) 41.6 (71,125) 8.4% (14,411) 8.2% (14,016) 25.0% (42,698) 
Region 7 58.1% (30,617) 41.9% (22,109) 5.7% (3,017) 9.0% (4,738) 27.2% (14,354) 
Region 8 57.3% (23,575) 42.6% (17,529) 4.7% (1,917) 13.8% (5,686) 24.1% (9,926) 
Region 9 66.8% (103,62) 33.2% (51,563) 4.7% (7,376) 5.4% (8,379) 23.1% (35,808) 
Region 10 58.5% (30,329) 41.5% (21,502) 5.3% (2,749) 13.0% (6,736) 23.2% (12,017) 
Unknown 61.3% (23,122) 38.7% (14,573) 7.2% (2,712) 7.0% (2,628) 24.5% (9,233) 













LARC  Moderately 
Effective 
Methods  
Yes 64.1% (243,857) 35.9% (136,411) 6.4% (24,531) 6.5% (24,914) 22.9% (86,966) 
No 61.7% (562,246) 38.3% (348,838) 6.0% (54,599) 7.2% (65,477) 25.1% (228,762) 
Delivery in State with ≥20% Black Population 
Yes 57.9% (124,342) 42.1% (90,424) 8.1% (17,478) 7.8% (16,780) 26.1% (56,166) 
No 63.3% (681,761) 36.7% (394,825) 5.7% (61,652) 6.8% (73,611) 24.1% (259,562) 
Delivery in State with ≥15% Population in Poverty 
Yes 56.0% (97,736) 36.6% (408,437) 8.5% (14,801) 7.7% (13,530) 27.8% (48,481) 
No 63.4% (708,367) 44.0% (76,812) 5.8% (64,329) 6.9% (76,861) 23.9% (267,247) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 67.3% (87,980) 32.6% (42,643) 4.6% (5,966) 5.7% (7,439) 22.4% (29,238) 
No 61.9% (718,123) 38.1% (442,606) 6.3% (73,164) 7.1% (82,952) 24.7% (286,490) 
Insurance Plan Type 
PPO 62.3% (478,058) 37.7% (289,457) 6.3% (48,161) 7.0% (53,791) 24.4% (187,505) 
Comprehensive 63.8% (8,378) 36.1% (4,744) 5.6% (742) 7.4% (972) 23.1% (3,030) 
HMP/EPO 62.5% (118,576) 37.5% (71,266) 5.5% (10,422) 7.0% (13,282) 25.0% (47,562) 
POS 62.0% (58,605) 37.9% (35,839) 6.7% (6,357) 6.8% (6,387) 24.4% (23,095) 
CDHP 61.7% (65,033) 38.3% (40,412) 6.1% (6,389) 7.7% (8,139) 24.5% (25,884) 
HDHP 64.8% (50,765) 35.2% (27,537) 5.2% (4,098) 7.0% (5,480) 22.9% (17,959) 
Unknown 62.5% (26,688) 37.5% (15,994) 6.9% (2,961) 5.5% (2,340) 25.0% (10,693) 
Year of Delivery      
2011 62.4% (168,929) 37.5% (101,576) 6.9% (18,713) 5.8% (15,650) 24.8% (67,213) 
2012 62.2% (161,856) 37.8% (98,327) 6.5% (17,036) 6.3% (16,341) 24.9% (64,950) 
2013 60.8% (117,953) 39.2% (76,088) 6.2% (12,043) 6.8% (13,152) 26.2% (50,893) 
2014 61.7% (112,372) 38.3% (69,843) 5.9% (10,780) 7.4% (13,465) 25.0% (45,598) 
2015 62,5% (90,276) 37.5% (54,191) 5.5% (8,010) 8.0% (11,612) 23.9% (34,569) 
2016 63.2% (86,618) 36.8% (50,360) 5.3% (7,233) 8.1% (11,095) 23.4% (32,032) 
2017 66.1% (68,099) 33.9% (34,864) 5.2% (5,315) 8.8% (9,076) 19.9% (20,473) 
Delivery Mode      













LARC  Moderately 
Effective 
Methods  
Cesarean 56.9% (261,389) 43.1% (197,640) 13.6% (62,488) 6.1% (27,980) 23.3% (107,172) 
Non-Opioid SUD      
Yes 62.1% (10,919) 37.9% (6,665) 6.0% (1,050) 9.4% (1,661) 22.5% (3,954) 
No 62.4% (795,184) 37.6% (478,584) 6.1% (78,080) 7.0% (88,730) 24.5% (311,774) 
Psychiatric Disorder, Any     
Yes 60.5% (43,353) 39.5% (28,354) 7.0% (5,040) 8.8% (6,283) 23.7% (17,031) 
No 62.5% (762,750) 37.5% (456,895) 6.1% (74,090) 6.9% (84,108) 24.5% (298,697) 
Chronic Hypertension     
Yes 58.0% (62,979) 42.0% (45,524) 10.0% (10,856) 7.7% (8,309) 24.3% (26,359) 
No 62.8% (743,124) 37.2% (439,725) 5.8% (68,274) 6.9% (82,082) 24.5% (289,369) 
Gestational Hypertension     
Yes 59.4% (92,804) 40.6% (63,413) 7.0% (10,997) 7.7% (12,090) 25.8% (40,326) 
No 62.8% (713,299) 37.2% (421,836) 6.0% (68,133) 6.9% (78,301) 24.3% (275,402) 
Diabetes Mellitus      
Yes 61.6% (33,259) 38.4% (20,764) 11.6% (6,296) 5.9% (3,215) 20.8% (11,253) 
No 62.5% (772,844) 37.5% (464,485) 5.9% (72,834) 7.0% (87,176) 24.6% (304,475) 
Gestational Diabetes      
Yes 62.2% (115,968) 37.7% (70,322) 9.1% (17,042) 6.1% (11,371) 22.5% (41,909) 
No 62.4% (690,135) 37.5% (414,927) 5.6% (62,088) 7.1% (79,020) 24.8% (273,819) 
Asthma      
Yes 60.0% (37,610) 40.0% (25,108) 6.4% (4,029) 8.2% (5,127) 25.4% (15,952) 
No 62.5% (768,493) 37.4% (460,141) 6.1% (75,101) 6.9% (85,264) 24.4% (299,776) 
Autoimmune Disease     
Yes 63.1% (15,624) 36.9% (9,145) 7.3% (1,816) 6.7% (1668) 22.9% (5,661) 
No 62.4% (790,479) 37.6% (476,104) 6.1% (77,314) 7.0% (88,723) 24.5% (310,067) 
Pain Condition      
Yes 61.2% (65,714) 38.8% (41,730) 7.2% (7,762) 8.4% (9,082) 23.2% (24,886) 
No 62.5% (740,389) 37.5% (443,519) 6.0% (71,368) 6.9% (81,309) 24.6% (290,842) 













LARC  Moderately 
Effective 
Methods  
Yes 65.0% (616) 35.0% (332) 7.2% (68) 8.0% (76) 19.8% (188) 
No 62.4% (805,487) 37.6% (484,917) 6.1% (79,062) 7.0% (90,315) 24.4% (315,540) 
Any ANC      
Yes 62.3% (778,439) 37.7% (471,331) 6.1% (76,840) 7.0% (88,024) 24.5% (306,467) 
No 66.5% (27,664) 33.5% (13,918) 5.5% (2,290) 5.7% (2,367) 22.3% (9,261) 
Postpartum Care Visit within 60 Days of Delivery 
Yes 54.3% (316,214) 45.7% (265,864) 6.2% (35,943) 13.6% (79,347) 25.9% (150,574) 
No 69.1% (489,889) 30.9% (219,385) 6.1% (43,187) 1.6% (11,044) 23.3% (165,154) 
 
Aim 1: Logistic Regression Models, Unadjusted and Adjusted for Outcome 1 
With a sample of over one million livebirths, most variables in the bivariate logistic 
regression models were significantly associated (p<<0.001) with receipt of any postpartum 
prescription contraception within 60 days postpartum.  Each category of opioid use was 
significantly associated with receipt of any postpartum contraception compared to women who 
did not use opioids during pregnancy.  Table 4.5 shows the unadjusted and adjusted odds of 
receipt of a prescription for postpartum contraception for the categories of opioid use and 
covariates.  For the sake of brevity, only the results for the adjusted model will be discussed.   
Table 4.5 Unadjusted and Adjusted Odds of Postpartum Prescription Contraceptive 
Provision within 60 Days Postpartum, Aim 1 (N=1,291,352) 
 Unadjusted OR Adjusted OR 
Opioid Use   
No Opioid Use During Pregnancy (ref.) (ref.) 
Non-Chronic Prescription Opioid Use 1.27 (1.25-1.28)*** 1.13 (1.12-1.15)*** 
Chronic Prescription Opioid Use 1.36 (1.31-1.42)*** 1.19 (1.14-1.24)*** 
OUD Diagnosis/Buprenorphine Prescription 0.89 (0.84-0.94)*** 0.80 (0.75-0.85)*** 
Age, Categorical   
<20 0.96 (0.94-0.98)** 0.98 (0.95-1.00)* 
20-24 0.99 (0.98-1.01) 0.99 (0.98-1.00) 
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 Unadjusted OR Adjusted OR 
25-29 (ref.) (ref.) 
30-34 0.85 (0.84-0.86)*** 0.86 (0.85-0.87)*** 
35-39 0.74 (0.73-0.75)*** 0.75 (0.74-0.76)*** 
40+ 0.61 (0.60-0.62)*** 0.60 (0.59-0.61)*** 
HRSA Region   
Region 1 0.95 (0.93-0.97)*** 0.99 (0.97-1.01) 
Region 2 0.65 (0.64-0.67)*** 0.69 (0.68-0.70)*** 
Region 3 (ref.) (ref.) 
Region 4 1.35 (1.33-1.37)*** 1.22 (1.19-1.25)*** 
Region 5 1.09 (1.07-1.11)*** 1.02 (1.00-1.04)* 
Region 6 1.34 (1.32-1.36)*** 1.36 (1.33-1.40)*** 
Region 7 1.36 (1.33-1.39)*** 1.28 (1.25-1.31)*** 
Region 8 1.40 (1.37-1.43)*** 1.45 (1.41-1.48)*** 
Region 9 0.93 (0.92-0.95)*** 1.05 (1.02-1.08)*** 
Region 10 1.33 (1.30-1.36)*** 1.26 (1.24-1.29)*** 
Unknown 1.18 (1.16-1.21)*** 1.14 (1.11-1.17)*** 
Delivery in State with ≥20% Hispanic 
Population 
0.90 (0.89-0.91)*** 0.86 (0.84-0.88)*** 
Delivery in State with ≥20% Black 
Population 
1.25 (1.24-1.27)*** 0.99 (0.98-1.01) 
Delivery in State with ≥15% Population in 
Poverty 
1.36 (1.35-1.38)*** 1.11 (1.10-1.13)*** 
Delivery in State with ≥35% Women with 
College Degree or More 
0.79 (0.78-0.80)*** 0.96 (0.94-0.98)*** 
Insurance Plan Type   
PPO (ref.) (ref.) 
Comprehensive 0.93 (0.90-0.97)*** 0.92 (0.88-0.95)*** 
HMO/EPO 0.99 (0.98-1.00) 1.05 (0.103-1.06)*** 
POS/POS+Capitation 1.01 (0.99-1.02) 1.00 (0.99-1.01) 
CDHP 1.03 (1.01-1.04)*** 1.01 (0.99-1.02) 
HDHP 0.89 (0.88-0.91)*** 0.95 (0.93-0.96)*** 
Unknown 0.99 (0.97-1.00) 1.06 (1.04-1.09)*** 
Year of Delivery   
2011 1.00 (0.98-1.01) Omitted 
2012 1.01 (1.00-1.02)* 1.01 (1.00-1.03)* 
2013 1.08 (1.07-1.09)*** 1.09 (1.07-1.10)*** 
2014 1.04 (1.03-1.05)*** 1.04 (1.03-1.06)*** 
2015 0.99 (0.98-1.00) 0.98 (0.97-0.99)** 
2016 0.96 (0.95-0.97)*** 0.95 (0.93-0.96)*** 
2017 0.84 (0.83-0.85)*** 0.83 (0.81-0.84)*** 
Delivery Mode   
Vaginal (ref.) (ref.) 
Cesarean 1.43 (1.42-1.44)*** 1.47 (1.46-1.48)*** 
Non-Opioid Substance Use Disorder 1.01 (0.98-1.04) 0.97 (0.94-1.01) 
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 Unadjusted OR Adjusted OR 
Psychiatric Disorder, Any 1.09 (1.07-1.11)*** 1.05 (1.03-1.07)*** 
Chronic Hypertension 1.22 (1.21-1.24)*** 1.10 (1.09-1.12)*** 
Gestational Hypertension 1.01 (1.00-1.01) 0.98 (0.97-1.00)* 
Diabetes Mellitus 1.04 (1.02-1.06)*** 1.00 (0.98-1.02) 
Gestational Diabetes 1.15 (1.14-1.17)*** 0.97 (0.96-0.99)*** 
Asthma 1.11 (1.09-1.13)*** 1.09 (1.07-1.11)*** 
Autoimmune Disease 0.97 (0.95-1.00)* 0.96 (0.94-0.99)* 
Hepatitis C 0.89 (0.78-1.02) - 
Pain Condition 1.06 (1.05-1.07)*** 0.99 (0.98-1.01) 
Any ANC 1.20 (1.18-1.23)*** - 
Postpartum Care Visit within 60 Days of 
Delivery 
1.88 (1.86-1.89)*** 1.84 (1.83-1.86)*** 
*p<0.05, **p<0.01, ***p<<0.001 
The fully adjusted, multivariable logistic regression model included adjustments for 
maternal age at delivery, HRSA region of delivery, state-level demographic characteristics, 
insurance plan type, year of delivery, mode of delivery, non-opioid SUD, psychiatric disorders, 
chronic hypertension, gestational hypertension, diabetes mellitus, gestational diabetes, asthma, 
autoimmune disease, pain conditions, and receipt of a postpartum care visit within 60 days of 
delivery.  The results of the fully adjusted logistic regression model are presented in Table 4.5. 
After adjustment for all covariates, the relationship between type of opioid use during 
pregnancy and postpartum contraceptive provision was unchanged.  Women with non-chronic 
prescription opioid use (aOR: 1.13, 95% CI: 1.12-1.15) and chronic prescription opioid use 
(aOR: 1.19, 95% CI: 1.14-1.24) had significantly increased odds of receiving any postpartum 
prescription contraception than women who did not use opioids during pregnancy.  Women with 
OUD/Bup had significantly decreased odds of receiving postpartum contraception compared 
with women who did not use opioids during pregnancy (aOR: 0.80, 95% CI: 0.75-0.85).     
Several demographic variables remained significantly associated with the odds of 
receiving postpartum contraception in the fully adjusted model.  Maternal age at the time of 
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delivery remained significant for the oldest women (30 years or older), who had decreased odds 
of receipt, with the odds decreasing as age increased, like the findings in the unadjusted model.  
HRSA Region of delivery was also significant, with significantly increased odds of receiving any 
postpartum prescription contraception for women in all Regions except 1 (ME, NH, VT, MA, RI, 
CT) and 2 (NY, NJ, PR) compared with the reference region (Region 3- MD, VA, PA, DE, WV).  
Consistent with the unadjusted results, women who delivered in states with 20% or more 
Hispanic population had significantly decreased odds of receiving postpartum contraception 
(aOR: 0.86, 95% CI: 0.84-0.88), but delivering in a state with 20% or more Black population 
was no longer significantly associated with receipt of postpartum contraception.  Women 
delivering in a state with 15% or more of the population living in poverty remained significantly 
more likely to receive postpartum contraception.  Similarly, women delivering in a state where 
35% or more of the women have at least a college degree, remained significantly less likely to 
receive postpartum contraception although the magnitude of the relationship was attenuated in 
the adjusted model.  The relationship between year of delivery and receipt of postpartum 
contraception was largely unchanged from the unadjusted model.  
Women with a cesarean delivery had 1.47 (95% CI: 1.46-1.48) times the odds of receipt 
of postpartum contraception than women with a vaginal delivery.  In addition, women who 
attended a postpartum care visit within 60 days of delivery had significantly increased odds of 
receiving postpartum contraception (aOR: 1.84, 95% CI: 1.83-1.86).  Women with a psychiatric 
disorder (aOR: 1.05, 95% CI: 1.03-1.07), chronic hypertension (aOR: 1.10, 95% CI: 1.09-1.12), 
or asthma (aOR: 1.09, 95% CI: 1.07-1.10) had significantly increased odds of receiving 
postpartum contraception in the adjusted model.  Women with gestational hypertension (aOR: 
0.98, 95% CI: 0.97-1.00), gestational diabetes (aOR: 0.97, 95% CI: 0.96-0.99), or an 
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autoimmune disease (aOR: 0.96, 95% CI: 0.94-0.99) had decreased odds of receiving postpartum 
contraception.  The odds of receipt of postpartum prescription contraception did not differ 
significantly for women with non-opioid SUD, diabetes mellitus, or pain conditions compared to 
women without these conditions.        
Model Fit Diagnostics 
Model diagnostics were assessed using the Bayesian information criteria (BIC) and 
Akaike information criteria (AIC), both of which assess model fit, with lower scores indicating 
better model fit (Table 4.6).  Although commonly used to assess goodness-of-fit for logistic 
regression, the Hosmer-Lemeshow goodness-of-fit test is not recommended for sample sizes 
over 25,000.  At sample sizes greater than 25,000, the Hosmer-Lemeshow goodness-of-fit test is 
over powered and will result in a significant p-value even with small deviations between the 
observed and expected probability of the outcome [2].  Therefore, the combined information 
from the AIC and BIC were used to select the final model.  The final model was built by adding 
successive blocks of similar variables to the model, with each block improving the model fit.      
Several variables were excluded from the fully adjusted model.  Hepatitis C, although 
included in the descriptive tables, was excluded from the final model because of its low 
prevalence of <1.0% in the total sample.  Women with OUD are known to have significantly 
higher rates of hepatitis C; it was included for descriptive purposes for this reason [3].  Similarly, 
the receipt of any antenatal care was also considered in the descriptive tables; because of the low 
percentage of the cohort with no indication of receiving antenatal care it was excluded from the 
models.  Furthermore, because it was necessary to define ANC as “any” or “none”, it did not add 
substantive information to address the research question.  Finally, to avoid multiple collinearity 
among the year of delivery dummy variables, the dummy variable for 2011 was omitted from the 
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fully adjusted model.  All odds ratios for the year of delivery variables are interpreted relative to 
delivery in 2011.  
Table 4.6 Aim 1 Multivariable Logistic Regression Model Fit Diagnostics 
 Model Description  BIC AIC 
Model 1 Demographic variables (Maternal Age, 
HRSA Region, State Characteristics, 
Insurance Place Type, Year of Delivery) 
-1.648e+07 1.309 
Model 2  Model 1 + Opioid Use -1.648e+07 1.308 
Model 3 Model 2 + Chronic Conditions -1.648e+07 1.307 
Model 4 (Final) Model 3 + Delivery Mode + PNC visit -1.652e+07 1.279 
 
Aim 1: Multinomial Regression Models, Unadjusted and Adjusted for Outcome 2 
The second set of models in the Aim 1 analysis examined receipt of postpartum 
contraception within 60 days of delivery by method type using multinomial logistic regression 
models.  The categories for these models were no evidence of provision of prescription 
contraception (reference), female sterilization, LARC, and MEM.  The results from the 
unadjusted and fully adjusted multinomial models are presented as relative risk ratios (RRR) in 
Tables 4.7 and 4.8, respectively.  For the sake of brevity, only results from the fully adjusted 
model are discussed below for all method types.   
Table 4.7 Multinomial Results: Unadjusted Relative Risk Ratios for Provision of 
Contraception within 60 Days Postpartum, Relative to No Provision, by Method Type 
(N=1,291,352) 
 Sterilization LARC Moderately Effective 
Methods 
Opioid Use    
No Opioid Use During 
Pregnancy 
(ref.) (ref.) (ref.) 
Non-Chronic Prescription 
Opioid Use 
1.87 (1.83-1.91)*** 1.28 (1.25-1.31)*** 1.12 (1.11-1.14)*** 
Chronic Prescription Opioid 
Use 
2.99 (1.81-3.17)*** 1.20 (1.11-1.30)*** 1.03 (0.97-1.08) 
OUD Diagnosis/Buprenorphine 
Prescription 
1.15 (1.03-1.29)** 1.10 (0.99-1.22) 0.76 (0.71-0.82)*** 
Age, Categorical    
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 Sterilization LARC Moderately Effective 
Methods 
<20 0.01 (0.00-0.2)*** 1.66 (1.61-1.72)*** 0.89 (0.87-0.92)*** 
20-24 0.46 (0.44-0.47)*** 1.42 (1.39-1.45)*** 0.94 (0.93-0.96)*** 
25-29 (ref.) (ref.) (ref.) 
30-34 1.55 (1.52-1.58)*** 0.69 (0.68-0.71)*** 0.80 (0.79-0.81)*** 
35-39 2.65 (2.60-2.71)*** 0.48 (0.47-0.50)*** 0.56 (0.55-0.57)*** 
40+ 3.30 (3.21-3.41)*** 0.29 (0.27-0.31)*** 0.34 (0.33-0.35)*** 
HRSA Region    
Region 1 0.64 (0.61-0.68)*** 1.39 (1.33-1.45)*** 0.93 (0.91-0.96)*** 
Region 2 0.61 (0.59-0.64)*** 0.51 (0.49-0.53) *** 0.69 (0.67-0.70)*** 
Region 3 (ref.) (ref.) (ref.) 
Region 4 1.57 (1.53-1.62)*** 1.87 (1.81-1.93)*** 1.20 (1.18-1.22)*** 
Region 5 0.88 (0.86-0.91)*** 1.35 (1.31-1.40)*** 1.09 (1.07-1.11)*** 
Region 6 1.63 (1.58-1.68)*** 1.95 (1.89-2.01)*** 1.15 (1.13-1.17)*** 
Region 7 1.11 (1.06-1.16)*** 2.15 (2.06-2.24)*** 1.26 (1.23-1.29)*** 
Region 8 0.91 (0.87-0.97)** 3.35 (3.22-3.49)*** 1.13 (1.10-1.16)*** 
Region 9 0.80 (0.78-0.83)*** 1.12 (1.08-1.16)*** 0.93 (0.91-0.95)*** 
Region 10 1.02 (0.98-1.07) 3.08 (2.97-3.21)*** 1.07 (1.04-1.09)*** 
Unknown 1.32 (1.26-1.39)*** 1.58 (1.50-1.66)*** 1.07 (1.04-1.10)*** 
Delivery in State with ≥20% 
Hispanic Population 
1.03 (1.02-1.05)*** 0.88 (0.86-0.89)*** 0.87 (0.87-0.88)*** 
Delivery in State with ≥20% 
Black Population 
1.55 (1.52-1.58)*** 1.25 (1.23-1.27)*** 1.19 (1.17-1.20)*** 
Delivery in State with ≥15% 
Population in Poverty 
1.67 (1.63-1.70)*** 1.27 (1.25-1.30)*** 1.31 (1.30-1.33)*** 
Delivery in State with ≥35% 
Women with College Degree 
or More 
0.66 (0.65-0.68)*** 0.73 (0.71-0.75)*** 0.83 (0.82-0.84)*** 
Insurance Plan Type    
PPO (ref.) (ref.) (ref.) 
Comprehensive 0.88 (0.81-0.95)** 1.03 (0.96-1.10) 0.92 (0.88-0.96)*** 
HMO/EPO 0.87 (0.85-0.89)*** 0.99 (0.97-1.01) 1.02 (1.01-1.03)*** 
POS 1.07 (1.05-1.11)*** 0.97 (0.94-0.99)* 1.00 (0.99-1.02) 
CDHP 0.97 (0.95-1.00) 1.11 (1.08-1.14)*** 1.01 (1.00-1.03) 
HDHP 0.80 (0.77-0.83)*** 0.96 (0.93-0.99)** 0.90 (0.89-0.92)*** 
Unknown 1.10 (1.06-1.14)*** 0.78 (0.75-0.81)*** 1.02 (0.99-1.04) 
Year of Delivery    
2011 1.17 (1.15-1.19)*** 0.79 (0.77-0.80)*** 1.02 (1.01-1.03)*** 
2012 1.09 (1.07-1.11)*** 0.88 (0.86-0.89)*** 1.03 (1.02-1.04) 
2013 1.05 (1.03-1.07)*** 0.99 (0.97-1.01) 1.12 (1.11-1.13)*** 
2014 0.97 (0.95-0.99)* 1.08 (1.06-1.10)*** 1.04 (1.03-1.05)*** 
2015 0.89 (0.87-0.91)*** 1.17 (1.14-1.19)*** 0.97 (0.96-0.99)*** 
2016 0.83 (0.81-0.86)*** 1.16 (1.14-1.19)*** 0.94 (0.92-0.95)*** 
2017 0.78 (0.76-0.80)*** 1.21 (1.18-1.24)*** 0.75 (0.74-0.76)*** 
Delivery Mode    
Vaginal (ref.) (ref.) (ref.) 
Cesarean 7.82 (7.69-7.96)*** 0.93 (0.92-0.95)*** 1.07 (1.06-1.08)*** 
Non-Opioid Substance Use 
Disorder 
0.98 (0.92-1.04) 1.36 (1.29-1.43)*** 0.92 (0.89-0.96)*** 
Psychiatric Disorder, Any 1.19 (1.16-1.23)*** 1.31 (1.28-1.35)*** 1.00 (0.98-1.02) 
Chronic Hypertension 1.87 (1.83-1.92)*** 1.19 (1.17-1.22)*** 1.07 (1.06-1.09)*** 
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 Sterilization LARC Moderately Effective 
Methods 
Gestational Hypertension 1.24 (1.21-1.27)*** 1.19 (1.16-1.21)*** 1.12 (1.11-1.14)*** 
Diabetes Mellitus 2.01 (1.95-2.06)*** 0.86 (0.82-0.89)*** 0.86 (0.84-0.88)*** 
Gestational Diabetes 1.63 (1.60-1.66)*** 0.86 (0.84-0.87)*** 0.91 (0.90-0.92)*** 
Asthma 1.09 (1.06-1.13)*** 1.23 (1.19-1.27)*** 1.09 (1.06-1.11)*** 
Autoimmune Disease 1.19 (1.13-1.24)*** 0.95 (0.90-1.00) 0.92 (0.89-0.95)*** 
Hepatitis C 1.12 (0.87-1.44) 1.10 (0.87-1.39) 0.78 (0.66-0.92)** 
Pain Condition 1.22 (1.19-1.26)*** 1.26 (1.23-1.29)*** 0.96 (0.95-0.98)*** 
Any ANC 1.19 (1.14-1.24)*** 1.32 (1.27-1.38)*** 1.18 (1.15-1.20)*** 
Postpartum Care Visit within 
60 Days of Delivery 
1.29 (1.27-1.31)*** 11.13 (10.90-11.36)*** 1.41 (1.40-1.42)*** 
*p<0.05, **p<0.01, ***p<<0.001 
In the fully adjusted multinomial model (Table 4.8), women with each type of opioid use 
during pregnancy had significantly higher relative risks of receiving sterilization relative to no 
prescription method compared with women who did not use opioids during pregnancy. This 
finding was also noted in the unadjusted analysis.  Women with chronic prescription opioid use 
during pregnancy had the highest aRRR for sterilization relative to no prescription method 
(aRRR: 2.12, 95% CI: 1.99-2.26).  In the fully adjusted analysis, the relative risk for provision of 
LARC or MEM relative to no method did not differ significantly for women with chronic 
prescription opioid use compared with women who did not use opioids during pregnancy.  As 
observed in the unadjusted analysis, the risk of provision of sterilization, LARC, and MEM 
relative to no method was significantly higher for women with non-chronic prescription opioid 
use than for women who did not use opioids during pregnancy.  Women with OUD/Bup had 
significantly higher relative risks for provision of sterilization, and significantly lower relative 
risks for provision of LARC and MEM relative to the provision of no prescription method 
compared with women who did not use opioids during pregnancy.  This finding represents a shift 
from the unadjusted analysis in which women with OUD/Bup had a non-significantly higher 
RRR for LARC provision compared with no method.  In the fully adjusted model, women with 
an OUD diagnosis/buprenorphine prescription had an aRRR of 0.73 (95% CI: 0.65-0.82) for 
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receipt of LARC verses no method and an aRRR of 0.73 (95% CI: 0.68-0.79) for receipt of 
MEM verses no method. 
    The patterns for aRRRs among the different age groups were the same for the unadjusted 
and adjusted models.  The aRRR for sterilization verses no method increased with age; the aRRR 
for LARC verses no method decreased with age; and the aRRR for MEM verses no method was 
lower for each age group in comparison to the reference group (25-29 years).  Across HRSA 
regions, associations remained largely the same between the adjusted and unadjusted models.  
The aRRR for sterilization ranged from a low of 0.54 in Region 2 (NY, NJ, PR) (95% CI: 0.52-
0.56) to a high of 1.35 in Region 6 (LA, AR, OK, TX, NM) (95% CI: 1.28-1.43).  All regions 
except Region 2 (NY, NJ, PR) and 5 (MN, WI, IL, IN, MI, OH) had a significantly increased 
aRRR for LARC relative to no provision compared with the reference region, Region 3.  The 
aRRR for MEM provision was significantly increased for all regions relative to Region 3 (PA, 
MD, DE, VA, WV) except Regions 1 (ME, NH, VT, MA, RI, CT) and 2 (NY, NJ, PR).   
The RRRs varied significantly by the state-level characteristics.  The adjusted RRRs and 
unadjusted RRRs for women who delivered in states with 20% or more Hispanic population 
were similar in magnitude and effect, higher RRRs for sterilization and lower RRRs for LARC 
and MEM.  The fully adjusted results for women who delivered in states with 20% or more 
Black population changed substantively from the unadjusted analysis.  They had a significantly 
higher aRRR for sterilization and a significantly lower aRRR for LARC verses no methods, but 
no significant difference for MEM provision verses no method in the fully adjusted model. 
Women living in states with 15% or more of the population living in poverty had significantly 
higher aRRRs for sterilization and MEM provision verses no method and significantly lower 
aRRR for LARC provision verses no method.  Compared with the unadjusted models, the aRRRs 
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for women in states where 35% or more of women have at least a college degree were similar but 
attenuated, with significantly lower aRRRs for sterilization and LARC verses no method, and no 
significant differences for MEM provision.  Finally, trends across the study time period were the 
same in the adjusted and unadjusted models.  The aRRR for sterilization decreased over the 
study period while the aRRR for LARC provision increased; the aRRR for MEM provision was 
significantly higher relative to 2011 from 2012-14, but it was significantly lower beginning in 
2015.    
Several chronic disease and clinical variables were significant in the fully adjusted 
model. Women with non-opioid SUDs, psychiatric disorders, chronic hypertension, diabetes 
mellitus, gestational diabetes, asthma, and pain conditions had significantly higher aRRRs for 
sterilization verses no prescription method.  Women with gestational hypertension and 
autoimmune disease had significantly lower aRRRs for sterilization.  Women with psychiatric 
disorders, chronic hypertension, and asthma had significantly higher aRRRs for LARC verses no 
method, while those with gestational diabetes had a significantly lower aRRR.  Women with 
chronic hypertension, gestation hypertension, and asthma had significantly higher aRRRs for 
MEM provision verses no method; women with non-opioid SUD, diabetes mellitus, gestational 
diabetes, and with a pain condition had significantly lower aRRRs for MEM provision verses no 
method. The remaining conditions were not significantly related to method type.  Finally, women 
who had a postpartum care visit within 60 days of delivery had significantly higher aRRRs for 
sterilization, LARC, and MEM, with a pronounced relationship for LARC provision (aRRR: 
10.98, 95% CI: 10.75-11.20).  
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Table 4.8 Multinomial Results: Adjusted Relative Risk Ratios for Provision of 
Contraception within 60 Days Postpartum, Relative to No Provision, by Method Type 
(N=1,291,352) 
 Sterilization LARC Moderately 
Effective Methods 
Opioid Use    
No Opioid Use During 
Pregnancy 
(ref.) (ref.) (ref.) 
Non-Chronic Prescription 
Opioid Use 
1.49 (1.46-1.53)*** 1.10 (1.07-1.12)*** 1.05 (1.03-1.06)*** 
Chronic Prescription Opioid 
Use 
2.12 (1.99-2.26)*** 0.97 (0.89-1.06) 0.98 (0.93-1.03) 
OUD Diagnosis/Buprenorphine 
Prescription 
1.32 (1.16-1.50)*** 0.73 (0.65-0.82)*** 0.73 (0.68-0.79)*** 
Age, Categorical    
<20 0.01 (0.01-0.02)*** 1.68 (1.62-1.74)*** 0.89 (0.87-0.91)*** 
20-24 0.48 (0.46-0.50)*** 1.39 (1.36-1.42)*** 0.94 (0.93-0.96)*** 
25-29 (ref.) (ref.) (ref.) 
30-34 1.51 (1.48-1.55)*** 0.73 (0.71-0.74)*** 0.82 (0.81-0.83)*** 
35-39 2.42 (2.37-2.48)*** 0.52 (0.51-0.53)*** 0.58 (0.57-0.59)*** 
40+ 2.72 (2.63-2.80)*** 0.32 (0.30-0.33)*** 0.36 (0.35-0.37)*** 
HRSA Region    
Region 1 0.69 (0.66-0.73)*** 1.46 (1.39-1.54)*** 0.97 (0.95-1.00) 
Region 2 0.54 (0.52-0.56)*** 0.52 (0.49-0.55)*** 0.77 (0.76-0.79)*** 
Region 3 (ref.) (ref.) (ref.) 
Region 4 1.21 (1.15-1.27)*** 1.59 (1.51-1.67)*** 1.16 (1.13-1.19)*** 
Region 5 0.91 (0.87-0.94)*** 1.01 (0.97-1.04) 1.06 (1.04-1.08)*** 
Region 6 1.35 (1.28-1.43)*** 2.08 (1.96-2.20)*** 1.24 (1.20-1.28)*** 
Region 7 1.26 (1.20-1.33)*** 1.61 (1.54-1.69)*** 1.23 (1.19-1.26)*** 
Region 8 1.16 (1.09-1.23)*** 3.04 (2.91-3.18)*** 1.20 (1.16-1.23)*** 
Region 9 0.67 (0.63-0.71)*** 1.34 (1.26-1.43)*** 1.12 (1.09-1.16)*** 
Region 10 1.14 (1.08-1.20)*** 2.34 (2.24-2.44)*** 1.06 (1.03-1.09)*** 
Unknown 1.25 (1.18-1.31)*** 1.49 (1.41-1.57)*** 1.07 (1.03-1.10)*** 
Delivery in State with ≥20% 
Hispanic Population 
1.10 (1.06-1.15)*** 0.72 (0.69-0.75)*** 0.84 (0.82-0.86)*** 
Delivery in State with ≥20% 
Black Population 
1.14 (1.10-1.17)*** 0.88 (0.86-0.91)*** 0.99 (0.97-1.01) 
Delivery in State with ≥15% 
Population in Poverty 
1.35 (1.31-1.39)*** 0.91 (0.88-0.94)*** 1.12 (1.10-1.14)*** 
Delivery in State with ≥35% 
Women with College Degree 
or More 
0.79 (0.76-0.83)*** 0.91 (0.88-0.95)*** 1.02 (0.99-1.04) 
Insurance Plan Type    
PPO (ref.) (ref.) (ref.) 
Comprehensive 1.20 (1.11-1.30)*** 0.82 (0.76-0.88)*** 0.91 (0.87-0.94)*** 
HMO/EPO 0.93 (0.90-0.95)*** 1.07 (1.05-1.10)*** 1.07 (1.05-1.08)*** 
POS/POS + Capitation 0.99 (0.96-1.02) 0.98 (0.95-1.01) 1.01 (0.99-1.02) 
CDHP 0.99 (0.96-1.02) 1.01 (0.99-1.04) 1.02 (1.00-1.03)* 
HDHP 0.92 (0.89-0.95)*** 0.93 (0.90-0.96)*** 0.96 (0.94-0.98)*** 
Unknown 1.16 (1.11-1.22)*** 0.96 (0.91-1.01) 1.06 (1.04-1.09)*** 
Year of Delivery    
2011 Omitted Omitted Omitted 
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 Sterilization LARC Moderately 
Effective Methods 
2012 0.96 (0.94-0.99)** 1.10 (1.07-1.12)*** 1.01 (0.99-1.02) 
2013 0.96 (0.94-0.99)** 1.19 (1.16-1.22)*** 1.10 (1.08-1.11)*** 
2014 0.88 (0.86-0.91)*** 1.31 (1.28-1.34)*** 1.03 (1.02-1.05)*** 
2015 0.79 (0.76-0.81)*** 1.34 (1.30-1.37)*** 0.95 (0.94-0.97)*** 
2016 0.73 (0.71-0.75)*** 1.32 (1.29-1.36)*** 0.92 (0.91-0.94)*** 
2017 0.68 (0.66-0.70)*** 1.37 (1.33-1.41)*** 0.75 (0.73-0.76)*** 
Delivery Mode    
Vaginal (ref.) (ref.) (ref.) 
Cesarean 6.75 (6.63-6.87)*** 0.99 (0.98-1.01) 1.11 (1.10-1.120)*** 
Non-Opioid Substance Use 
Disorder 
1.19 (1.11-1.29)*** 1.00 (0.94-1.06) 0.92 (0.88-0.96)*** 
Psychiatric Disorder, Any 1.08 (1.05-1.12)*** 1.14 (1.11-1.17)*** 1.02 (1.00-1.04) 
Chronic Hypertension 1.29 (1.25-1.32)*** 1.11 (1.08-1.14)*** 1.04 (1.02-1.06)*** 
Gestational Hypertension 0.75 (0.73-0.77)*** 1.00 (0.97-1.02) 1.06 (1.05-1.09)*** 
Diabetes Mellitus 1.19 (1.15-1.23)*** 0.96 (0.93-1.01) 0.92 (0.88-0.96)*** 
Gestational Diabetes 1.13 (1.11-1.16)*** 0.92 (0.90-0.94)*** 0.94 (0.93-0.95)*** 
Asthma 1.06 (1.02-1.10)** 1.11 (1.07-1.14)*** 1.09 (1.07-1.11)*** 
Autoimmune Disease 0.93 (0.89-0.98)* 0.98 (0.93-1.03) 0.97 (0.94-1.00) 
Pain Condition 1.11 (1.08-1.14)*** 1.02 (1.00-1.05) 0.96 (0.94-0.97)*** 
Postpartum Care Visit within 
60 Days of Delivery 
1.21 (1.19-1.22)*** 10.98 (10.75-11.21)*** 1.40 (1.39-1.41)*** 
*p<0.05, **p<0.01, ***p<<0.001        
Model Fit Diagnostics 
 The model fit diagnostics used to evaluate the multinomial models involved a combination of 
AIC and BIC to assess model fit and the same method of model building was applied, as used for 
the multivariable logistic regressions.  The final model had an AIC of 1.819 and a BIC of -
1.582e+07, the lowest AIC and BIC of the four models included in Table 4.9.   
Table 4.9 Aim 1 Multinomial Logistic Regression Model Fit Diagnostics 
 Model Description  BIC AIC 
Model 1 Demographic variables (Maternal Age, 
HRSA Region, State Characteristics, 
Insurance Place Type, Year of Delivery) 
-1.568e+07 1.928 
Model 2  Model 1 + Opioid Use -1.568e+07 1.926 
Model 3 Model 2 + Chronic Conditions -1.569e+07 1.923 




Aim 1 Sensitivity Analysis 
A sensitivity analysis was done comparing women who met the inclusion criteria for Aim 
1 and those who did not to ensure there were no major differences between these groups.  Table 
4.10 displays the descriptive characteristics for women who met the Aim 1 inclusion criteria, of 
women who did not meet the inclusion criteria, and all women with a livebirth captured in the 
MarketScan database between January 01, 2011 and December 31st, 2017. 
Women were included in the Aim 1 analysis if they had a livebirth between January 1st, 
2011 and November 1st, 2017, and maintained continuous health and pharmaceutical insurance 
coverage for the duration of pregnancy and for at least the first 60 days postpartum.  Of the 
approximately 2.3 million live births identified in the MarketScan database, nearly 55% met the 
inclusion criteria for Aim 1.  Overall, there were no significant differences in the characteristics 
of women who did and did not meet the inclusion criteria, however, only variables captured at 
the time of delivery were examined.   
Table 4.10 Sensitivity Analysis: Characteristics of Women with a Livebirth During Study 
Period (January 2011-November 2017), by Inclusion Criteria* 
 Met Aim 1 Inclusion 
Criteria 
Did Not Meet Aim 1 
Inclusion Criteria 
Full Sample with Live 
Birth 
Total N’s (%) 1,291,352 (54.5%) 1,075,511 (45.5%) 2,366,863 (100%) 
Age, mean years (SD) 30.3 (5.5) 29.7 (5.5) 30.0 (5.5) 
Age, Categorical    
<20 2.9% (36,882) 2.9% (31,623) 2.9% (68,505) 
20-24 12.3% (159,196) 14.8% (158,752) 13.4% (317,948) 
25-29 27.6% (356,299) 30.4% (326,761) 28.9% (683,060) 
30-34 35.3% (455,415) 32.9% (353,594) 34.2% (809,009) 
35-39 17.6% (227,946) 15.4% (165,647) 16.6% (393,593) 
40+ 4.3% (55,614) 3.6% (39,134) 4.0% (94,748) 
HRSA Region    
Region 1 4.3% (55,782) 3.7% (39,467) 4.0% (95,249) 
Region 2 7.5% (97,282) 9.1% (97,508) 8.2% (194,790) 
Region 3 8.6% (111,514) 9.4% (101,480) 9.0% (212,994) 
Region 4 21.7% (280,470) 18.7% (200,802) 20.3% (481,272) 
Region 5 18.3% (236,920) 18.3% (197,085) 18.3% (434,005) 
Region 6 13.2% (170,845) 13.6% (146,630) 13.4% (317,475) 
Region 7 4.1% (52,726) 3.8% (40,579) 3.9% (93,305) 
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 Met Aim 1 Inclusion 
Criteria 
Did Not Meet Aim 1 
Inclusion Criteria 
Full Sample with Live 
Birth 
Region 8 3.2% (41,104) 3.0% (32,097) 3.1% (73,201) 
Region 9 12.0% (155,183) 11.3% (121,373) 11.7% (276,556) 
Region 10 4.0% (51,831) 3.3% (35,115) 3.7% (86,946) 
Unknown 2.9% (37,695) 5.9% (63,375) 4.3% (101,070) 
Delivery in State with 
≥20% Hispanic 
Population 
29.4% (380,268) 27.7% (297,533) 28.6% (677,801) 
Delivery in State with 
≥20% Black Population 
16.6% (214,766) 14.7% (158,333) 15.8% (373,099) 
Delivery in State with 
≥15% Population in 
Poverty 
13.5% (174,548) 13.9% (149,827) 13.7% (324,375) 
Delivery in State with 
≥35% Women with 
College Degree or More 
10.1% (130,623) 8.9% (95,872) 9.6% (226,495) 
Insurance Plan Type    
PPO 59.4% (767,515) 62.1% (668,063) 60.7% (1,435,578) 
Comprehensive 1.0% (13,122) 0.7% (7,932) 0.9% (21,054) 
HMO/EPO 14.7% (189,842) 14.2% (152,639) 14.5% (342,481) 
POS/POS+Capitation 7.3% (94,444) 6.0% (64,606) 6.7% (159,050) 
CDHP 8.2% (105,445) 4.9% (52,470) 6.7% (157,915) 
HDHP 6.1% (78,302) 5.5% (58,985) 5.8% (137,287) 
Unknown 3.3% (42,682) 6.6% (70,816) 4.8% (113,498) 
Year of Delivery    
2011 20.9% (270,505) 20.6% (221,639) 20.8% (492,144) 
2012 20.1% (260,183) 20.4% (218,964) 20.2% (479,147) 
2013 15.0% (194,041) 16.7% (179,435) 15.8% (373,476) 
2014 14.1% (182,215) 18.0% (193,733) 15.9% (375,948) 
2015 11.2% (144,467) 7.4% (79,571) 9.5% (224,038) 
2016 10.6% (136,978) 7.5% (80,613) 9.2% (217,591) 
2017 8.0% (102,963) 9.4% (101,556) 8.6% (204,519) 
Delivery Mode    
Vaginal 64.5% (832,323) 65.3% (702,673) 64.8% (1,534,996) 
Cesarean 35.5% (459,029) 34.7% (372,838) 35.1% (831,867) 
*Notes for Table 4.10: only variables measured at time of delivery are assessed because this table includes women 
who did not meet inclusion criteria and therefore, did not have prenatal/postpartum data consistently available. 
 
4.4 Aim 2 Results 
As with Aim 1, the primary independent variable in the Aim 2 cohort was opioid use 
during pregnancy.  The prevalence of opioid use during pregnancy was similar to the levels 
observed in the Aim 1 cohort, with 89.9% of women having no evidence of opioid use during 
pregnancy, approximately 9% with evidence of non-chronic prescription opioid use, 0.8% with 
chronic prescription opioid use, and 0.4% with OUD/Bup (Table 4.11).  The prevalence and 
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distribution of opioid use across the covariates in Aim 2 were consistent with the patterns 
observed in the Aim 1 cohort.   
Table 4.11 Characteristics of Aim 2 Cohort by Type of Opioid Use During Pregnancy, Row 
Totals 








OUD Diagnosis or 
Buprenorphine 
Prescription  
Total N (%) 1,142,594 (89.9%) 113,273 (8.9%) 9,838 (0.8%) 5,127 (0.4%) 
Age, mean years (SD) 30.3 (5.4) 30.0 (5.7) 31.4 (5.6) 26.5 (5.9) 
Age, Categorical     
<20 88.4% (32,798) 10.1% (3,735) 0.3% (123) 1.2% (433) 
20-24 87.4% (138,270) 10.7% (16,891) 0.6% (1,007) 1.2% (1,963) 
25-29 90.1% (319,420) 8.9% (31,408) 0.7% (2,514) 0.3% (1,141) 
30-34 90.8% (404,560) 8.2% (36,639) 0.8% (3,398) 0.2% (987) 
35-39 90.0% (199,399) 8.8% (19,524) 0.9% (2,108) 0.2% (495) 
40+ 89.1% (48,147) 9.4% (5,076) 1.3% (688) 0.2% (108) 
HRSA Region     
Region 1 92.5% (51,123) 6.5% (3,613) 0.5% (256) 0.5% (262) 
Region 2 94.2% (88,321) 4.9% (4,588) 0.4% (420) 0.5% (454) 
Region 3 91.1% (101,337) 7.6% (8,491) 0.7% (830) 0.6% (624) 
Region 4 87.9% (233,441) 10.8% (28,693) 0.8% (2,245) 0.4% (1,081) 
Region 5 90.7% (214,663) 8.1% (19,211) 0.8% (1,797) 0.5% (1,060) 
Region 6 88.1% (149,436) 10.7% (18,186) 0.9% (1,518) 0.3% (503) 
Region 7 89.4% (45,819) 9.5% (4,877) 0.8% (406) 0.2% (130) 
Region 8 89.7% (36,740) 9.2% (3,758) 0.8% (330) 0.3% (141) 
Region 9 90.1% (139,540) 8.8% (13,680) 0.8% (1,267) 0.3% (419) 
Region 10 90.2% (45,271) 8.4% (4,244) 0.8% (398) 0.6% (297) 
Unknown 89.2% (36,863) 9.5% (3,932) 0.9% (371) 0.4% (156) 
Delivery in State with ≥20% Hispanic Population 
Yes 89.5% (335,333) 9.4% (35,337) 0.8% (2,949) 0.3% (1,051) 
No 90.1% (807,261) 8.7% (77,936) 0.8% (6,889) 0.5% (4,076) 
Delivery in State with ≥20% Black Population 
Yes 88.0% (177,889) 10.8% (21,852) 0.9% (1,747) 0.4% (733) 
No 90.3% (964,705) 8.6% (91,421) 0.8% (8,091) 0.4% (4,394) 
Delivery in State with ≥15% Population in Poverty 
Yes 87.9% (146,792) 10.6% (17,722) 1.0% (1,603) 0.5% (896) 
No 90.2% (995,802) 8.7% (95,551) 0.7% (8,235) 0.4% (4,231) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 91.7% (117,184) 7.3% (9,357) 0.6% (723) 0.4% (495) 
No 89.7% (1,025,410) 9.1% (103,916) 0.8% (9,115) 0.4% (4,632) 
Insurance Plan Type     
PPO 89.8% (686,956) 8.9% (68,490) 0.8% (6,250) 0.4% (3,117) 
Comprehensive 87.9% (10,130) 9.6% (1,107) 1.3% (151) 1.2% (135) 
HMP/EPO 89.4% (169,779) 9.5% (18,003) 0.7% (1,375) 0.4% (658) 
POS 89.5% (82,454) 9.3% (8,579) 0.7% (674) 0.4% (403) 
CDHP 90.4% (86,189) 8.6% (8,190) 0.7% (635) 0.4% (367) 
HDHP 91.8% (65,523) 7.3% (5,249) 0.6% (398) 0.3% (215) 
Unknown 90.7% (41,563) 8.0% (3,655) 0.8% (355) 0.5% (232) 
Year of Delivery     
2011 88.8% (251,027) 10.1% (28,517) 0.8% (2,329) 0.3% (797) 
2012 89.2% (253,071) 9.5% (27,088) 0.8% (2,359) 0.4% (1,034) 
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OUD Diagnosis or 
Buprenorphine 
Prescription  
2013 89.6% (184,301) 9.2% (18,839) 0.8% (1,646) 0.4% (893) 
2014 90.3% (181,569) 8.4% (16,912) 0.8% (1,599) 0.5% (977) 
2015 91.1% (138,442) 7.7% (11,698) 0.7% (1,055) 0.5% (743) 
2016 91.9% (134,184) 7.0% (10,219) 0.6% (850) 0.5% (683) 
Delivery Mode     
Vaginal 91.2% (746,720) 7.8% (63,909) 0.6% (5,278) 0.4% (3,238) 
Cesarean 87.6% (395,874) 10.9% (49,364) 1.0% (4,560) 0.4% (1,889) 
Non-Opioid SUD     
Yes 62.9% (10,720) 11.7% (1,992) 4.0% (686) 21.4% (3,646) 
No 90.3% (1,131,874) 8.9% (111,281) 0.7% (9,152) 0.1% (1,481) 
Psychiatric Disorder, Any 
Yes 80.7% (56,730) 14.2% (10,013) 2.7% (1,921) 2.3% (1,645) 
No 90.4% (1,085,864) 8.6% (103,260) 0.7% (7,917) 0.3% (3,482) 
Chronic Hypertension     
Yes 85.4% (90,270) 12.4% (13,144) 1.6% (1,733) 0.5% (515) 
No 90.3% (1,052,324) 8.6% (100,129) 0.7% (8,105) 0.4% (4,612) 
Gestational Hypertension 
Yes 86.6% (133,295) 11.7% (17,970) 1.2% (1,922) 0.4% (667) 
No 90.4% (1,009,299) 8.5% (95,303) 0.7% (7,916) 0.4% (4,460) 
Diabetes Mellitus     
Yes 86.7% (46,699) 11.5% (6,192) 1.4% (738) 0.4% (214) 
No 90.0% (1,095,895) 8.8% (107,081) 0.7% (9,100) 0.4% (4,913) 
Gestational Diabetes     
Yes 88.7% (165,913) 10.1% (18,879) 1.0% (1,796) 0.3% (543) 
No 90.1% (976,681) 8.7% (94,394) 0.7% (8,042) 0.4% (4,584) 
Asthma     
Yes 84.7% (51,468) 13.2% (8,008) 1.5% (903) 0.7% (412) 
No 90.2% (1,091,126) 8.7% (105,265) 0.7% (8,935) 0.4% (4,715) 
Autoimmune Disease     
Yes 83.6% (20,014) 12.3% (2,955) 3.2% (769) 0.8% (187) 
No 90.0% (1,122,580) 8.8% (110,318) 0.7% (9,069) 0.4% (4,940) 
Pain Condition     
Yes 78.2% (76,196) 17.4% (16,965) 3.4% (3,343) 1.0% (974) 
No 90.9% (1,066,398) 8.2% (96,308) 0.5% (6,495) 0.4% (4,153) 
Hepatitis C     
Yes 59.2% (515) 9.8% (85) 1.3% (11) 29.8% (259) 
No 89.9% (1,142,079) 8.9% (113,188) 0.8% (9,827) 0.4% (4,868) 
Any ANC     
Yes 89.8% (1,102,704) 9.0% (110,236) 0.8% (9,558) 0.4% (4,967) 
No 92.0% (39,890) 7.0% (3,037) 0.6% (280) 0.4% (160) 
Contraceptive provision within 365 Days Postpartum 
No Evidence of 
Provision 
91.2% (576,902) 7.8% (49,354) 0.6% (4,125) 0.4% (2,433) 
Evidence of Provision 88.7% (565,692) 10.0% (63,919) 0.9% (5,713) 0.4% (2,694) 
Sterilization 83.8% (70,762) 13.8% (11,679) 1.9% (1,612) 0.5% (397) 
LARC 88.6% (133,652) 10.1% (15,196) 0.8% (1,178) 0.5% (750) 
Moderately Effective 
Methods 





Dependent Variable: Postpartum prescription Contraceptive Provision 
The Aim 2 dependent variable was time to contraceptive provision within the first 365 
days postpartum.  In the Aim 2 cohort, 50.2% of women were provided prescription 
contraception within 365 days postpartum (Table 4.12), with the majority receiving a MEM. 
Trends in provision over the study period were similar to those observed in Aim 1 with 
sterilization declining (p for tend<0.00), LARC provision increasing (p for tend<0.00), and 
variable MEM provision with a decline in the final study year (Figure 4.5).  For all measured 
variables, levels of contraceptive provision increased compared with levels observed in Aim 1 
because of the extended postpartum observation period in Aim 2.    
Figure 4.5 Trends for Provision of Prescription Contraception within 365 Days 
Postpartum, overall and by Method Type, Aim 2 Cohort 
 
Levels of contraceptive provision by the different categories of opioid use were similar to 
those in Aim 1 with some noticeable exceptions.  Overall, women with chronic prescription 
opioid use had the highest levels of contraceptive provision and women with no opioid use 
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group had the lowest level of contraceptive provision.  Women across all categories of opioid use 
continued to have higher levels of sterilization than women who did not use opioids, with the 
highest prevalence among women with chronic prescription opioid use.  LARC provision was 
also higher across all categories of opioid use compared with no opioid use during pregnancy.  
Unlike for Aim 1 where women with non-chronic prescription opioid use had the highest levels 
of LARC provision, women in the OUD/Bup group had the highest prevalence of LARC 
provision among the Aim 2 cohort.  Finally, MEM provision was relatively consistent across 
groups, at approximately 30%.  
Patterns for age and by geographic region across the different contraceptive method types 
were similar to those noted in Aim 1.  Older women had the highest prevalence of sterilization 
while younger women, higher levels of LARC provision.  Levels of sterilization and LARC 
varied by geographic regions while MEM provision was more consistent.  For most 
comorbidities, women with the morbidity had higher levels of contraceptive provision than 
women without the morbidity but the relationships were not as consistent as in Aim 1.  Women 
with non-opioid SUD, diabetes, gestational diabetes, autoimmune disorders, and hepatitis C had 
lower levels of contraceptive provision than women who did not have these conditions.  
Conversely, women with psychiatric diagnoses, chronic and gestational hypertension, asthma, 
and pain conditions had higher contraceptive provision than women who did not have these 
conditions.  Women with cesarean deliveries had substantially higher levels of contraceptive 
provision than women with vaginal deliveries, largely due to high levels of sterilization.   
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Table 4.12 Characteristics of Aim 2 Cohort by Postpartum Contraceptive Method Within 
365 Days Postpartum, Row Totals 








LARC  Moderately 
Effective 
Methods  
Total N (%) 632,814 (49.8%) 638,018 (50.2%) 84,450 (6.6%) 150,776 (11.9%) 402,792 (31.7%) 
Opioid Use      
No Opioid Use 
During Pregnancy 




43.6% (49,354) 56.4% (63,919) 10.3% (11,679) 13.4% (15,196) 32.7% (37,044) 
Chronic Prescription 
Opioid Use 




47.4% (2,433) 52.5% (2,694) 7.7% (397) 14.6% (750) 30.2% (1,547) 
Age, mean years 
(SD) 
30.8 (5.5) 29.7 (5.4) 33.4 (4.5) 28.6 (5.5) 29.3 (5.2) 
Age, Categorical      
<20 39.1% (14,521) 60.8% (22,568) 0.05% (17) 22.2% (8,238) 38.6% (14,313) 
20-24 42.7% (67,599) 57.2% (90,532) 2.0% (3,196) 18.3% (28,903) 36.9% (58,433) 
25-29 46.9% (166,141) 53.1% (188,342) 4.2% (14,926) 12.8% (45,541) 36.1% (127,875) 
30-34 51.2% (227,945) 48.8% (217,639) 6.9% (30,666) 10.5% (46,700) 31.5% (140,273) 
35-39 55.6% (123,195) 44.4% (98,331) 12.2% (27,004) 8.3% (18,298) 23.9% (53,029) 
40+ 61.8% (33,413) 38.1% (20,606) 16.0% (8,641) 5.7% (3,096) 16.4% (8,869) 
HRSA Region      
Region 1 52.3% (28,916) 47.7% (26,338) 4.1% (2,291) 13.5% (7,440) 30.1% (16,607) 
Region 2 60.9% (56,922) 39.1% (36,463) 4.4% (4,069) 7.7% (7,168) 27.0% (25,226) 
Region 3 52.7% (58,621) 47.3% (52,701) 6.4% (7,102) 9.1% (10,182) 31.8% (35,417) 
Region 4 44.2% (117,332) 55.8% (148,128) 8.7% (23,211) 13.1% (34,672) 34.0% (90,245) 
Region 5 51.3% (121,377) 48.7% (115,354) 5.5% (12,930) 10.5% (24,984) 32.7% (77,440) 
Region 6 46.0% (78,077) 54.0% (91,566) 9.1% (15,414) 12.7% (21,482) 32.2% (54,670) 
Region 7 45.4% (23,257) 54.6% (27,975) 6.4% (3,268) 13.7% (7,020) 34.5% (17,687) 
Region 8 46.2% (18,910) 53.8% (22,059) 5.0% (2,032) 19.2% (7,865) 29.7% (12,162) 
Region 9 54.4% (84,335) 45.6% (70,571) 5.3% (8,178) 10.4% (16,061) 29.9% (46,332) 
Region 10 46.6% (23,415) 53.4% (26,795) 5.6% (2,812) 18.7% (9,375) 29.1% (14,608) 
Unknown 51.9% (21,652) 48.1% (20,068) 7.5% (3,143) 10.8% (4,527) 29.7% (12,398) 
Delivery in State with ≥20% Hispanic Population 
Yes 51.4% (192,501) 48.6% (182,169) 6.5% (58,099) 11.9% (107,049) 32.4% (290,701) 
No 49.1% (440,313) 50.9% (455,849) 7.0% (26,351) 11.7% (43,727) 29.9% (112,091) 
Delivery in State with ≥20% Black Population 
Yes 44.1% (89,115) 55.9% (113,106) 8.7% (17,703) 12.6% (25,393) 34.6% (70,010) 
No 50.9% (543,699) 49.1% (524,912) 6.2% (66,747) 11.7% (125,383) 31.1% (332,782) 
Delivery in State with ≥15% Population in Poverty 
Yes 42.7% (71,373) 57.3% (95,640) 6.3% (69,224) 11.8% (130,371) 31.0% (342,782) 
No 50.9% (561,441) 49.1% (542,378) 9.1% (15,226) 12.2% (20,405) 35.9% (60,009) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 53.7% (68,620) 46.3% (59,139) 6.8% (78,095) 11.9% (136,064) 31.9% (364,720) 
No 49.4% (564,194) 50.6% (578,879) 5.0% (6,355) 11.5% (14,712) 29.8% (38,072) 
Year of Delivery      
2011 48.3% (136,538) 51.7% (146,132) 7.4% (21,036) 10.6% (29,847) 33.7% (95,249) 
2012 50.2% (142,269) 49.8% (141,283) 7.0% (19,941) 10.9% (31,032) 31.8% (90,310) 
2013 48.3% (99,366) 51.7% (106,313) 6.6% (13,641) 11.8% (24,231) 33.3% (68,441) 
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LARC  Moderately 
Effective 
Methods  
2014 51.2% (102,902) 48.8% (98,155) 6.2% (12,555) 12.3% (24,778) 30.2% (60,822) 
2015 49.9% (75,764) 50.1% (76,174) 5.9% (9,016) 13.8% (21,012) 30.4% (46,146) 
2016 52.1% (75,975) 47.9% (69,961) 5.7% (8,261) 13.6% (19,876) 28.7% (41,824) 
Delivery Mode      
Vaginal 52.0% (426,070) 48.0% (393,070) 2.6% (21,153) 12.8% (105,183) 32.6% (266,739) 
Cesarean 45.8% (206,744) 54.2% (244,943) 14.0% (63,297) 10.1% (45,593) 30.1% (136,053) 
Non-Opioid SUD      
Yes 49.8% (625,045) 50.2% (628,743) 6.6% (83,298) 11.8% (148,079) 31.7% (397,266) 
No 45.6% (7,769) 54.4% (9,275) 6.8% (1,152) 15.8% (2,697) 31.8% (5,426) 
Psychiatric Disorder, Any 
Yes 46.5% (32,679) 53.5% (37,630) 7.7% (5,441) 14.7% (10,305) 31.1% (21,884) 
No 50.0% (600,135) 50.0% (600,388) 6.6% (79,009) 11.7% (140,471) 31.7% (380,908) 
Chronic Hypertension 
Yes 45.7% (48,304) 54.3% (57,358) 10.7% (11,353) 12.3% (13,043) 31.2% (32,962) 
No 50.2% (584,510) 49.8% (580,660) 6.3% (73,097) 11.8% (137,733) 31.7% (369,830) 
Gestational Hypertension 
Yes 46.7% (71,797) 53.3% (82,057) 7.6% (11,736) 12.5% (19,268) 33.2% (51,053) 
No 50.2% (561,017) 49.8% (555,961) 6.5% (72,714) 11.8% (131,508) 31.5% (351,739) 
Diabetes Mellitus      
Yes 50.1% (26,979) 49.9% (26,864) 12.4% (6,670) 10.2% (5,507) 27.3% (14,687) 
No 49.8% (605,835) 50.2% (611,154) 6.4% (77,780) 11.9% (145,269) 31.9% (388,105) 
Gestational Diabetes      
Yes 50.5% (94,503) 49.5% (92,628) 9.8% (18,328) 10.5% (19,571) 29.2% (54,729) 
No 49.7% (538,311) 50.3% (545,390) 6.1% (66,122) 12.1% (131,205) 32.1% (348,063) 
Asthma      
Yes 46.7% (28,411) 53.3% (32,380) 6.9% (4,211) 13.4% (8,119) 33.0% (20,050) 
No 49.9% (604,403) 50.1% (605,638) 6.6% (80,239) 11.8% (142,657) 31.6% (382,742) 
Autoimmune Disease 
Yes 50.3% (12,033) 49.7% (11,892) 7.9% (1,902) 11.7% (2,812) 30.0% (7,178) 
No 49.8% (620,781) 50.2% (626,126) 6.6% (82,548) 11.9% (147,964) 31.7% (395,614) 
Pain Condition      
Yes 47.8% (46,631) 52.2% (50,847) 8.1% (7,856) 13.8% (13,481) 30.3% (29,510) 
No 50.0% (586,183) 50.0% (587,171) 6.5% (76,594) 11.7% (137,295) 31.8% (373,282) 
Hepatitis C      
Yes 51.9% (452) 48.0% (418) 7.9% (69) 12.9% (112) 27.2% (237) 
No 49.8% (632,362) 50.2% (637,600) 6.6% (84,381) 11.9% (150,664) 31.7% (402,555) 
 
Aim 2: Univariate Analysis 
The univariate analysis for Aim 2 began by calculating the mean time to contraceptive 
provision among women who ultimately received contraception during the study period (Table 
4.13).  This measure provided a crude estimate of time to first contraceptive provision 
conditioned on receiving contraception.  A table with a limited set of covariates is presented 
below; a table with the full listing of covariates can be found in Appendix C.  Average time to 
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provision varied by opioid use group with both the non-chronic and chronic prescription use 
group having average times to provision less than 60 days postpartum.  Women in the OUD/Bup 
group, on average, did not receive contraception until 72.3 days postpartum (95% CI: 69.54-
75.10).  Time to first provision also varied substantially by method type with sterilization 
occurring, on average, 13.3 days after delivery (95% CI: 12.98-13.54), and LARC and MEM 
both having average times to provision exceeding 60 days.  Time to provision decreased with 
age, with the oldest age group receiving contraception 25 days, on average, before the youngest 
age group, most likely due to their greater use of sterilization.  Finally, for most comorbidities, 
except non-opioid SUDs, psychiatric disorders, and hepatitis C, the mean time to contraceptive 
provision was shorter for women with the comorbidity than for those without it.        
Table 4.13 Unadjusted Mean Time to Contraceptive Provision in Women Provided 
Contraception Within 365 Days Postpartum 
Covariates Mean Days to Contraceptive Provision 
(95% CI) 
Opioid Use During Pregnancy  
No use 61.92 (61.76-62.08) 
Non-Chronic Prescription Use 59.34 (58.84-59.82) 
Chronic Prescription Use 54.88 (53.23-56.52) 
OUD/BUP 72.32 (69.54-75.10) 
Contraceptive Method Type  
Any Method 61.66 (61.49-61.69) 
Sterilization 13.26 (12.98-13.54) 
LARC 76.58 (76.30-76.86) 
Moderately Effective Methods 66.19 (65.99-66.39) 
Age at Delivery  
>20 75.51 (74.64-76.38) 
20-24 69.32 (68.90-69.74) 
25-29 61.49 (61.23-61.76) 
30-34 60.82 (60.56-61.08) 
35-39 55.82 (55.41-56.23) 
40+ 50.54 (49,60-51.49) 
Delivery Mode  
Vaginal 67.58 (67.39-67.78) 
Cesarean 52.11 (51.86-52.35) 
Non-Opioid Substance Use Disorder  
No 61.55 (61.39-61.70) 
Yes 67.97 (66.56-69.37) 
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Covariates Mean Days to Contraceptive Provision 
(95% CI) 
Psychiatric Disorder, Any  
No 61.59 (61.43-61.75) 
Yes 62.50 (61.85-63.15) 
Chronic Hypertension  
No 62.21 (61.96-62.28) 
Yes 56.76 (56.26-57.26) 
Gestational Hypertension  
No 61.87 (61.71-62.04) 
Yes 60.09 (59.67-60.50) 
Diabetes Mellitus  
No 61.91 (61.75-62.06) 
Yes 55.61 (54.85-56.37) 
Gestational Diabetes  
No 62.26 (62.10-62.43) 
Yes 57.97 (57.57-58.38) 
Asthma  
No 61.65 (61.49-61.81) 
Yes 61.47 (60.79-62.15) 
Autoimmune Disease  
No 61.66 (61.50-61.81) 
Yes 60.89 (59.75-62.04) 
Pain Condition  
No 61.68 (61.52-61.84) 
Yes 61.18 (60.63-61.74) 
Hepatitis C  
No 61.64 (61.49-61.79) 
Yes 63.37 (57.31-69.42) 
 
An adjusted linear regression model was run to calculate the mean time to contraceptive 
provision by opioid use category, adjusted for all covariates including maternal age, HRSA 
region, state-level demographic characteristics, insurance plan type, year of delivery, delivery 
mode, and chronic conditions.  The results of the linear regression, which was restricted to 
women with evidence of contraceptive provision within 365 days postpartum (N=638,018), are 
presented in Table 4.14 and Figure 4.6.  In the adjusted analysis, women with no opioid use had 
an average time to contraceptive provision of 61.9 days (95% CI: 61.76-62.08).  Women with 
non-chronic and chronic prescription opioid use had significantly shorter times to contraceptive 
provision (Non-Chronic Mean: 59.34 days, 95% CI: 58.86-59.81; Chronic Mean: 54.88 days, 
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95% CI: 53.28-56.47).  In contrast, women with OUD/Bup had a significantly longer time to 
contraceptive provision (Mean: 72.32, 95% CI: 69.99-74.64).     
Table 4.14 Adjusted Mean Days to Contraceptive Provision and 95% CIs by Opioid-Use 
Among Women Provided Contraception Within 365 Days Postpartum* 
Opioid Use Group Adjusted Mean Days to Contraceptive Provision (95% 
CI) 
No Use 61.92 (61.76-62.08) 
Non-Chronic Use 59.34 (58.86-59.81) 
Chronic Use 54.88 (53.28-56.47) 
OUD/BUP 72.32 (69.99-74.64) 
*Adjusted for: maternal age, HRSA region, state-characteristics, insurance plan type, delivery mode, year of 
delivery, opioid use category, non-opioid SUD, psychiatric diagnosis, chronic hypertension, gestational 
hypertension, diabetes, gestational diabetes, asthma, pain condition, autoimmune condition 
Figure 4.6 Adjusted Mean Days to Contraceptive provision and 95% CIs by Opioid-Use 
Among Women Provided Contraception Within 365 Days Postpartum 
 
The next phase of the analysis involved estimating cumulative hazard and survival curves 
to visualize the overall pattern of contraceptive provision over the study period (Figures 4.7, 4.8).  
In both figures, there is a sharp increase in the hazard and number of “events” (e.g. contraceptive 
provision) around the 60-day postpartum timeframe.  By approximately 200 days postpartum, 
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50% of women have received postpartum contraception; the slope of the survival function 
plateaued at roughly this point (Figure 4.8).    
Figure 4.7 Nelson-Aalen Cumulative Hazard Estimate for Provision of Postpartum 
Contraception 
 
Figure 4.8 Kaplan-Meier Survival Estimate for Provision of Postpartum Contraception 
 
Kaplan-Meier curves for each categorical variable, including maternal age, year of 
delivery, HRSA region, state-level demographic characteristics, insurance plan type, delivery 
mode, and each comorbidity, were generated to assess the survival function for each category 
and provide a visual indication of whether the survival functions were proportional.  Log rank 
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tests were then performed to formally test for equality across strata in each categorical variable, 
with a p-value<0.05 indicating that the survival function is different across strata.  Log-log plots, 
which plot the log of the negative log of the survival function against log time, were also 
generated to examine the proportional hazards (PH) assumption for each categorical variable.  If 
the PH assumption holds, the lines in the log-log plot should be parallel.  Select Kaplan-Meier 
curves are included here. The full set of graphs for all categorical covariates can be found in 
Appendix E.     
Among women who received contraception, the Kaplan-Meier curve demonstrated that 
sterilization occurred most frequently in the immediate postpartum period (Figure 4.9).  MEM 
and LARC provision occurred later in the postpartum period, with rapid increases in provision 
occurring near the 60-day postpartum period.  No log-rank test was performed for the Kaplan-
Meier estimates by method of contraception as this variable was not included in the multivariable 
Cox model.     
Figure 4.9 Kaplan-Meier Survival Estimate for Women Who Received Contraception 




The Kaplan-Meier curves by opioid use group and the accompanying log rank test 
demonstrated that the survival curves were not equal across strata (Figure 4.10, Table 4.15).  
Women with chronic prescription opioid use had an immediate and substantial drop, driven by 
the high levels of sterilization, which tended to occur immediately postpartum.  All groups 
experienced an increase in contraceptive provision at approximately the 60-day mark, but the 
survival curve slopes are different.  At approximately 100 days postpartum, the curves for the 
OUD/Bup group and non-use group cross-over, indicating a probable violation of the 
proportional hazards’ assumption.  The log-rank test yielded a p-value <<0.001 indicating that 
the survival functions for the different groups of opioid use during pregnancy were not equal 
(Table 4.15).  The log rank tests for all other covariates, except autoimmune disease and hepatitis 
C, were significant (p<0.05).  The full results of the log rank tests for all categorical covariates 
can be found in Appendix D.     




Table 4.15 Log-Rank Test Result from Kaplan-Meier Curves for Type of Opioid Use 
Opioid Use Category Events Observed Events Expected P-Value 
No Opioid Use During Pregnancy 565,692 577,757.79 
<0.001 
Non-Chronic Prescription Opioid Use 63,919 53,233.95 
Chronic Prescription Opioid Use 5,713 4,432.52 
OUD/Buprenorphine 2,694 2,593.74 
 
Aim 2: Multivariable Cox Proportional Hazards Model Results 
The unadjusted and adjusted results of the Cox Proportional Hazards models are 
presented in table 4.16.  For the sake of brevity, the unadjusted results are discussed briefly and 
the adjusted model results are discussed at length below.          
Table 4.16 Unadjusted and Adjusted Hazard Ratios for Any Prescription Contraceptive 
Provision (N=1,270,832); Time Period: Delivery-365 Days Postpartum 
Variables Unadjusted HR Adjusted HR 
Opioid Use   
No Opioid Use During Pregnancy (ref.) (ref.) 
Non-Chronic Prescription Opioid Use 1.23 (1.22-1.24)*** 1.15 (1.14-1.16)*** 
Chronic Prescription Opioid Use 1.32 (1.29-1.36)*** 1.24 (1.21-1.27)*** 
OUD Diagnosis/Buprenorphine Prescription 1.06 (1.02-1.10)** 0.93 (0.89-0.97)** 
Age   
<20 1.13 (1.11-1.14)*** 1.14 (1.13-1.16)*** 
20-24 1.08 (1.07-1.09)*** 1.07 (1.06-1.08)*** 
25-29 (ref.) (ref.) 
30-34 0.87 (0.87-0.88)*** 0.89 (0.88-0.89)*** 
35-39 0.78 (0.77-0.78)*** 0.78 (0.78-0.79)*** 
40+ 0.64 (0.63-0.65)*** 0.64 (0.63-0.65)*** 
HRSA Region   
Region 1 0.96 (0.95-0.97)*** 1.00 (0.99-1.02) 
Region 2 0.73 (0.72-0.74)*** 0.78 (0.77-0.80)*** 
Region 3 (ref.) (ref.) 
Region 4 1.25 (1.24-1.26)*** 1.20 (1.18-1.22)*** 
Region 5 1.03 (1.02-1.04)*** 1.04 (1.02-1.05)*** 
Region 6 1.24 (1.22-1.25)*** 1.26 (1.24-1.28)*** 
Region 7 1.20 (1.18-1.22)*** 1.19 (1.17-1.21)*** 
Region 8 1.19 (1.18-1.21)*** 1.27 (1.25-1.29)*** 
Region 9 0.92 (0.91-0.94)*** 1.02 (1.00-1.04)* 
Region 10 1.16 (1.14-1.18)*** 1.19 (1.17-1.21)*** 
Unknown 1.12 (1.11-1.14)*** 1.12 (1.10-1.14)*** 
Delivery in State with ≥20% Hispanic 
Population 
0.93 (0.92-0.94)*** 0.92 (0.91-0.93)*** 
Delivery in State with ≥20% Black Population 1.20 (1.19-1.21)*** 1.02 (1.01-1.03)*** 
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Delivery in State with ≥15% Population in 
Poverty 
1.27 (1.26-1.28)*** 1.06 (1.05-1.08)*** 
Delivery in State with ≥35% Women with 
College Degree or More 
0.85 (0.84-0.86)*** 0.99 (0.98-1.00) 
Insurance Plan Type   
PPO (ref.) (ref.) 
Comprehensive 0.99 (0.96-1.01) 0.98 (0.95-1.00) 
HMO/EPO 0.99 (0.98-0.99)** 1.04 (1.03-1.05)*** 
POS/POS + Capitation 1.03 (1.02-1.04)*** 1.01 (1.00-1.02)* 
CDHP 1.01 (1.00-1.02)** 1.00 (0.99-1.01) 
HDHP 0.91 (0.90-0.92)*** 0.95 (0.94-0.96)*** 
Unknown 0.99 (0.97-1.00) 1.02 (1.00-1.03)* 
Year of Delivery   
2011 (ref.) (ref.) 
2012 0.99 (0.99-1.00) 0.99 (0.98-1.00) 
2013 1.02 (1.01-1.03)*** 1.02 (1.01-.103)*** 
2014 0.98 (0.97-0.99)*** 0.99 (0.98-0.99)** 
2015 0.96 (0.95-0.97)*** 0.94 (0.93-0.95)*** 
2016 0.92 (0.91-0.93)*** 0.91 (0.90-0.92)*** 
Delivery Mode   
Vaginal (ref.) (ref.) 
Cesarean 1.28 (1.27-1.28)*** 1.30 (1.29-1.31)*** 
Non-Opioid Substance Use Disorder 1.11 (1.08-1.13)*** 1.02 (0.99-1.04) 
Psychiatric Disorder, Any 1.11 (1.10-1.12)*** 1.10 (1.09-1.11)*** 
Chronic Hypertension 1.15 (1.14-1.16)*** 1.09 (1.08-1.10)*** 
Gestational Hypertension 1.11 (1.10-1.12)*** 1.00 (0.99-1.01) 
Diabetes Mellitus 1.02 (1.00-1.03)* 1.01 (0.99-1.02) 
Gestational Diabetes 0.99 (0.98-1.00)* 0.99 (0.98-1.00) 
Asthma 1.10 (1.09-1.11)*** 1.08 (1.07-1.10)*** 
Autoimmune Disease 0.99 (0.97-1.01) - 
Pain Condition 1.07 (1.06-1.08)*** 1.03 (1.02-1.04)*** 
Hepatitis C 0.97 (0.89-1.06) - 
*p<0.05, **p<0.01, ***p<0.001 
In the bivariate Cox regressions, the hazard of contraceptive provision was significantly 
higher for all categories of opioid use compared with women who did not use opioids during 
pregnancy (Table 4.16).  Women with chronic prescription opioid use had the highest hazard of 
contraceptive provision (HR: 1.32, 95% CI: 1.29-1.36).  The hazard of contraceptive provision 
decreased with age, with women in the oldest age groups significantly less likely to receive 
contraception than women aged 25-29.  Women with a comorbidity had a higher hazard of 
contraceptive provision compared with women who did not across all comorbidities, except for 
gestational diabetes, autoimmune disease, and hepatitis C.    
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Variables that reached a significance level of p<0.05 in the bivariate analysis or variables 
with a known or theoretical association with postpartum contraception were included in the 
multivariable model.  After adjustment, the association for the OUD/Bup group changed from an 
increased hazard in the bivariate analysis to a significantly decreased hazard in the multivariable 
model, compared to women who did not use opioids during pregnancy (Table 4.16).  The 
direction of association for the non-chronic and chronic prescription opioid use groups did not 
change, although the magnitude of the hazard was attenuated.   
The relationship between age and provision of contraception was unchanged after 
adjustment.  Women in the youngest age groups had significantly higher hazard of contraceptive 
provision, while women in the oldest age groups (≥30 years) a significantly lower hazard, 
compared to the reference group of women aged 25-29.  Several comorbidities were not 
significant in the multivariable model including non-opioid SUD, gestational hypertension, 
diabetes, and gestational diabetes.  Psychiatric disorders, chronic hypertension, asthma, and pain 
conditions remained significant; women with these conditions had a higher hazard of 
contraceptive provision than those without the conditions.  
A test of the proportion-hazards assumption for the multivariable Cox model was 
performed using Schoenfeld residual’s test, which tests whether the Schoenfeld residuals for 
each variable included in the model has a non-zero slope.  A non-zero slope, indicated by a p-
value<0.05, suggests that a given variable violates the PH assumption.  A global PH test was also 
performed on the full model.  The results of the Schoenfeld residual’s test and global test are 
displayed in Table 4.17.  Virtually every variable in the model included at least one category that 
violated the PH assumption.  The global test also indicated a violation of the PH assumption 
(p<<0.001).  These violations of the PH assumption were due in part to the large Aim 2 sample 
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size as p-values are dependent on sample size, even a small departure from a zero slope may 
result in a significant p-value.  However, in order to further assess the PH violations, an 
extensive sensitivity analysis was conducted.           
Table 4.17 Rho and P-Values for Schoenfeld Residual Tests of Proportional Hazards for 
Multivariable Cox Model 
Variable Rho P-Value 
Opioid Use   
No Opioid Use During Pregnancy Ref. - 
Non-Chronic Prescription Opioid Use 0.001 0.251 
Chronic Prescription Opioid Use -0.004 0.004 
OUD Diagnosis/Buprenorphine Prescription -0.004 0.001 
Age   
<20 0.04 <0.001 
20-24 0.04 <0.001 
25-29 Ref. - 
30-34 -0.02 <0.001 
35-39 -0.06 <0.001 
40+ -0.05 <0.001 
HRSA Region   
Region 1 0.006 <0.001 
Region 2 0.023 <0.001 
Region 3 Ref.  
Region 4 0.001 0.391 
Region 5 -0.000 0.752 
Region 6 -0.002 0.068 
Region 7 -0.003 0.007 
Region 8 -0.012 <0.001 
Region 9 0.003 0.011 
Region 10 -0.011 <0.001 
Unknown -0.002 0.195 
Delivery in State with ≥20% Hispanic 
Population 
-0.001 0.445 
Delivery in State with ≥20% Black Population 0.000 0.976 
Delivery in State with ≥15% Population in 
Poverty 
-0.011 <0.001 
Delivery in State with ≥35% Women with 
College Degree or More 
0.011 <0.001 
Insurance Plan Type   
PPO Ref. - 
Comprehensive -0.001 0.293 
HMO/EPO -0.010 <0.001 
POS/POS + Capitation 0.003 0.011 
CDHP -0.001 0.542 
HDHP -0.000 0.708 
Unknown -0.007 <0.001 
Year of Delivery   
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Variable Rho P-Value 
2011 Ref. - 
2012 -0.004 0.003 
2013 -0.015 <0.001 
2014 -0.016 <0.001 
2015 -0.012 <0.001 
2016 -0.013 <0.001 
Delivery Mode   
Vaginal Ref. - 
Cesarean -0.108 <0.001 
Non-Opioid Substance Use Disorder 0.002 0.138 
Psychiatric Disorder, Any 0.012 <0.001 
Chronic Hypertension -0.007 <0.001 
Gestational Hypertension 0.014 <0.001 
Diabetes Mellitus -0.007 <0.001 
Gestational Diabetes -0.008 <0.001 
Asthma 0.003 0.011 
Pain Condition 0.006 <0.001 
Global Test  <0.001 
 
Aim 2: Sensitivity Analyses 
Two separate sensitivity analyses were conducted for Aim 2.  The first analysis compared 
the cohort of women who met the inclusion criteria for Aim 2, those who did not meet the 
criteria, and the full cohort of women with a live birth during the study period.  This sensitivity 
analysis was designed to detect possible selection bias during creation of the analytic sample.  
The second sensitivity analysis addressed the PH violations in the multivariable Cox models.     
No major differences emerged between the women included in the Aim 2 analysis 
compared with those who were excluded.  However, they were only compared on the covariates 
available at the time of delivery which did not include opioid use during pregnancy, 
comorbidities, or postpartum contraceptive provision.  Among the covariates available for 
comparison, the groups were similar in age and geographic distribution, as well as for mode of 
delivery (Table 4.18).    
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Table 4.18 Sensitivity Analysis: Characteristics of Women with a Livebirth During Study 
Period (January 2011-December 2016), by Inclusion Criteria* 
 Met Aim 2 Inclusion 
Criteria 
Did Not Meet Aim 2 
Inclusion Criteria 
Full Sample with Live 
Birth 
Total N’s (%) 1,270,832 (53.7%) 1,096,031 (46.3%) 2,366,863 (100%) 
Age, mean years (SD) 30.2 (5.5) 29.8 (5.5) 30.0 (5.5) 
Age, Categorical    
<20 2.9% (37,089) 2.9% (31,416) 2.9% (68,505) 
20-24 12.4% (158,131) 14.6% (159,817) 13.4% (317,948) 
25-29 27.9% (354,483) 30.0% (328,577) 28.9% (683,060) 
30-34 35.1% (445,584) 33.2% (363,425) 34.2% (809,009) 
35-39 17.4% (221,526) 15.7% (172,067) 16.6% (393,593) 
40+ 4.2% (54,019) 3.7% (40,729) 4.0% (94,748) 
HRSA Region    
Region 1 4.3% (55,254) 3.6% (39,995) 4.0% (95,249) 
Region 2 7.3% (93,385) 9.2% (101,405) 8.2% (194,790) 
Region 3 8.8% (111,322) 9.3% (101,672) 9.0% (212,994) 
Region 4 20.9% (265,460) 19.7% (215,812) 20.3% (481,272) 
Region 5 18.6% (236,731) 18.0% (197,274) 18.3% (434,005) 
Region 6 13.3% (169,643) 13.5% (147,832) 13.4% (317,475) 
Region 7 4.0% (51,232) 3.8% (42,073) 3.9% (93,305) 
Region 8 3.2% (40,969) 2.9% (32,232) 3.1% (73,201) 
Region 9 12.2% (154,906) 11.1% (121,650) 11.7% (276,556) 
Region 10 3.9% (50,210) 3.3% (36,736) 3.7% (86,946) 
Unknown 3.3% (41,720) 5.4% (59,350) 4.3% (101,070) 
Delivery in State with 
≥20% Hispanic 
Population 
29.5% (374,670) 27.7% (303,131) 28.6% (677,801) 
Delivery in State with 
≥20% Black Population 
15.9% (202,221) 15.6% (170,878) 15.8% (373,099) 
Delivery in State with 
≥15% Population in 
Poverty 
13.1% (167,013) 14.4% (157,362) 13.7% (324,375) 
Delivery in State with 
≥35% Women with 
College Degree or More 
10.0% (127,759) 9.0% (98,736) 9.6% (226,495) 
Insurance Plan Type    
PPO 60.2% (764,813) 61.2% (670,765) 60.7% (1,435,578) 
Comprehensive 0.9% (11,523) 0.9% (9,531) 0.9% (21,054) 
HMO/EPO 14.9% (189,815) 13.9% (152,666) 14.5% (342,481) 
POS/POS+Capitation 7.2% (92,110) 6.1% (66,940) 6.7% (159,050) 
CDHP 7.5% (95,381) 5.7% (62,534) 6.7% (157,915) 
HDHP 5.6% (71,385) 6.0% (65,902) 5.8% (137,287) 
Unknown 3.6% (45,805) 6.2% (67,693) 4.8% (113,498) 
Year of Delivery    
2011 22.2% (282,670) 19.1% (209,474) 20.8% (492,144) 
2012 22.3% (283,552) 17.8% (195,595) 20.2% (479,147) 
2013 16.2% (205,679) 15.3% (167,797) 15.8% (373,476) 
2014 15.8% (201,057) 16.0% (174,891) 15.9% (375,948) 
2015 11.9% (151,938) 6.6% (72,100) 9.5% (224,038) 
2016 11.5% (145,936) 6.5% (71,655) 9.2% (217,591) 
2017 N/A 18.7% (204,519) 8.6% (204,519) 
Delivery Mode    
Vaginal 64.5% (819,145) 65.3% (715,851) 64.8% (1,534,996) 
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 Met Aim 2 Inclusion 
Criteria 
Did Not Meet Aim 2 
Inclusion Criteria 
Full Sample with Live 
Birth 
Cesarean 35.5% (451,687) 34.7% (380,180) 35.1% (831,867) 
*Notes for Table 4.18: only variables measured at time of delivery are assessed because this table includes women 
who did not meet inclusion criteria and therefore, did not have prenatal/postpartum data consistently available. 
N/A= Not applicable; indicates a variable that was not included in the research aim 
 
The second sensitivity analysis addressed the PH violations in the multivariable Cox 
model presented above.  Three multivariable Cox models were run across three different follow 
up time periods to address the PH assumption violations.  The first model (Model A) included 
the entire follow up period, from the date of delivery through 365 days postpartum and reflects 
the multivariable model presented in table 4.16.  The second model (Model B) followed women 
from the date of delivery through the first 60 days postpartum.  Model B included women who 
were provided contraception within 60 days postpartum, lost continuous coverage within 60 days 
postpartum, or were administratively censored at 60 days postpartum.  The final model, Model 
C, included the period from 61 days postpartum through 365 days postpartum.  Women included 
in Model C were those who maintained continuous coverage through at least 61 days postpartum 
but had not yet received postpartum contraception by that time.  These timeframes were selected 
because in both the Kaplan-Meier curves and log-log plots, the 60-day mark consistently 
coincided with a large increase in contraceptive provision.  The objective of running these three 
models was to estimate whether the direction of association between a given covariate and 
provision of contraception changed over the different time periods and what impact the 
conflicting hazard ratios had on the hazard ratio in Model A.  This approach also helped 
illuminate changing patterns in contraceptive provision over the postpartum period. 
Opioid use during pregnancy was the primary independent variable for which any 
potential PH violation was of concern.  Among women with non-chronic and chronic 
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prescription opioid use during pregnancy, the relationship with postpartum contraceptive 
provision was consistent across all three models; they had a higher hazard of contraceptive 
provision in all models than women who did not use opioids during pregnancy (Table 4.19).  The 
results for the OUD/Bup category, however, were not consistent across the models.  In the first 
zero-60 days postpartum (Model B), women with OUD/Bup had a significantly lower hazard of 
contraceptive provision than women who did not use opioids during pregnancy.  In Model C, 
covering 61-365 days postpartum, women in the OUD/Bup group who had not yet been provided 
contraception had a non-significant increased hazard of provision compared to women who did 
not use opioids during pregnancy and had yet to be provided contraception by 60 days 
postpartum.  This change in association over the two time periods resulted in a significant but 
attenuated hazard ratio in Model A (aHR: 0.93, 95% CI: 0.89-0.97), weighted towards the 
decreased hazard results of Model B.  This finding indicates that women in the OUD/Bup group 
had a lower hazard of provision of contraception in the early postpartum period, but after the first 
60 days postpartum, there was no significant difference in the instantaneous risk of contraceptive 
provision between OUD/Bup and non-opioid users among women who had not received 
contraception by 60 days postpartum.                        
 The age variable also displayed significant changes in the association across the three 
models.  Although age and postpartum contraceptive provision was not the focus of this analysis, 
age is an important adjustment variable and the magnitude of difference across the models is 
worth noting.  The direction of association was consistent for the three oldest age groups: 30-34, 
35-39, and 40+, with each group having a significantly lower hazard of contraceptive provision 
in each model.  Women in the two youngest age groups, <20 and 20-24, had a significantly lower 
hazard of contraception provision in the first 60 days postpartum than women aged 25-29 (Model 
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B), but in Model C, women aged <20 and 20-24 had a significantly increased hazard of 
contraceptive provision among women who had not received contraception by 60 days 
postpartum.  Model A results were weighted towards the model C results, with women aged <20 
(aHR: 1.14, 95% CI: 1.13-1.16) and 20-24 (aHR:  1.07, 95% CI: 1.06-1.08) having a 
significantly increased hazard of contraceptive provision.     
There were several other variables that demonstrated a change in association across the 
three models including selected HRSA regions, delivering in a state with 35% or more of women 
with at least a college degree, years 2012-2014, mode of delivery, non-opioid SUD, gestational 
hypertension, diabetes, and gestational diabetes.  These PH violations were of minimal concern 
because the analysis was not focused on the relationship between the covariates and postpartum 
contraceptive provision, rather, they were included to adjusted for potential confounding. 
Table 4.19 Adjusted Hazard Ratios for Prescription Contraceptive Provision, Comparing 
Three Time Periodsǂ 
 Model A Model B Model C 
Sample Size N=1,270,832 N=1,270,832 N=742,035 
Opioid Use    
No Opioid Use During Pregnancy (ref.) (ref.) (ref.) 
Non-Chronic Prescription Opioid 
Use 
1.15 (1.14-1.16)*** 1.13 (1.12-1.14)*** 1.19 (1.17-1.21)*** 
Chronic Prescription Opioid Use 1.24 (1.21-1.27)*** 1.23 (1.19-1.27)*** 1.27 (1.21-1.34)*** 
OUD Diagnosis/Buprenorphine Rx 0.93 (0.89-0.97)** 0.85 (0.81-0.90)*** 1.05 (0.99-1.13) 
Age    
<20 1.14 (1.13-1.16)*** 0.95 (0.94-0.97)*** 1.65 (1.62-1.69)*** 
20-24 1.07 (1.06-1.08)*** 0.97 (0.96-0.98)*** 1.35 (1.33-1.37)*** 
25-29 (ref.) (ref.) (ref.) 
30-34 0.89 (0.88-0.89)*** 0.91 (0.90-0.92)*** 0.82 (0.81-0.83)*** 
35-39 0.78 (0.78-0.79)*** 0.85 (0.84-0.86)*** 0.65 (0.64-0.66)*** 
40+ 0.64 (0.63-0.65)*** 0.73 (0.72-0.74)*** 0.47 (0.46-0.48)*** 
HRSA Region    
Region 1 1.00 (0.99-1.02) 0.96 (0.94-0.98)*** 1.11 (1.08-1.14)*** 
Region 2 0.78 (0.77-0.80)*** 0.73 (0.71-0.74)*** 0.91 (0.89-0.93)*** 
Region 3 (ref.) (ref.) (ref.) 
Region 4 1.20 (1.18-1.22)*** 1.21 (1.18-1.23)*** 1.18 (1.15-1.22)*** 
Region 5 1.04 (1.02-1.05)*** 1.05 (1.04-1.07)*** 0.99 (0.97-1.01) 
Region 6 1.26 (1.24-1.28)*** 1.30 (1.28-1.33)*** 1.15 (1.11-1.19)*** 
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 Model A Model B Model C 
Region 7 1.19 (1.17-1.21)*** 1.23 (1.21-1.25)*** 1.08 (1.05-1.11)*** 
Region 8 1.27 (1.25-1.29)*** 1.35 (1.32-1.37)*** 1.06 (1.03-1.10)*** 
Region 9 1.02 (1.00-1.04)* 1.04 (1.01-1.06)** 0.98 (0.94-1.01) 
Region 10 1.19 (1.17-1.21)*** 1.25 (1.22-1.27)*** 1.03 (1.01-1.07)* 
Unknown 1.12 (1.10-1.14)*** 1.12 (1.10-1.15)*** 1.09 (1.05-1.12)*** 
Delivery in State with ≥20% 
Hispanic Population 
0.92 (0.91-0.93)*** 0.89 (0.88-0.91)*** 0.97 (0.95-0.99)* 
Delivery in State with ≥20% 
Black Population 
1.02 (1.01-1.03)*** 1.02 (1.00-1.03)* 1.04 (1.02-1.06)*** 
Delivery in State with ≥15% 
Population in Poverty 
1.06 (1.05-1.08)*** 1.08 (1.07-1.09)*** 1.02 (0.99-1.04) 
Delivery in State with ≥35% 
Women with College Degree or 
More 
0.99 (0.98-1.00) 0.96 (0.94-0.97)*** 1.04 (1.02-1.07)*** 
Insurance Plan Type    
PPO (ref.) (ref.) (ref.) 
Comprehensive 0.98 (0.95-1.00) 0.97 (0.94-1.01) 0.97 (0.93-1.02) 
HMO/EPO 1.04 (1.03-1.05)*** 1.06 (1.05-1.07)*** 0.99 (0.98-1.01) 
POS/POS + Capitation 1.01 (1.00-1.02)* 1.00 (0.99-1.01) 1.03 (1.02-1.05)*** 
CDHP 1.00 (0.99-1.01) 1.01 (1.00-1.02) 0.98 (0.96-0.99)* 
HDHP 0.95 (0.94-0.96)*** 0.96 (0.94-0.97)*** 0.95 (0.93-0.97)*** 
Unknown 1.02 (1.00-1.03)* 1.04 (1.03-1.06)*** 0.94 (0.91-0.97)*** 
Year of Delivery    
2011 (ref.) (ref.) (ref.) 
2012 0.99 (0.98-1.00) 1.01 (1.00-1.02) 0.96 (0.95-0.97)*** 
2013 1.02 (1.01-.103)*** 1.06 (1.05-1.07)*** 0.93 (0.92-0.95)*** 
2014 0.99 (0.98-0.99)** 1.03 (1.02-1.04)*** 0.90 (0.88-0.91)*** 
2015 0.94 (0.93-0.95)*** 0.98 (0.97-0.99)*** 0.86 (0.85-0.88)*** 
2016 0.91 (0.90-0.92)*** 0.95 (0.94-0.96)*** 0.81 (0.79-0.82)*** 
Delivery Mode    
Vaginal (ref.) (ref.) (ref.) 
Cesarean 1.30 (1.29-1.31)*** 1.43 (1.42-1.44)*** 1.00 (0.99-1.01) 
Non-Opioid Substance Use 
Disorder 
1.02 (0.99-1.04) 0.99 (0.97-1.02) 1.05 (1.01-1.09)* 
Psychiatric Disorder, Any 1.10 (1.09-1.11)*** 1.06 (1.04-1.07)*** 1.21 (1.19-1.24)*** 
Chronic Hypertension 1.09 (1.08-1.10)*** 1.09 (1.08-1.11)*** 1.08 (1.06-1.10)*** 
Gestational Hypertension 1.00 (0.99-1.01) 0.98 (0.97-0.99)*** 1.06 (1.05-1.08)*** 
Diabetes Mellitus 1.01 (0.99-1.02) 1.02 (1.01-1.03)** 0.97 (0.95-1.00) 
Gestational Diabetes 0.99 (0.98-1.00) 1.00 (0.99-1.01) 0.97 (0.96-0.99)** 
Asthma 1.08 (1.07-1.10)*** 1.08 (1.06-1.09)*** 1.11 (1.08-1.13)*** 
Pain Condition 1.03 (1.02-1.04)*** 1.01 (1.00-1.02)* 1.08 (1.06-1.10)*** 
*p<0.05, **p<0.01, ***p<0.001 
ǂ Italicized hazard ratios are those that change in direction of association across the presented models 
 
4.5 Aim 3 Results 
The Aim 3 analysis was restricted to women with evidence of opioid use during 
pregnancy; the sample excluded women with no evidence of opioid use.  Table 4.20 displays the 
descriptive characteristics of the Aim 3 cohort.  The majority of live births were to women ages 
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30-34 and who lived in HRSA Region’s 4, 5, and 6 which primarily include states in the South, 
Southwest, and Midwest.  Approximately 3.0% of livebirths were to women with unknown 
geographic region.  The majority of women were insured through a PPO plan type.  Clinically, 
over 45% of women had a cesarean delivery and the most common comorbidity experienced 
during pregnancy was gestational diabetes, followed closely by gestational hypertension.  
Provision of prescription contraception was 41.6% by 60 days postpartum.  Approximately 1% 
of infants born to women in the Aim 3 cohort were diagnosed with NAS and 13% were admitted 
to the NICU.  The mean hospital length of stay for infants was 4.6 days.   
The cohort for Aim 3 was substantially smaller and differed from the samples for Aims 1 
and 2 across several key variables because Aim 3 included only women with evidence of opioid 
use.  The average age of delivery was slightly older for Aim 3 compared with Aims 1 and 2, as 
noted by a slightly higher percentage of women in the Aim 3 cohort aged 30 years or older at the 
time of delivery.  The distribution of livebirths across HRSA regions was similar for Aims 1-3, 
with the Aim 3 cohort having slightly less representation in the Northeast regions (HRSA 
Regions 1-3) and slightly more from the South and Midwest (HRSA Regions 6-8).  The Aim 3 
cohort had a higher prevalence of every comorbidity, with a pronounced increase in the 
proportion of women with non-opioid SUD, psychiatric diagnoses, and pain conditions. 
Postpartum contraceptive provision within 60 days postpartum was slightly higher in the Aim 3 
cohort compared to Aim 1, with the major difference stemming from higher levels of female 
sterilization in the Aim 3 cohort.               
Table 4.20 Descriptive Characteristics of Aim 3 Cohort, Column Totals 
Variable Aim 3 Cohort, % (N) 
Total N 63,897 
Opioid Use During Pregnancy  
Non-Chronic Prescription Use 89.8% (57,394) 
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Variable Aim 3 Cohort, % (N) 
Chronic Prescription Use 7.6% (4,875) 
OUD Diagnosis/Bup Prescription 2.5% (1,628) 
Age, mean years (SD) 31.3 (4.8) 
Age, Categorical  
<20 0.4% (272) 
20-24 6.9% (4,409) 
25-29 28.9% (18,487) 
30-34 38.1% (24,350) 
35-39 20.5% (13,116) 
40+ 5.1% (3,263) 
HRSA Region  
Region 1 3.6% (2,334) 
Region 2 6.1% (3,909) 
Region 3 6.3% (4,046) 
Region 4 23.0% (14,687) 
Region 5 19.0% (12,154) 
Region 6 17.2% (11,005) 
Region 7 4.8% (3,102) 
Region 8 4.2% (2,665) 
Region 9 8.0% (5,128) 
Region 10 4.7% (3,007) 
Unknown 2.9% (1,860) 
Delivery in State with ≥20% Hispanic 
Population 
30.3% (19,368) 
Delivery in State with ≥20% Black Population 16.0% (10,213) 
Delivery in State with ≥15% Population in 
Poverty 
13.0% (8,307) 
Delivery in State with ≥35% Women with 
College Degree or More 
8.1% (5,190) 
Insurance Plan Type  
PPO 62.1% (39,652) 
Comprehensive 1.1% (681) 
HMO/EPO 13.3% (8,486) 
POS/POS+Capitation 7.7% (4,924) 
CDHP 7.7% (4,892) 
HDHP 5.0% (3,169) 
Unknown 3.3% (2,093) 
Year of Delivery  
2011 25.7% (16,456) 
2012 22.8% (14,555) 
2013 15.6% (9,974) 
2014 13.5% (8,628) 
2015 10.1% (6,452) 
2016 8.6% (5,529) 
2017 3.6% (2,303) 
Delivery Mode  
Vaginal 53.4% (34,120) 
Cesarean Section 46.6% (29,777) 
Non-Opioid Substance Use Disorder 3.1% (1,965) 
Any Psychiatric Diagnoses 9.7% (6,191) 
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Variable Aim 3 Cohort, % (N) 
Chronic Hypertension 12.6% (8,068) 
Gestational Hypertension 17.2% (11,010) 
Diabetes Mellitus 5.0% (3,017) 
Gestational Diabetes 17.9% (11,431) 
Asthma 6.9% (4,397) 
Autoimmune Disease 3.3% (2,137) 
Pain Condition 16.8% (10,754) 
Hepatitis C 0.1% (86) 
Any ANC 98.1% (62,699) 
Postpartum Care Visit within 60 Days 50.4% (32,218) 
Contraceptive provision within 60 Days 
Postpartum 
 
No Provision 58.3% (37,287) 
Evidence of Provision 41.6% (26,610) 
Sterilization 10.1% (6,478) 
LARC 7.0% (4,468) 
Moderately Effective Methods 24.5% (15,664) 
NAS Diagnosis, Infant 1.3% (852) 
NICU Admissions, Infant 13.0% (8,310) 
Mean Hospital Length of Stay (Days), Infant 4.6 (8.8) 
 
Approximately 90% of women in the Aim 3 cohort had evidence of non-chronic 
prescription use during pregnancy; 9.6% with chronic prescription opioid use; and 2.5% 
OUD/Bup use (Table 4.21).  As with cohorts for Aims 1 and 2, women in the chronic 
prescription opioid group were the oldest and women in the OUD/Bup group, the youngest.  
Women who had cesarean delivery were more likely to have chronic prescription opioid use than 
women with vaginal deliveries.  With the exception of hepatitis C, women with a given 
comorbidity had a higher prevalence of chronic prescription opioid use than women who did not 
have a comorbidity.  Women with non-opioid SUD, a psychiatric diagnosis, autoimmune 
disease, and pain conditions had particularly high levels of chronic prescription opioid use.  Over 
50% of women with non-opioid SUD or with hepatitis C had OUD/Bup.   
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Total N (%) 57,394 (89.8%) 4,875 (9.6%) 1,628 (2.5%) 
Age, mean years (SD) 31.3 (4.8) 32.2 (4.7) 30.4 (5.3) 
Age, Categorical    
<20 87.1% (237) 2.2% (6) 10.7% (29) 
20-24 90.7% (4,000) 4.6% (202) 4.7% (207) 
25-29 91.0% (16,822) 6.7% (1,231) 2.3% (434) 
30-34 89.5% (21,805) 8.1% (1,964) 2.4% (581) 
35-39 88.8% (11,647) 8.8% (1,160) 2.4% (309) 
40+ 88.3% (2,883) 9.6% (312) 2.1% (68) 
HRSA Region    
Region 1 90.6% (2,114) 5.8% (135) 3.6% (85) 
Region 2 86.4% (3,377) 7.8% (307) 5.8% (225) 
Region 3 88.1% (3,565) 8.3% (336) 3.6% (145) 
Region 4 90.9% (13,348) 6.9% (1,022) 2.2% (317) 
Region 5 88.7% (10,785) 8.5% (1,028) 2.8% (341) 
Region 6 91.4% (10,061) 6.9% (764) 1.6% (180) 
Region 7 91.4% (2,824) 7.7% (239) 1.3% (39) 
Region 8 89.6% (2,389) 8.3% (222) 2.0% (54) 
Region 9 89.5% (4,590) 8.5% (434) 2.0% (104) 
Region 10 88.9% (2,674) 7.9% (238) 3.2% (95) 
Unknown 89.6% (1,667) 8.1% (150) 2.3% (43) 
Delivery in State with ≥20% Hispanic Population 
Yes 90.9% (17,613) 7.3% (1,410) 1.8% (345) 
No 89.3% (39,781) 7.8% (3,465) 2.8% (1,283) 
Delivery in State with ≥20% Black Population 
Yes 90.9% (9,285) 6.9% (711) 2.1% (217) 
No 89.6% (48,109) 7.7% (4,164) 2.6% (1,411) 
Delivery in State with ≥15% Population in Poverty 
Yes 89.5% (7,434) 7.6% (631) 2.9% (242) 
No 89.9% (49,960) 7.6% (4,244) 2.5% (1,386) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 90.1% (4,674) 7.0% (365) 2.9% (151) 
No 89.8% (52,720) 7.7% (4,510) 2.5% (1,477) 
Insurance Plan Type    
PPO 89.5% (35,477) 7.9% (3,118) 2.7% (1,057) 
Comprehensive 83.0% (565) 11.4% (78) 5.6% (38) 
HMO/EPO 91.1% (7,728) 7.0% (594) 1.9% (164) 
POS/POS+Capitation 90.3% (4,449) 6.9% (340) 2.7% (135) 
CDHP 90.5% (4,426) 7.4% (361) 2.1% (105) 
HDHP 91.0% (2,884) 6.8% (215) 2.2% (70) 
Unknown 89.1% (1,865) 8.1% (169) 2.8% (59) 
Year of Delivery    
2011 91.0% (14,974) 7.1% (1,177) 1.8% (305) 








2013 90.0% (8,974) 7.7% (773) 2.3% (227) 
2014 88.6% (7,641) 8.7% (748) 2.8% (239) 
2015 88.4% (5,706) 8.0% (517) 3.5 (229) 
2016 89.2% (4,930) 7.5% (413) 3.4% (186) 
2017 88.3% (2,033) 5.9% (136) 5.8% (134) 
Delivery Mode    
Vaginal 90.2% (30,773) 7.2% (2,460) 2.6% (887) 
Cesarean 89.4% (26,621) 8.1% (2,415) 2.5% (741) 
Non-Opioid Substance Use Disorder 
Yes 32.2% (632) 15.9% (312) 51.9% (1,021) 
No 91.6% (56,762) 7.4% (4,563) 1.0% (607) 
Any Psychiatric Diagnoses    
Yes 76.9% (4,762) 15.0% (927) 8.1% (502) 
No 91.2% (52,632) 6.8% (3,948) 1.9% (1,126) 
Chronic Hypertension    
Yes 86.0% (6,938) 11.0% (885) 3.0% (245) 
No 90.4% (50,456) 7.1% (3,990) 2.5% (1,383) 
Gestational Hypertension    
Yes 88.0% (9,693) 9.6% (1,057) 2.4% (260) 
No 90.2% (47,701) 7.2% (3,818) 2.6% (1,368) 
Diabetes Mellitus    
Yes 87.6% (3,407) 9.5% (368) 2.9% (114) 
No 90.0% (53,987) 7.5% (4,507) 2.5% (1,514) 
Gestational Diabetes    
Yes 89.9% (10,280) 8.2% (935) 1.9% (216) 
No 89.8% (47,114) 7.5% (3,940) 2.7% (1,412) 
Asthma    
Yes 87.2% (3,834) 10.0% (440) 2.8% (123) 
No 90.0% (53,560) 7.4% (4,435) 2.5% (1,505) 
Autoimmune Disease    
Yes 78.4% (1,675) 18.3% (391) 3.3% (71) 
No 90.2% (55,719) 7.3% (4,484) 2.5% (1,557) 
Pain Condition    
Yes 80.4% (8,643) 16.0% (1,723) 3.6% (388) 
No 91.7% (48,751) 5.9% (3,152) 2.3% (1,240) 
Hepatitis C    
Yes 38.4% (33) 4.6% (4) 57.0% (49) 
No 89.9% (57,361) 7.6% (4,871) 2.5% (1,579) 
Any ANC    
Yes 89.8% (56,307) 7.6% (4,797) 2.5% (1,595) 
No 90.7% (1,087) 6.5% (78) 2.7% (33) 
Postpartum Care Visit within 60 Days 








No 90.8% (28,765) 6.8% (2,159) 2.4% (764) 
Provision of Prescription Contraceptive within 60 Days Postpartum 
No Evidence of Provision 90.0% (33,560) 7.2% (2,692) 2.8% (1,035) 
Evidence of Provision 89.6% (23,834) 8.2% (2,183) 2.2% (593) 
Sterilization 85.8% (5,556) 11.4% (736) 2.9% (186) 
LARC 90.1% (4,028) 7.3% (327) 2.5% (113) 
Moderately Effective Methods 91.0% (14,250) 7.1% (1,120) 1.9% (294) 
 
Dependent Variable: Postpartum prescription Contraceptive Provision 
The dependent variable in Aim 3 was provision of prescription contraception within 60 
days postpartum, measured as a binary variable.  In the Aim 3 cohort, 41.6% of women were 
provided prescription contraception within 60 days postpartum (Table 4.22), higher than the 
37.6% of women in the Aim 1 cohort.  This finding was expected as women with non-chronic 
and chronic prescription opioid use had higher levels of contraceptive provision within 60 days 
postpartum than women who did not use opioids during pregnancy.  The trends in provision 
across the study period mirrored those observed in Aim 1 showing an overall decline in 
contraception provision, with sterilization declining (p for tend<0.00), LARC provision 
increasing (p for tend<0.00), and variable MEM provision, but declining in the final study year 
(Figure 4.11)  
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Figure 4.11 Trends for Provision of Prescription Contraception within 60 Days 
Postpartum, Overall and by Method Type, Aim 3 Cohort 
 
Levels of contraceptive provision among the different categories of opioid use paralleled 
those in Aim 1, with contraceptive provision highest among women with chronic prescription 
opioid use and lowest in the OUD/Bup group.  The covariates included in the Aim 3 analysis 
were explored using a binary measure of contraceptive provision rather than stratifying by 
method type due to a smaller number of observations in the sample.  Patterns for contraceptive 
provision by age group and geographic region were similar to those in Aim 1.  Contraceptive 
provision decreased with age.  There was substantial regional variation in contraceptive 
provision by HRSA regions, ranging from a low of 30.4% in Region 2 (NY, NJ, PR) to a high of 
46.2% in Region 8 (MT, ND, SD, WY, UT, CO).  Contraceptive provision was variable across 
the different comorbidities: women with non-opioid SUD, diabetes, gestational diabetes, 
autoimmune disease, and hepatitis C has lower levels of contraceptive provision compared to 
some without these comorbidities.  For the remaining comorbidities, including psychiatric 
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with the comorbidity had higher levels of contraceptive provision.  Women with cesarean 
deliveries had substantially higher levels of contraceptive provision than women with vaginal 
deliveries, a trend observed across all three Aims.  Women with a postpartum care visit within 60 
days also had considerably higher levels of contraceptive provision than women with no 
postpartum visit.     
Table 4.22 Characteristics of Aim 3 Cohort by Postpartum Contraceptive Provision within 
60 Days of Delivery, Row Totals 
 Not Provided Contraception  Provided Contraception  
Total N 37,287 (58.3%) 26,610 (41.6%) 
Opioid Use During Pregnancy   
Non-Chronic Prescription Use 58.5% (33,560) 41.5% (23,834) 
Chronic Prescription Use 55.2% (2,692) 44.8% (2,183) 
OUD Diagnosis/Bup Prescription 63.6% (1,035) 36.4% (593) 
Age, mean years (SD) 31.6 (4.9) 31.0 (4.7) 
Age, Categorical   
<20 57.7% (157) 42.3% (115) 
20-24 54.5% (2,401) 45.5% (2,008) 
25-29 54.9% (10,157) 45.1% (8,330) 
30-34 58.8% (14,318) 41.2% (10,032) 
35-39 61.8% (8,105) 38.2% (5,011) 
40+ 65.9% (2,149) 34.1% (1,114) 
HRSA Region   
Region 1 65.5% (1,528) 34.5% (806) 
Region 2 69.6% (2,722) 30.4% (1,187) 
Region 3 63.8% (2,581) 36.2% (1,465) 
Region 4 55.4% (8,137) 44.6% (6,550) 
Region 5 59.5% (7,231) 40.5% (4,923) 
Region 6 54.3% (6,001) 45.5% (5,004) 
Region 7 54.5% (1,691) 45.5% (1,411) 
Region 8 53.8% (1,433) 46.2% (1,232) 
Region 9 63.7% (3,266) 36.3% (1,862) 
Region 10 55.1% (1,657) 44.9% (1,350) 
Unknown  44.1% (820) 
Delivery in State with ≥20% Hispanic Population 
Yes 59.2% (11,470) 40.8% (7,898) 
No 58.0% (25,817) 42.0% (18,712) 
Delivery in State with ≥20% Black Population 
Yes 54.7% (5,589) 45.3% (4,624) 
No 59.0% (31,698) 40.9% (21,986) 
Delivery in State with ≥15% Population in Poverty 
Yes 53.2% (4,422) 46.8% (3,885) 
No 59.1% (32,865) 40.9% (22,725) 
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 Not Provided Contraception  Provided Contraception  
Delivery in State with ≥35% Women with College Degree or More 
Yes 66.1% (3,433) 33.8% (1,757) 
No 57.7% (33,854) 42.3% (24,853) 
Insurance Plan Type   
PPO 58.4% (23,161) 41.6% (16,491) 
Comprehensive 55.6% (379) 44.3% (302) 
HMO/EPO 58.4% (4,955) 41.6% (3,531) 
POS/POS+Capitation 58.1% (2,859) 41.9% (2,065) 
CDHP 57.1% (2,795) 42.9% (2,097) 
HDHP 60.5% (1,918) 39.5% (1,251) 
Unknown 58.3% (1,220) 41.7% (873) 
Year of Delivery   
2011 58.5% (9,635) 41.4% (6,821) 
2012 57.7% (8,406) 42.3% (6,149) 
2013 57.0% (5,682) 43.0% (4,292) 
2014 57.6% (4,971) 42.4% (3,657) 
2015 59.9% (3,865) 40.1% (2,587) 
2016 59.4% (3,284) 40.6% (2,245) 
2017 62.7% (1,444) 37.3% (859) 
Delivery Mode   
Vaginal 62.2% (21,231) 37.8% (12,889) 
Cesarean 53.9% (16,056) 46.1% (13,721) 
Non-Opioid Substance Use Disorder 
Yes 59.4% (1,168) 40.6% (797) 
No 58.3% (36,119) 41.7% (25,813) 
Any Psychiatric Diagnoses   
Yes 57.0% (3,529) 43.0% (2,662) 
No 58.5% (33,758) 41.5% (23,948) 
Chronic Hypertension   
Yes 55.4% (4,471) 44.6% (3,597) 
No 58.8% (32,816) 41.2% (23,013) 
Gestational Hypertension   
Yes 56.9% (6,262) 43.1% (4,748) 
No 58.7% (31,025) 41.3% (21,862) 
Diabetes Mellitus   
Yes 59.5% (2,315) 40.5% (1,574) 
No 58.3% (34,972) 41.7% (25,036) 
Gestational Diabetes   
Yes 58.8% (6,726) 41.2% (4,705) 
No 58.2% (30,561) 41.7% (21,905) 
Asthma   
Yes 57.0% (2,507) 43.0% (1,890) 
No 58.4% (34,780) 41.5% (24,720) 
Autoimmune Disease   
Yes 58.8% (1,256) 41.2% (881) 
No 58.3% (36,031) 41.7% (25,729) 
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 Not Provided Contraception  Provided Contraception  
Pain Condition   
Yes 56.7% (6,101) 43.3% (4,653) 
No 58.7% (31,186) 41.3% (21,957) 
Hepatitis C   
Yes 65.1% (56) 34.9% (30) 
No 58.3% (37,231) 41.6% (26,580) 
Any ANC   
Yes 58.4% (36,595) 41.6% (26,104) 
No 57.7% (692) 42.2% (506) 
Postpartum Care Visit within 60 Days 
Yes 52.2% (16,831) 47.8% (15,387) 
No 64.6% (20,456) 35.4% (11,223) 
 
Aim 3: Additional Exploratory Data Analysis 
Inclusion of infant-level variables related to NAS, NICU admission, and hospital length 
of stay (LOS) required additional exploratory data analysis for the Aim 3 cohort.  Cross-
tabulations of the data were run to assess the distribution of opioid use and contraceptive 
methods across infant level variables.  Of the 63,897 infant-mother dyads included in the 
analysis for Aim 3, 852 infants (1.3%) were diagnosed with non-iatrogenic NAS.  Among infants 
with mothers in the OUD/Bup group, 27.8% were diagnosed with NAS, as were 5.2% of infants 
born to women with chronic prescription opioid use (Table 4.23).  Approximately 13% of infants 
in the Aim 3 cohort were admitted to the NICU (n=8,310).  Women in the OUD/Bup group were 
more likely to have infants admitted to the NICU (Table 4.23).  The average infant hospital 
length of stay for the Aim 3 cohort was 4.6 days (SD: 8.8).  Infants born to women in the 
OUD/Bup group had the longest average length of stay, while infants born to women with non-
chronic prescription opioid use had the shortest stays, 30% shorter in length than infants born to 
women in the OUD/Bup group.      
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Table 4.23 Type of Opioid Use by Infant-Level Variables (N=63,897), Column Totals 
 Type of Opioid Use 





Yes 0.2% (146) 5.2% (254) 27.8% (452) 
No 99.8% (57,248) 94.8% (4,621) 72.2% (1,176) 
NICU Admission    
Yes 12.7% (7,320) 14.3% (697) 18.0% (293) 
No 87.2% (50,074) 85.7% (4,178) 82.0% (1,335) 
Infant Hospital LOS (mean, SD) 4.5 (8.8) 4.8 (8.6) 6.5 (9.5) 
 
Contraceptive provision differed significantly by the infant variables (Table 4.24).  
Women whose infants were diagnosed with NAS had substantially lower levels of contraceptive 
provision than women whose infants did not have NAS (35.3% vs 41.7%) (Table 4.24).  Despite 
the lower overall levels of contraceptive provision, sterilization was higher among women with 
infants diagnosed with NAS, while LARC and MEM provision was lower.  Women with infants 
admitted to the NICU for any length of time also had lower levels of contraceptive provision, 
overall and for all method types.  Infant hospital LOS varied significantly for women who were 
and were not provided contraception.  Among women provided contraception, the average 
hospital length of stay for their infants was 4.2 days (95% CI: 4.13-4.32)) compared with 4.8 
days (95% CI: 4.74-9.93) for women who were not provided contraception (Figure 4.12; Table 
4.24).  Women ultimately provided LARC had infants with the shortest average LOS (3.8 days, 
95% CI: 3.60-4.04).      
Table 4.24 Method of Prescription Contraception Provided within 60 Days Postpartum by 
Infant Variables (N=63,897), Row Totals 
Infant Variable, 
% (N) 
No Provision Provided 
Contraception 
Sterilization LARC Moderately 
Effective 
Methods 
NAS Diagnosis      
Yes 64.7% (551) 35.3% (301) 13.1% (112) 5.0% (43) 17.1% (146) 
No 58.3% (36,736) 41.7% (26,309) 10.1% (6,366) 7.0% (4,425) 24.6% (15,518) 
NICU 
Admission 
     
Yes 61.0% (5,070) 39.0% (3,240) 9.8% (815) 6.1% (509) 23.1% (1,916) 






4.8 (4.74-9.93) 4.2 (4.13-4.32) 4.3 (4.12-4.47) 3.8 (3.60-4.04) 4.3 (4.19-4.45) 
 
Figure 4.12 Average Infant Hospital Length of Stay (Mean, 95% CI) by Contraceptive 
Method Type 
 
Severity of the NAS diagnosis was also explored in relation to contraceptive provision.  
A table of contraceptive method type stratified by NAS diagnosis and NICU admission was 
created to assess if levels contraceptive provision changed across strata of NAS diagnosis and 
NICU admission (Table 4.25).  Women with infants who were both admitted to the NICU and 
had an NAS diagnosis had the lowest overall levels of contraceptive provision, particularly the 
lowest levels of LARC and MEM provision.  In contrast, women with infants who had neither an 
NAS diagnosis nor an admission to the NICU had the highest levels of contraceptive provision, 
including for LARC and MEM.         
Table 4.25 Contraceptive Method Provided within 60 Days Postpartum by Infant NAS 
Status and NICU Admission, Column Totals 
 NAS Diagnosis in Infant (N=852) No NAS Diagnosis in Infant (N=63,045) 
Contraceptive Method 
Type 
Admitted to NICU 
(N=243) 
Not Admitted to 
NICU 
(N=609) 
Admitted to NICU 
(N=8,067) 



























No Provision 69.1% (168) 62.9% (383) 60.8% (4,902) 57.9% (31,834) 
Provided 
Contraception 
30.8% (75) 37.1% (226) 39.2% (3,165) 42.1% (23,144) 
Sterilization 11.5% (28) 13.8% (84) 9.8% (787) 10.1% (5,579) 
LARC 4.9% (12) 5.1% (31) 6.2% (497) 7.1% (3,928) 
Moderately Effective 
Methods 
14.4% (35) 18.2 (111) 23.3% (1,881) 24.9% (13,637) 
         
Aim 3: Logistic Regression Models, Unadjusted and Adjusted 
The unadjusted and adjusted odds of contraceptive provision within 60 days postpartum 
are presented in Table 4.26.  Insurance plan type, hepatitis C, and any ANC were not included in 
the multivariable model because they were not significant (p<0.05) in the bivariate analysis and 
did not have a compelling theoretical reason for remaining in the multivariable model.  The 
relationship between type of opioid use during pregnancy and contraceptive provision in the 
adjusted model was consistent with the findings in the unadjusted model.  Women with chronic 
prescription use had increased odds of contraceptive provision (aOR: 1.11, 95% CI: 1.05-1.18) 
whereas women with OUD/Bup had decreased odds (aOR: 0.83, 95% CI: 0.72-0.94) compared 
to women with non-chronic prescription opioid use.  NAS diagnosis and NICU admission for the 
infant were no longer significant after adjustment for confounders but the relationship between 
hospital LOS and contraceptive provision not only remained significant but increased in 
magnitude (aOR: 0.989, 95% CI: 0.986-0.991).  The relationship between age and contraceptive 
provision was unchanged from the unadjusted model, with the odds of provision decreasing with 
increasing age.  Women with cesarean deliveries were significantly more likely to receive 
contraception than women with vaginal deliveries in both the adjusted and unadjusted models.   
Women in HRSA regions 4, 6-8, 10, (South, Southwest, West) and those from an 
unknown region had significantly higher odds of contraceptive provision than women in Region 
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3 (reference- PA, MD, DE, VA, WV).  Women who delivered in states with 20% or more 
Hispanic population or in a state where 35% of more of women had a least a college degree had 
significantly lower odds of contraceptive provision.  Women delivering in states with 20% or 
more Black population or states with 15% or more of the population in poverty had significantly 
higher odds of contraceptive provision.  Among the chronic conditions, women with a 
psychiatric diagnosis or chronic hypertension had significantly increased odds of provision while 
women with diabetes had significantly lower odds of contraceptive provision compared to 
women without those conditions.  Non-opioid SUD, gestational diabetes, asthma, and 
autoimmune disease remained non-significant in the adjusted model; gestational hypertension 
and pain conditions became non-significantly in the multivariable model.  Finally, a postpartum 
care visit within 60 days continued to be significantly associated with provision of contraception 
(aOR: 1.64, 95% CI: 1.59-1.69).   
Table 4.26 Unadjusted and Adjusted Odds of Any Prescription Contraceptive Provision 
within 60 Days Postpartum Among Women Who used Opioids During Pregnancy 
(N=63,897) 
 Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Opioid Use During Pregnancy   
Non-Chronic Prescription Use (ref.) (ref.) 
Chronic Prescription Use 1.14 (1.08-1.21)*** 1.11 (1.05-1.18)*** 
OUD Diagnosis/Bup Prescription 0.81 (0.73-0.89)*** 0.83 (0.72-0.94)* 
Age   
<20 0.89 (0.70-1.14) 0.98 (0.77-1.26) 
20-24 1.02 (0.95-1.09) 1.05 (0.98-1.12) 
25-29 (ref.) (ref.) 
30-34 0.85 (0.82-0.89)*** 0.86 (0.82-0.89)*** 
35-39 0.75 (0.72-0.79)*** 0.75 (0.71-0.79)*** 
40+ 0.63 (0.58-0.68)*** 0.62 (0.57-0.67)*** 
HRSA Region   
Region 1 0.93 (0.83-1.03) 1.01 (0.90-1.14) 
Region 2 0.77 (0.70-0.84)*** 0.79 (0.71-0.87)*** 
Region 3 (ref.) (ref.) 
Region 4 1.42 (1.32-1.52)*** 1.17 (1.04-1.30)** 
Region 5 1.20 (1.11-1.29)*** 1.07 (0.99-1.16) 
Region 6 1.47 (1.36-1.58)*** 1.43 (1.26-1.61)*** 
Region 7 1.47 (1.34-1.62)*** 1.33 (1.20-1.48)*** 
Region 8 1.52 (1.37-1.67)*** 1.52 (1.37-1.69)*** 
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 Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Region 9 1.00 (0.92-1.09) 1.05 (0.92-1.20) 
Region 10 1.43 (1.30-1.58)*** 1.29 (1.16-1.43)*** 
Unknown 1.39 (1.24-1.55)*** 1.27 (1.13-1.43)*** 
Delivery in State with ≥20% Hispanic 
Population 
0.95 (0.92-0.98)** 0.88 (0.81-0.97)** 
Delivery in State with ≥20% Black 
Population 
1.19 (1.14-1.24)*** 1.09 (1.01-1.17)* 
Delivery in State with ≥15% 
Population in Poverty 
1.27 (1.21-1.33)*** 1.08 (1.01-1.16)* 
Delivery in State with ≥35% Women 
with College Degree or More 
0.70 (0.66-0.74)*** 0.84 (0.76-0.92)*** 
Insurance Plan Type  N/A 
PPO (ref.)  
Comprehensive 1.12 (0.96-1.30)  
HMO/EPO 1.00 (0.95-1.05)  
POS/POS+Capitation 1.01 (0.95-1.08)  
CDHP 1.05 (0.99-1.12)  
HDHP 0.92 (0.85-0.99)*  
Unknown 1.00 (0.92-1.10)  
Year of Delivery   
2011 (ref.) (ref.) 
2012 1.03 (0.99-1.08) 1.04 (0.99-1.09) 
2013 1.07 (1.01-1.12)* 1.09 (1.04-1.15)** 
2014 1.04 (0.98-1.09) 1.07 (1.01-1.13)* 
2015 0.94 (0.89-1.00) 0.97 (0.91-1.03) 
2016 0.96 (0.91-1.03) 0.98 (0.91-1.04) 
2017 0.84 (0.77-0.92)*** 0.84 (0.77-0.93)*** 
Delivery Mode   
Vaginal (ref.) (ref.) 
Cesarean 1.41 (1.36-1.45)*** 1.54 (1.49-1.59)*** 
Non-Opioid Substance Use Disorder 0.95 (0.87-1.05) 1.06 (0.95-1.19) 
Any Psychiatric Diagnoses 1.06 (1.01-1.12)* 1.06 (1.01-1.13)* 
Chronic Hypertension 1.15 (1.09-1.20)*** 1.11 (1.06-1.18)*** 
Gestational Hypertension 1.08 (1.03-1.12)** 0.96 (0.92-1.01) 
Diabetes Mellitus 0.95 (0.89-1.01) 0.92 (0.86-0.99)* 
Gestational Diabetes 0.97 (0.94-1.02) 0.96 (0.92-1.00) 
Asthma 1.06 (1.00-1.13) 1.05 (0.99-1.12) 
Autoimmune Disease 0.98 (0.90-1.07) 0.97 (0.89-1.06) 
Pain Condition 1.08 (1.04-1.13)*** 1.04 (1.00-1.09) 
Hepatitis C 0.75 (0.48-1.17) N/A 
Any ANC 0.97 (0.87-1.09) N/A 
Postpartum Care Visit within 60 Days 1.67 (1.61-1.72)*** 1.64 (1.59-1.69)*** 
NAS Diagnosis, Infant 0.76 (0.66-0.89)*** 0.86 (0.74-1.01) 
NICU Admission, Infant 0.88 (0.84-0.92)*** 0.95 (0.90-1.00) 
Mean Hospital Length of Stay in Days, 
Infant 
0.992 (0.990-0.994)*** 0.989 (0.986-0.991)*** 
*p<0.05, **p<0.01, ***p<0.001 




Aim 3: Sensitivity Analysis 
A sensitivity analysis was conducted comparing the characteristics of women who were 
successfully linked with an infant record and included in the Aim 3 analysis to those of women 
who were not linked with an infant, and the full sample of women who used opioids during 
pregnancy from the Aim 1 cohort (Table 4.27).  An assessment of the magnitude and direction of 
potential selection bias in the Aim 3 cohort was assessed using the relative risk ratio (ROR).  The 
aim of this sensitivity analysis was to understand differences among the three groups and how 
they may impact the interpretation of the Aim 3 results. 
Overall, 51.5% of women who used opioids during pregnancy from the Aim 1 cohort 
were successfully linked with an infant record.  Important differences emerged between women 
who were and were not included in the Aim 3 analysis.  The linkage rates were different across 
the three types of opioid use: 52.3% of women with non-chronic prescription use were linked 
(57,394 linked/109,622 total); 52.1% of women with chronic prescription use were linked ( 
4,875 linked/9,347 total); but only 31.6% of women with OUD/Bup were linked with their 
newborn (1,628 linked/5,155 total).  It is not known why women in the OUD/Bup category had 
significantly lower linkage levels than women in the other opioid use categories.   
Women included in the Aim 3 analysis were older, less likely to live in a state with a high 
proportion of Black residents or a state with a high poverty rate and had a different comorbidity 
profile than the women excluded from the analysis.  Importantly, the fact that women with 
OUD/Bup were less likely to be included in the Aim 3 analysis may have impacted the infant-
related variables, specifically infants diagnosed with NAS; the number with this diagnosis is 
likely underestimated as a result.  Women with a non-opioid SUD, a psychiatric diagnosis, 
diabetes, asthma, pain condition, or hepatitis C were also less likely to be included in the Aim 3 
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analysis.  These conditions, except for asthma and diabetes, also occur more frequently in 
women with OUD/Bup.  Hypertension, gestational hypertension, gestational diabetes, and 
autoimmune disease were more common among women included in the Aim 3 analysis 
compared with excluded women.  Despite these differences, there was only slight variation in the 
levels of contraceptive provision across the three groups, both overall and by method type.  
Women included in the Aim 3 analysis had lower levels of LARC provision, but comparable 
levels of sterilization and MEM compared to excluded women.       
Table 4.27 Sensitivity Analysis: Characteristics of Women Included and Excluded from 
Aim 3 Cohort 
 Linked with Infant Not Linked with 
Infant 
All Women with Opioid Use 
During Pregnancy from Aim 1 
Total N (%) 63,897 (51.5%) 60,227 (48.5%) 124,124 (100%) 
Opioid Use During Pregnancy    
Non-Chronic Prescription Use 89.8% (57,394) 86.7% (52,228) 88.3% (109,622) 
Chronic Prescription Use 7.6% (4,875) 7.4% (4,472) 7.5% (9,347) 
OUD Diagnosis/Bup Prescription 2.5% (1,628) 5.9% (3,527) 4.1% (5,155) 
Age, mean years (SD) 31.3 (4.8) 28.5 (6.2) 30.0 (5.7) 
Age, Categorical    
<20 0.4% (272) 6.4% (3,862) 3.3% (4,134) 
20-24 6.9% (4,409) 24.4% (14,681) 15.4% (19,090) 
25-29 28.9% (18,487) 24.9% (14,971) 26.9% (33,458) 
30-34 38.1% (24,350) 26.0% (15,641) 32.2% (39,991) 
35-39 20.5% (13,116) 14.2% (8,570) 17.5% (21,686) 
40+ 5.1% (3,263) 4.1% (2,502) 4.6% (5,765) 
HRSA Region    
Region 1 3.6% (2,334) 2.7% (1,642) 3.2% (3,976) 
Region 2 6.1% (3,909) 2.6% (1,570) 4.4% (5,479) 
Region 3 6.3% (4,046) 9.1% (5,461) 7.7% (9,507) 
Region 4 23.0% (14,687) 28.1% (16,925) 25.5% (31,612) 
Region 5 19.0% (12,154) 14.9% (9,012) 17.0% (21,166) 
Region 6 17.2% (11,005) 14.0% (8,454) 15.7% (19,459) 
Region 7 4.8% (3,102) 3.6% (2,200) 4.3% (5,302) 
Region 8 4.2% (2,665) 2.3% (1,412) 3.3% (4,077) 
Region 9 8.0% (5,128) 16.0% (9,665) 11.9% (14,793) 
Region 10 4.7% (3,007) 3.0% (1,810) 3.9% (4,817) 
Unknown 2.9% (1,860) 3.4% (2,076) 3.2% (3,936) 
Delivery in State with ≥20% 
Hispanic Population 
30.3% (19,368) 31.2% (18,809) 30.8% (38,177) 
Delivery in State with ≥20% Black 
Population 
16.0% (10,213) 22.9% (13,811) 19.3% (24,024) 
Delivery in State with ≥15% 
Population in Poverty 
13.0% (8,307) 19.0% (11,437) 15.9% (19,744) 
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 Linked with Infant Not Linked with 
Infant 
All Women with Opioid Use 
During Pregnancy from Aim 1 
Delivery in State with ≥35% 
Women with College Degree or 
More 
8.1% (5,190) 8.4% (5,054) 8.2% (10,244) 
Insurance Plan Type    
PPO 62.1% (39,652) 58.3% (35,108) 60.2% (74,760) 
Comprehensive 1.1% (681) 1.3% (772) 1.2% (1,453) 
HMO/EPO 13.3% (8,486) 18.0% (10,839) 15.6% (19,325) 
POS/POS+Capitation 7.7% (4,924) 7.4% (4,450) 7.5% (9,374) 
CDHP 7.7% (4,892) 7.6% (4,568) 7.6% (9,460) 
HDHP 5.0% (3,169) 4.6% (2,748) 4.8% (5,917) 
Unknown 3.3% (2,093) 2.9% (1,742) 3.1% (3,835) 
Year of Delivery    
2011 25.7% (16,456) 23.0% (13,859) 24.4% (30,315) 
2012 22.8% (14,555) 22.0% (13,259) 22.4% (27,814) 
2013 15.6% (9,974) 16.7% (10,079) 16.2% (20,053) 
2014 13.5% (8,628) 15.0% (9,067) 14.3% (17,695) 
2015 10.1% (6,452) 10.4% (6,257) 10.2% (12,709) 
2016 8.6% (5,529) 9.0% (5,453) 8.8% (10,982) 
2017 3.6% (2,303) 3.7% (2,253) 3.7% (4,556) 
Delivery Mode    
Vaginal 53.4% (34,120) 59.3% (35,740) 56.3% (69,860) 
Cesarean 46.6% (29,777) 40.7% (24,487)  43.7% (54,264) 
Non-Opioid Substance Use 
Disorder 
3.1% (1,965) 7.2% (4,320) 5.1% (6,285) 
Any Psychiatric Diagnoses 9.7% (6,191) 11.3% (6,792) 10.5% (12,983) 
Chronic Hypertension 12.6% (8,068) 11.3% (6,815) 12.0% (14,883) 
Gestational Hypertension 17.2% (11,010) 14.7% (8,889) 16.0% (19,899) 
Diabetes Mellitus 5.0% (3,017) 6.1% (3,889) 5.6% (6,906) 
Gestational Diabetes 17.9% (11,431) 14.8% (8,912) 16.4% (20,343) 
Asthma 6.9% (4,397) 7.7% (4,620) 7.3% (9,017) 
Autoimmune Disease 3.3% (2,137) 2.8% (1,680) 3.1% (3,817) 
Pain Condition 16.8% (10,754) 17.3% (10,451) 17.1% (21,205) 
Hepatitis C 0.1% (86) 0.5% (306) 0.3% (392) 
Any ANC 98.1% (62,699) 96.6% (58,183) 97.4% (120,882) 
Postpartum Care Visit within 60 
Days 
50.4% (32,218) 50.8% (30,571) 50.6% (62,789) 
Contraceptive provision within 60 
Days Postpartum 
   
No Provision 58.3% (37,287) 56.5% (34,050) 57.5% (71,337) 
Evidence of Provision 41.6% (26,610) 43.5% (26,177) 42.5% (52,787) 
Sterilization 10.1% (6,478) 9.9% (5,946) 10.0% (12,424) 
LARC 7.0% (4,468) 9.0% (5,445) 8.0% (9,913) 
Moderately Effective Methods 24.5% (15,664) 24.5% (14,786) 24.5% (30,450) 
 
The magnitude and direction of potential selection bias in the Aim 3 cohort was evaluated 
using the relative odds ratio (ROR).  A ROR equal to 1 suggests no differential selection bias; a 
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ROR>1 indicates an overestimation of the true association between the exposure and outcome in 
the subpopulation compared to the source population; a ROR<1 indicates an underestimation.  
The resulting ROR can be used as a selection-bias adjustment factor by multiplying the ROR by 
the subpopulation odds ratio. 
Tables 4.28 and 4.29 show the number of women from the OUD/Bup and Non-chronic 
prescription opioid groups who received and did not receive postpartum contraception in the 
cohorts for Aim 1 and 3, respectively.  The crude odds ratio, comparing the odds of postpartum 
contraceptive provision for women with OUD/Bup to women with non-chronic prescription 
opioid use, was 0.700 for Aim 1 and 0.808 for Aim 3.  The resulting ROR of 1.15 indicated a 
positive (overestimation) bias of the true association between opioid use group and postpartum 
prescription contraception provision in the Aim 3 cohort.  Multiplying the Aim 3 OR by a factor 
of 1.15 results in a ROR-adjusted OR of 0.93, indicating that after adjustment for possible 
selection bias, women with OUD/Bup have an attenuated but lower odds of contraceptive 
provision than women with non-chronic prescription opioid use.  The ROR-adjusted OR of 0.93 
is closer to the adjusted OR in main Aim 3 multivariable analysis (Table 4.26) of 0.87 (95% CI: 
0.77-0.97).   
Based on this ROR analysis, selection bias appears to have affected the results of Aim 3: 
either women with non-chronic prescription opioid use who were more likely to receive 
postpartum contraception were also more likely to be linked with an infant or women with 
OUD/Bup who were less likely to receive postpartum contraception were also more likely to be 
linked with an infant, resulting in the overestimation of the association observed in Aim 3.  
Although the magnitude of the relationship between OUD/Bup and contraceptive provision was 
likely overestimated in the Aim 3 results, women with OUD/Bup were still less likely to receive 
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postpartum prescription contraception compared to women with non-chronic prescription opioid 
use.  The results of the ROR analysis do not offer insight into possible bias related to the infant 
level variables, therefore, it is possible that relationships observed between the infant variables 
and postpartum contraceptive provision are also subject to over or underestimation.  Because 
there was no available source population with linked infant variables to compare the Aim 3 
cohort to, an additional ROR analysis for the infant variables was not possible.                 
Table 4.28 Sensitivity Analysis: Crude Odds Ratio of Contraceptive Provision within 60 






OUD/Bup 1,769 3,386 
0.700 Non-chronic Prescription 
Opioid Use 
46,859 62,763 
*Aim 1 numbers are from table 4.4. 
Table 4.29 Sensitivity Analysis: Crude Odds Ratio of Contraceptive Provision within 60 












*Aim 3 numbers are from table 4.22 
4.6 Summary of Results 
Overall, the results of this study consistently indicate that women with non-chronic and 
chronic prescription opioid use were significantly more likely to receive prescription 
contraception over the postpartum period while women with OUD/Bup were significantly less 
likely to receive prescription contraception than women who did not use opioids during 
pregnancy.  This result was consistent across all the study Aims.  In the Aim 1 analysis, women 
with non-chronic and chronic prescription opioid use were significantly more likely to receive 
187 
 
postpartum prescription contraception by 60 days postpartum and women with OUD/Bup were 
significantly less likely to receive postpartum contraception than women who did not use 
opioids.  In an analysis by contraceptive method type, women with each type of opioid use 
during pregnancy had a significantly higher relative risk of receiving sterilization relative to no 
prescription method compared with women who did not use opioids during pregnancy.  
Aim 2 examined contraceptive provision within 365 days postpartum.  Women with 
OUD/Bup had the longest average time to contraceptive provision and women with chronic 
prescription opioid use had the shortest time to contraceptive provision among all women 
provided contraception in the Aim 2 cohort.  In adjusted models, a similar pattern of 
contraceptive provision emerged: women with non-chronic and chronic prescription opioid use 
had a significantly increased hazard of contraceptive provision while women with OUD/Bup had 
a significantly lower hazard of provision compared to women who did not use opioids.  An 
extensive sensitivity analysis highlighted the need for a nuanced approach in understanding 
contraceptive provision over the first year postpartum as the pattern of provision changed 
overtime for women with OUD/Bup compared to women who did not use opioids.   
The Aim 3 analysis was restricted to women with evidence of opioid use during 
pregnancy.  In adjusted models, increasing infant hospital length of stay was significantly 
associated with decreased provision of prescription contraception by 60 days postpartum, but 
NAS diagnosis and NICU admission were not associated with contraceptive provision.  Women 
who were not provided contraception by 60 days postpartum had infants with the longest average 
hospital length of stay than women who were provided any form of prescription contraception.  
Although the results from Aim 3 were consistent with the results from Aims 1 and 2, there were 
issues of differential selection bias in the Aim 3 cohort as women with OUD/Bup were less 
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likely to be linked with an infant record compared to women with non-chronic and chronic 
prescription opioid use.     
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This chapter discusses the results of the three research aims examined in this dissertation.  
The aims were: Aim 1) Evaluate the association between opioid use during pregnancy and 
prescription contraception provision by 60 days postpartum, including by contraceptive method 
type; Aim 2) Evaluate the time to first prescription contraception provision during the 
postpartum period for women who did and did not use opioids during pregnancy, including by 
type of opioid; and Aim 3) Assess if adverse newborn outcomes are associated with provision of 
prescription contraception within 60 days postpartum among women who used opioids during 
pregnancy.  This chapter begins with a brief overview of the study methods, a discussion of the 
main findings from each aim, followed by a discussion of the study strengths and limitations, 
public health implications, and conclusions of the research.    
5.2 Study Overview 
Aim 1 evaluated the relationship between opioid use during pregnancy and provision of 
prescription contraception within 60 days postpartum.  The analytic cohort included women with 
a livebirth between January 2011 and November 2017 who maintained health and 
pharmaceutical insurance coverage for the duration of pregnancy and for at least the first 60 days 
postpartum (n=1,291,352).  Aim 1 addressed two outcomes: a binary measure of any postpartum 
prescription contraception within 60 days postpartum and a categorical measure of contraceptive 
provision by method type, again measured over the first 60 days postpartum.  Contraceptive 
method type included female sterilization, LARC, and moderately effective methods (MEM), 
with no evidence of prescription contraception provision as the reference category.  Bivariate and 
multivariable logistic regression models were used for the analysis of any postpartum 
prescription contraception.  Multinomial regression models were used for the categorical 
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measure of contraceptive provision by method type.  Covariates included maternal age, several 
geographic-based variables (HRSA region, state-level characteristics), year of delivery, and 
select clinical variables including several comorbidities (non-opioid substance use disorders, 
psychiatric conditions, chronic hypertension, gestational hypertension, diabetes mellitus, 
gestational diabetes, asthma, autoimmune disease, pain conditions),  delivery mode, and 
postpartum care visit attendance within 60 days postpartum. 
Aim 2 evaluated the association between opioid use during pregnancy and time to 
provision of contraception within the first 365 days postpartum.  Women in the Aim 2 analytic 
cohort had a livebirth between January 2011 and December 2016 and maintained continuous 
health and pharmaceutical insurance coverage for the duration of pregnancy and for some length 
of time during the postpartum period (n=1,270,832).  Aim 2 relied on survival analysis 
techniques beginning with several univariate analyses calculating the mean time to contraceptive 
provision, Kaplan-Meier curves, and Log-Log plots. Bivariate Cox Proportional Hazard models 
were used to assess the unadjusted relationship between the covariates and postpartum 
contraceptive provision.  Finally, multivariable Cox Proportional Hazards models estimated the 
adjusted hazard ratio for contraceptive provision up to 365 days postpartum.  The multivariable 
Cox models were adjusted for maternal age, the geographic-based variables, year of delivery, 
and select clinical variables including several comorbidities and delivery mode. 
Aim 3 evaluated if adverse newborn outcomes impacted contraceptive provision within 
60 days postpartum among women who used opioids during pregnancy.  The newborn outcomes 
examined were neonatal abstinence syndrome (NAS) diagnosis, neonatal intensive care unit 
(NICU) admission, and hospital length of stay.  The Aim 3 analytic cohort began with the 
subgroup of women from Aim 1 who used opioids during pregnancy.  Women who were 
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successfully linked with an infant record were included in the sample for the Aim 3 analysis 
(n=63,897).  Bivariate and multivariable logistic regression models were used to evaluate the 
relationship of type of opioid use during pregnancy and infant outcomes with any prescription 
contraceptive provision within 60 days postpartum.  The multivariable model was adjusted for 
maternal age, the geographic-based variables, year of delivery, select comorbidities, and other 
clinical variables.        
5.3 Aim 1 Discussion 
Aim 1: Evaluate the association between opioid use during pregnancy and prescription 
contraception provision by 60 days postpartum, including by contraceptive method type.  
Opioid use during pregnancy was documented in 9.6% of women in the Aim 1 cohort 
from 2010-2017, with 88.3% having non-chronic prescription opioid use, 7.5% with chronic 
prescription opioid use, and 4.1% with an OUD diagnosis or Buprenorphine prescription 
(OUD/Bup).  Over the study period, 37.6% of women were provided some form of prescription 
contraception within 60 days postpartum.  Results showed that women with non-chronic and 
chronic prescription opioid use during pregnancy had significantly higher odds of prescription 
contraceptive provision than women who did not use opioids; women with OUD/Bup had 
significantly lower odds of contraceptive provision.  The adjusted odds of contraceptive 
provision within 60 days postpartum was 1.13 (95% CI: 1.12-1.15) and 1.19 (CI: 1.14-1.24) 
times higher for women with non-chronic and chronic prescription opioid use compared to 
women who did not use opioids.  Women with OUD/Bup had 20 percent lower odds of receiving 
postpartum prescription contraception (aOR: 0.80, 95% CI: 0.75-0.85) than women who did not 
use opioids.   
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Significant differences in contraceptive provision were also observed by method type.  
Women in every category of opioid use had a significantly increased adjusted relative risk ratio 
(aRRR) of sterilization verses no method than women who did not use opioids.  The aRRR of 
sterilization verses no method for women with non-chronic prescription use was 1.49 (95% CI: 
1.46-1.53); 2.12 (95% CI: 1.99-2.26) for women with chronic prescription use; and 1.32 (95% 
CI: 1.16-1.50) for women with OUD/Bup.  Women with non-chronic prescription use also had 
significantly increased aRRR for LARC (aRRR: 1.10, 95% CI: 1.07-1.12) and MEM (aRRR: 
1.05, 95% CI: 1.03-1.06) provision verses no method relative to women who did not use opioids.  
The aRRR for LARC and MEM provision for women with chronic prescription use did not differ 
significantly compared to women with no opioid use during pregnancy.  Women with OUD/Bup 
had significantly lower aRRR for LARC (aRRR: 0.73, 95% CI:0.65-0.82) and MEM (aRRR: 
0.73, 95% CI: 0.68-0.79) provision verses no method compared to women who did not use 
opioids.              
Our study results are comparable to prior literature for women with OUD/Bup, but few 
studies had included women by other types of opioid use, as defined in our study.  The level of 
opioid use during pregnancy observed in this study was consistent with prior literature 
examining the privately insured population [1].  Similarly, the results of previous research 
examining contraception use among women who use opioids, including during pregnancy, has 
generally noted that women who use opioids have lower or comparable levels of contraception 
use to that for women who do not use opioids [2-11].  Many studies, however, lack a direct 
comparison group of women who do not use opioids and generally only included women with 
OUD or who were currently enrolled in medication-assisted therapy (MAT) programs for OUD 
treatment.  Few studies specifically examined postpartum contraception among women who used 
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opioids or other substances during pregnancy.  The results of a study of pregnant women 
enrolled in a randomized trial to treat substance use disorders (SUD) showed postpartum 
contraceptive rates of approximately 70% over the first 24 months postpartum, comparable to 
postpartum contraceptive levels observed in non-SUD populations [9].  Several other studies 
reported postpartum contraception levels for women with OUD or other SUDs far below this 
rate, ranging from 25%-50% [3-5, 11].   
Investigators using Tennessee PRAMS data reported that women with substance use 
during pregnancy had lower levels of postpartum contraception use than women who did not use 
substances (79.6% vs 88.1%, P=0.019) [7].   A single study examining contraceptive claims 
among non-pregnant women of reproductive age with chronic prescription opioid use reported 
that 23.4% of women had any indication of prescription contraception, again lower than the 
national average of 64.9% [10, 12].  The results of studies among the broader population of 
women of reproductive age with OUD or other SUDs have consistently indicated that women 
with SUDs have lower contraceptive prevalence, favor less effective methods such as condoms, 
and generally have lower use of highly effective methods such as LARC than women without 
SUDs [2, 6, 8].   
The current study involved stratifying by type of opioid use during pregnancy, and the 
observed findings indicated that both the overall level of use and type of postpartum 
contraceptive method differed across the three opioid use groups in comparison to women who 
did not use opioids.  Furthermore, the study results demonstrated that women who use opioids 
during pregnancy are not a homogenous group, but in fact, differ across important variables such 
as age and prevalence of comorbidities depending on the pattern and type of opioid use.  The 
higher levels of postpartum contraception among women with chronic and non-chronic 
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prescription use, particularly for sterilization, seem logical.  Women prescribed opioids during 
pregnancy are likely experiencing acute pain or chronic conditions which may complicate their 
pregnancy and require more frequent contacts with healthcare providers [1, 13-15].  Women with 
complicated pregnancies have higher rates of postpartum visit attendance which is also 
associated with higher postpartum contraceptive provision [16, 17].  Furthermore, women in the 
chronic prescription opioid group were older, on average, compared to the larger Aim 1 cohort; 
age is directly related to parity and parity is highly predictive of postpartum contraception use 
[18, 19].  Parity could not be examined in the current study, but taken together, these factors may 
explain the higher levels of postpartum contraception observed in the non-chronic and chronic 
prescription opioid use groups.   
The lower odds of any prescription contraception provision among women with 
OUD/Bup is supported by prior literature.  However, the observed increase in sterilization and 
simultaneous lower relative risk ratio of LARC or MEM provision is a new finding.  Women 
with OUD/Bup may have high risk pregnancies resulting in a higher likelihood of sterilization at 
the time of delivery while also having lower rates of postpartum follow up care within 60 days of 
delivery, and, accordingly, reduced levels of LARC and MEM provision [20].  Prior literature 
has documented low levels of postpartum visit attendance in women with OUD, which is 
common when LARC and MEM are provided to postpartum women [11, 21].   
The overall level of opioid use documented in this study was consistent with prior 
literature examining opioid use during pregnancy among the privately insured population [1].  
Bateman et al reported 14.4% of privately insured pregnant women were prescribed at least one 
opioid during pregnancy, with a prevalence of 12.9% in 2011, similar to the level of opioid 
exposure observed in this study in 2011, 11.2% [1].  A second study within a large health system 
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in the Midwest reported 12.3% of pregnancies from 2006-2014 had evidence of opioid use [15].  
Like the trends reported in the population at large, opioid use during pregnancy decreased over 
the study period from a high of 11.2% in 2011 to 4.4% in 2017 [22].   
The observed decrease in opioid use over time in the current study, particularly for 
prescription opioids, is also consistent with larger national trends over a similar time period, 
which reflect decreased use and prescribing of prescription opioids [22].  Despite declining rates 
of opioid prescribing in the US, use of illicit opioids such as heroin and illicitly manufactured 
fentanyl has been increasing since 2007 [23, 24].  Use of illicit forms of opioids is difficult to 
measure in administrative claims data without an explicit diagnosis of OUD or other substance 
use disorder, or an overdose event and may result in some exposure misclassification.  The level 
of opioid use during pregnancy observed in this study was lower than levels documented among 
Medicaid recipients. The results of two studies noted that 21%-29% of pregnant women enrolled 
in Medicaid were prescribed an opioid at some point during pregnancy; however, these estimates 
are somewhat dated, ranging from 1995-2009 [13, 25].   OUD/Bup was more common in the 
Aim 1 cohort among younger women, women with concomitant non-opioid SUDs, and 
psychiatric illness. Chronic prescription opioid use was more common among older women, and 
women with chronic conditions such as autoimmune disorders, pain conditions, diabetes, and 
hypertension.   
The levels and method-specific results for postpartum prescription contraception found in 
this study were consistent with a similar study conducted in 2015, which used the MarketScan 
database and the NQF postpartum contraception performance measures.  The 2015 study 
examined postpartum contraception among privately insured women from 2005-2014 [26].  Law 
et al reported age stratified results but the levels of provision for woman aged 21-44 were similar 
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to those in the overall Aim 1 cohort for the overlapping years (2011-2014).  The study authors 
also reported increased LARC provision during their study period and decreasing levels of 
sterilization, both of which were observed in the current study.   
Postpartum prescription contraceptive provision also was significantly associated with 
several demographic characteristics including maternal age, HRSA region, state-level 
characteristics, and year of delivery in the Aim 1 cohort.  Several studies have documented 
decreased odds of postpartum contraceptive provision as age increases, a trend observed in this 
research [18, 27, 28].  Although increasing age was associated with decreased odds of any 
contraceptive provision, the aRRR for sterilization increased with age; conversely, the aRRR for 
LARC provision was highest for younger women (<25 years).   The aRRR for MEM provision 
was significantly lower for every age group relative to the reference group, women aged 25-29.  
The method-specific age patterns observed in this study are consistent with prior literature [18, 
19, 29, 30].   
Regional differences in postpartum contraception are well-documented in the literature 
with higher levels in the Southern US, driven by high levels of sterilization and MEM provision 
[18, 29-32].  In this study, HRSA Region 6 (TX, LA, AR, OK, NM), had the highest aRRR for 
sterilization and MEM provision; Region 8 (Western Region) had the highest aRRR for LARC 
provision.  Year of delivery was associated with a gradual decrease in the odds of any 
postpartum contraceptive provision; based on the method-specific models, this decrease was 
largely driven by a decline in sterilization over the study time period, a trend observed in 
national-level data [12, 30].  LARC provision increased over the study period, with the highest 
aRRR observed in 2017, again consistent with broader trends indicating increased postpartum 
LARC use in the US [12, 30, 33].                
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Consistent with results from other studies, mode of delivery and attending a postpartum 
care visit within 60 days of delivery were both positively associated with provision of 
contraception.  Cesarean deliveries were associated with higher odds of postpartum contraceptive 
provision, particularly sterilization.  Prior literature has shown cesarean delivery to be a strong 
predictor of completed female sterilization [30, 34-36].  Results of prior studies have also 
documented a strong relationship between a postpartum care visit and postpartum contraception, 
with a pronounced relationship between postpartum care visits and use of highly effective 
contraception, including LARCs as observed in the current study [16, 18, 37].   
Psychiatric disorders, chronic hypertension, and asthma were associated with increased 
contraceptive provision; gestational hypertension, gestational diabetes, and autoimmune disease 
were associated with decreased provision of any postpartum prescription contraception.  The 
relative risk for sterilization was significantly increased for women with every comorbidity, 
except gestational hypertension and autoimmune disease.  LARC provision was not as strongly 
associated with maternal comorbidities.  Psychiatric disorders, chronic hypertension, and asthma 
significantly increased the relative risk ratio of LARC provision whereas gestational diabetes 
significantly decreased the relative risk ratio verses no provision.  Chronic hypertension, 
gestational hypertension, and asthma were associated with an increased relative risk of MEM 
provision verses no provision compared to women without these conditions.  Non-opioid SUD, 
diabetes, both pre-existing and gestational, as well as pain conditions were associated with a 
decreased relative risk of MEM provision verses no provision compared to women without these 
conditions.   
There is limited research examining how experiencing a medically complex pregnancy 
influences postpartum contraceptive provision or use.  The results of a 2015 study suggested that 
199 
 
women with high-risk pregnancies had slightly higher interest in highly effective contraception 
at the time of hospital discharge and at the postpartum visit, but similar rates of provision 
compared to women with low-risk pregnancies [38].  In a second study examining immediate 
postpartum LARC and sterilization, maternal medical comorbidities were significantly 
associated with both immediate LARC and sterilization, with a stronger relationship for 
immediate LARC provision [30].  Women who experience a medically complex or high-risk 
pregnancy may be motivated to avoid unintended pregnancy and thus be inclined to choose 
highly effective methods such as sterilization or LARC.  Future research is needed to clarify the 
relationship between experiencing a medically complex pregnancy and postpartum maternal 
care-seeking behavior, including provision of postpartum contraception.         
The finding that chronic and gestational hypertension were associated with a significantly 
increased aRRR for MEM provision relative to no provision compared to women without 
hypertension was unexpected.  The US Medical Eligibility Criteria for Contraceptive Use rates 
combined hormonal contraceptives (CHC) as a “3” and “4” for women with hypertension, 
indicating that the risks associated with CHC use in women with hypertension outweigh the 
advantages [39].  Although there are progestin-only and non-hormonal methods of contraception 
included in the definition for MEM, the combined hormonal pill is among the most popular 
forms of contraception in the US and it is likely that a significant proportion of MEM users in 
this population are using a combined hormonal pill [40].  Future research is needed to examine 
the use of postpartum CHCs in women with hypertension as it may increase the risk of stroke, 
myocardial infarction, and venous thromboembolism [41-48].  The decreased aRRR of provision 
of MEM for women with pain conditions may be due to the inclusion of headaches in the 
definition of pain conditions.  Women who experience migraines with aura are at significantly 
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increased risk for ischemic stroke and the use of CHCs further increases this risk; therefore, 
CHCs are not recommended for women with this condition [39, 49-52].         
5.4 Aim 2 Discussion 
Aim 2: Evaluate the time to first prescription contraception provision during the postpartum 
period for women who did and did not use opioids during pregnancy, including by type of opioid. 
The Aim 2 analysis examined postpartum prescription contraception provision over the 
first 365 days postpartum using survival analysis.  The prevalence of opioid use during 
pregnancy was comparable to levels observed in Aim 1: overall, 10.1% of women had any 
evidence of opioid use.  Among women with evidence of opioid use, 88.3% had non-chronic 
prescription use; 7.7% had chronic prescription use; and 4.0% had OUD/Bup.  Within 365 days 
of delivery, 50.2% of women were provided some form of prescription contraception, with 
31.7% receiving MEM, 11.9% receiving LARC, and 6.6% undergoing sterilization.  In the fully 
adjusted Cox models, women with non-chronic and chronic prescription opioid use were more 
likely to receive contraception, whereas women with OUD/Bup were significantly less likely to 
receive any prescription contraception.  The adjusted-average time to contraceptive provision 
among women who received contraception within 365 days postpartum was significantly 
different for women in all categories of opioid use compared to women who did not use opioids.  
Women with OUD/Bup had the longest average time to contraceptive provision while women 
with chronic prescription use had the shortest average time to provision among the opioid use 
groups, including women who did not use opioids during pregnancy. 
 Women with non-chronic prescription opioid use had an adjusted hazard of 
contraceptive provision 1.15 (95% CI: 1.14-1.16) times higher than women who did not use 
opioids during pregnancy.  The adjusted hazard for women with chronic prescription opioid use 
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was even higher at 1.24 (95% CI: 1.21-1.27) compared to women who did not use opioids.  
Women with OUD/Bup had a significantly lower hazard of 0.93 (95% CI: 0.89-0.97) compared 
to women who did not use opioids.  These results reflect the larger overall pattern in this study of 
higher postpartum contraceptive provision among women with non-chronic and chronic 
prescription opioid use and lower provision for women with OUD/Bup compared to women who 
did not use opioids.  The pattern of contraceptive provision in the OUD/Bup group changed over 
the postpartum period.   In the first 60 days postpartum, women with OUD/Bup had a 
significantly lower hazard of contraceptive provision (aHR: 0.85, 95% CI: 0.81-0.90), but from 
61-365 days postpartum, the hazard of contraceptive provision for women with OUD/Bup did 
not differ significantly from that for women who did not use opioids (aHR: 1.05, 95% CI: 0.99-
1.13).  This finding suggests that women with OUD/Bup may be less likely to receive 
postpartum contraception in the first 60 days following delivery but after that time, the disparity 
in contraceptive provision attenuates for women with OUD/Bup compared to women who did 
not use opioids and did not receive contraception within 60 days postpartum.   
There are several possible reasons for the changing hazard over time for women with 
OUD/Bup based on prior literature and findings from the current study.  Foremost, women with 
OUD/Bup have low rates of postpartum visit attendance [4, 11, 21].  Women with OUD/Bup 
may eventually attend a postpartum visit but after the recommended 60 days following delivery.  
Secondly, women identified as having OUD during pregnancy, even those currently in treatment, 
are often subject to increased stigma and scrutiny, which may make them less likely to return for 
a postpartum visit [53-55].  Finally, their infants may be at high risk for complications and if 
their infant is hospitalized for a prolonged period of time, it may delay postpartum care-seeking 
for the mother [20, 28, 56-59].  This hypothesis is supported by the results from Aim 3, showing 
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that among women who use opioids during pregnancy, increased infant hospital length of stay 
significantly reduced the odds of postpartum contraceptive provision.  Infants born to women 
with OUD/Bup had the longest average hospital length of stay of the three opioid-use groups.  
The hazard of contraceptive provision for women with non-chronic and chronic prescription 
opioid use compared to women who did not use opioids was consistent across all time periods. 
To our knowledge, this study is the first to examine time to contraceptive provision over the first 
365 days postpartum by type of opioid use during pregnancy.     
The adjusted mean days to postpartum contraceptive provision was calculated for women 
who received prescription contraception at any point during the first 365 days postpartum.  The 
analysis was adjusted for maternal age, the geographic variables, year of delivery, and select 
clinical variables including several comorbidities and delivery mode.  In the adjusted analysis, 
women with OUD/Bup had the longest average time to contraceptive provision at 72.32 days 
(95% CI: 69.99-74.64) while women with chronic prescription use had the shortest time at 54.88 
days (95% CI: 53.28-56.47).  Women with non-chronic use had an average time to contraceptive 
provision of 59.34 days (95% CI: 58.86-59.81) and women with no opioid use received 
contraception, on average, at 61.92 days postpartum (95% CI: 61.76-62.08).  The longer average 
time to contraceptive provision among women with OUD/Bup helps explain the earlier finding 
of shifting hazards of contraceptive provision over the postpartum period.  Many women with 
OUD/Bup who ultimately used contraception received it after the recommended time period for 
a postpartum care visit.   
The overall pattern of time to contraceptive provision in the first year postpartum 
observed in this study is similar to that reported in a 2018 study examining postpartum 
contraceptive use by birth intendedness [60]. The study authors observed a sharp increase in 
203 
 
contraceptive uptake in the first three months postpartum, a slower increase in uptake in months 
three through six, and a plateauing there after [60].         
In general, the adjusted hazard ratio of contraceptive provision for the covariates was 
consistent with the overall associations observed in Aim 1.  The hazard for contraceptive 
provision for maternal age and delivery mode, however, exhibited changes over the postpartum 
period that require further explanation.  Women in the two youngest age groups, <20 and 20-24 
years, had a slight but significantly decreased hazard of contraceptive provision in the first 60 
days postpartum.  In the 61-365 days postpartum period, women in these age groups had a 
significantly increased hazard of contraceptive provision compared to women age 25-29 who had 
not received prescription contraception in the first 60 days postpartum.  This pattern is likely due 
to the higher prevalence of LARC provision in the youngest age groups, which is also the 
method type with the longest average time to provision at 76.58 days following delivery (95% 
CI: 76.30-76.86) [19].   
A similar, but inverse, relationship was observed for women with cesarean deliveries: in 
the first 60 days postpartum, women with cesarean deliveries had a significantly higher hazard of 
contraceptive provision (aHR: 1.43, 95% CI: 1.42-1.44) than women with vaginal births.  In the 
61-365 days postpartum, there was no significant difference in the hazard of contraceptive 
provision for women with a cesarean delivery compared to those with a vaginal delivery.  This 
relationship is likely due to the high prevalence of sterilization in women with cesarean 
deliveries [30, 35, 36].  The shortest average time to provision of any method following delivery 
was sterilization at 13.26 days (95% CI: 12.98-13.54).    
204 
 
5.5 Aim 3 Discussion 
Aim 3: Assess if adverse newborn outcomes are associated with provision of prescription 
contraception within 60 days postpartum among women who used opioids during pregnancy. 
The Aim 3 analysis was restricted to women with evidence of opioid use during 
pregnancy for whom infant data were linked; 89.8% of women had evidence of non-chronic 
prescription use during pregnancy; 7.6% of women had chronic prescription opioid use; and 
2.5% OUD/Bup use.  Over the study period, 41.6% of these women were provided some form of 
prescription contraception within 60 days postpartum.  The study results showed that among 
women who used opioids during pregnancy, each one-day increase in infant hospital length of 
stay (LOS) resulted in a 1.1% decrease in the odds of receiving postpartum prescription 
contraception within 60 days of delivery (aOR: 0.989, 95% CI: 0.986-0.991).  NAS diagnosis 
and NICU admission for the infant were not significantly associated with provision of 
postpartum contraception in the fully adjusted analysis.   
In unadjusted analyses, the mean hospital LOS varied significantly by contraceptive 
provision and method type.  Newborns of women not provided contraception within 60 days 
postpartum had an average hospital LOS of 4.8 days (95% CI: 4.74-9.93) whereas the average 
hospital LOS for newborns of women provided contraception was 4.2 days (95% CI: 4.13-4.32).  
The shortest average LOS was noted for women ultimately provided LARC (mean days: 3.8, 
95% CI: 3.60-4.04).   
The significant decrease in postpartum contraceptive provision with each one-day 
increase in infant hospital LOS in the fully adjusted model suggests a relationship between 
severity of illness in the newborn and postpartum contraception use.  Few studies have examined 
the relationship between infant hospital LOS and postpartum contraception use; rather studies 
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have focused on specific adverse outcomes in the infant such as preterm birth or low birth 
weight.  Prior studies show lower levels of postpartum contraception use among women with 
preterm infants and medically complicated pregnancies [28, 61] with a general trend towards the 
prioritization of infant well-being [56-58, 62].  A 2019 qualitative study found that women with 
preterm infants in the NICU prioritized decision-making related to infant well-being and 
questioned the timing of immediate postpartum contraceptive counseling because of existing 
stress associated with having a traumatic birth experience and hospitalized infant [56].  A second 
qualitative study noted that women with infants still-hospitalized six weeks after delivery were 
reluctant or unable to attend a postpartum care visit because they did not want to leave the 
hospital and felt emotionally unable to focus on their own care [62].  In the current study, longer 
hospital LOS for infants born to women with evidence of opioid use during pregnancy resulted 
in lower postpartum contraceptive provision, in keeping with previous findings but adding 
information to our understanding of how adverse infant outcomes impact maternal postpartum 
care.  Future studies will need to expand the study population to include women without opioid 
use and explore the mechanisms underlying lower postpartum contraception use among women 
with severely ill infants more generally.    
Approximately 13% of newborns in the Aim 3 cohort were admitted to the NICU, higher 
than the national average of 7.8% of all livebirths [63].  This finding was expected for two 
reasons. First, the Aim 3 analysis was restricted to women with evidence of opioid use during 
pregnancy, increasing the likelihood of a medically complex pregnancy with consequences in the 
infant [20].  Secondly, the successful linkage between women and their infants may be biased 
towards certain groups of women with infants who are more likely to be admitted to the NICU.  
Women from the OUD/Bup group were underrepresented in the final Aim 3 cohort because a 
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lower percentage of women from this group were successfully linked with their newborns.  Over 
50% of women in the non-chronic and chronic prescription opioid use groups were successfully 
linked, whereas just 31.6% of women from the OUD/Bup group were linked with their newborn.  
The reason why the linkage rate for women in the OUD/Bup group was substantially lower is 
unknown, but an important area for future research.  In the unadjusted analysis, NICU admission 
was associated with lower odds of contraceptive provision but after adjustment, this association 
was no longer significant, likely due to its relation to longer infant hospital length of stay. 
The percentage of infants diagnosed with NAS in the Aim 3 cohort increased over the 
study period from 0.9% in 2011 to 3.5% in 2017, consistent with national trends indicating an 
increase in NAS and neonatal opioid withdrawal syndrome (NOWS) diagnoses [64].  The 
proportion of newborns with NAS was substantially higher in the Aim 3 cohort than levels 
observed in national data, as expected because the Aim 3 cohort was restricted to women with 
evidence of opioid use during pregnancy [64].  In 2014, 0.2% of hospital births paid for by 
private insurance had an NAS or NOWS diagnosis, where-as 1.7% of the infants born in 2014 in 
the Aim 3 cohort were diagnosed with NAS [64].  Like the findings for NICU admission, NAS 
was associated with lower odds of contraceptive provision in the unadjusted analysis but was no 
longer significant in the fully adjusted analysis.       
The association between contraceptive provision and type of opioid use during pregnancy 
was consistent with the relationship observed in Aim 1.  Women with chronic prescription opioid 
use during pregnancy had significantly higher odds of prescription contraceptive provision while 
women with OUD/Bup had significantly lower odds compared to women with non-chronic 
prescription opioid use.  The adjusted odds of contraceptive provision within 60 days postpartum 
was 1.11 (95% CI: 1.05-1.18) times higher for women chronic prescription opioid and 17% 
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lower for women with OUD/Bup (aOR: 0.83, 95% CI: 0.72-0.94) than women with non-chronic 
prescription opioid use.  The association between the other covariables and provision of 
contraception were similar to those observed in Aim 1 and largely supported by prior literature.     
5.6 Study Strengths 
This research has several strengths.  To our knowledge, this study is the first to examine 
postpartum contraceptive provision among privately insured patients in the US, comparing 
women who used opioids during pregnancy with those who did not.  The inclusion of a 
comparison group of women who did not use opioids during pregnancy is a significant strength 
as few studies with similar research aims included a comparison group.  While the study of 
Medicaid patients and women without health insurance remains important, privately insured 
patients are a significant population of interest, representing 46% of births annually in the US 
[65].  
The sample size afforded by MarketScan provided this study with ample power to detect 
meaningful differences between different groups of opioid users, the first study to do so.  This 
study strength is particularly important as significant differences in contraceptive provision were 
found for each group as well as distinct demographic and clinical profiles.  Although the 
MarketScan database is a convenience sample of individuals with employer-based health 
insurance plans, the large number of individuals captured on an annual basis helps increase the 
external validity of this research.  For example, in 2018, the MarketScan database contained data 
for more than 41.2 million individuals, a large enough cohort to create a nationwide sample of 
patients with employer-based insurance in the US [66].  The large number of observations in this 
research lent stability to the survival analysis and hazard estimates, which can often be unreliable 
as the number of observations decreases with increasing length of follow-up.  
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Prior to making the MarketScan data public, the data undergoes numerous quality checks 
and has limited missingness. The unique enrollment and family identification codes assigned to 
individuals in the MarketScan database allow for follow up of individuals over time. The current 
study leveraged the longitudinal nature the data and included variables from the prenatal, 
perinatal, and postnatal time periods as well as using multiple time points to measure 
contraceptive provision. The study employed evidence-based performance quality measures for 
postpartum contraception [67]. These measures have been used in prior studies and increase both 
the interpretability and applicability of the study results [26, 67]. Finally, because the dataset 
captured all inpatient, outpatient, and outpatient prescriptions claims for a woman over the 
enrollment period, it included critical variables that may not be accessible when using sources 
such as electronic medical records or national survey data. 
5.7 Study Limitations 
This research also has limitations. Foremost, the MarketScan database only contains 
claims for privately insured patients, a limitation for several reasons. First, while close to half of 
births in the US were covered by private insurance in 2017, just over 40% were insured by 
Medicaid; therefore, these births are not captured by the MarketScan database [68].  Secondly, 
prior research indicates that rates of opioid prescribing, opioid misuse, and OUD are higher in 
Medicaid populations than the general and privately insured populations [13, 69, 70].  Finally, 
the use of MarketScan data limits the generalizability of these results to privately insured patients 
with employer-provided insurance, who are more likely to be White, have higher incomes, and 
higher education [71].  While this is a major limitation of the current study, two-thirds of 
Americans are covered through private health insurance plans and there are currently no studies 
that have examined these research aims in a privately insured population [71].  Although the data 
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source limits the generalizability of the results, the privately insured population is under-studied 
and this research addresses a gap in the existing literature. 
A second limitation of this research is the lack of available data about non-prescription 
contraceptive methods such as male condoms and sterilization procedures among male partners. 
Prior research indicates that condoms are the preferred method among women with OUD, thus 
the exclusion of non-prescription contraceptive methods may result in an underestimation of 
postpartum contraception use [2].  The findings can only be interpreted to use of moderately and 
highly effective prescription methods, an important consideration nevertheless regarding 
pregnancy prevention.  
There also were limitations identifying the full spectrum of opioid use during pregnancy. 
Due to regulations surrounding the administration of methadone as treatment for OUD, 
methadone was not captured in private insurance claims data. This limitation likely resulted in 
missed cases of women with OUD.  However, both buprenorphine and naltrexone, the other two 
FDA approved medications for treating OUD, are not subject to the same restrictions and were 
captured in the MarketScan database.  Prior research indicates that among people on MAT, use 
of buprenorphine is increasing particularly since 2009, which may help decrease the degree of 
exposure misclassification in this study if fewer patients are being treated with methadone in 
favor of buprenorphine [72].     
The MarketScan database also lacks important sociodemographic variables such as 
race/ethnicity, parity, education, and marital status which are strongly associated with 
postpartum contraceptive use [73].  Efforts were made to attenuate the impact of these missing 
sociodemographic variables by incorporating state-level characteristics such as racial 
composition, poverty level, and educational attainment.  There was also concern over differential 
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loss to follow up because women with the most severe addiction or those with serious 
comorbidities may be less likely to have continuous insurance enrollment or may qualify for 
public forms of insurance. The continuous enrollment inclusion criterion for each Aim were 
designed to minimize the potential impact of this bias. A sensitivity analysis was performed for 
each research Aim comparing women who met the inclusion criteria with those who did not; 
except for Aim 3, no major differences emerged.   
A limitation of the Aim 3 analysis is the relatively low percentage of women who were 
successfully linked with an infant record (51.5%), which may bias the results as women in the 
OUD/Bup group were underrepresented in the final Aim 3 cohort.  A sensitivity analysis 
indicated selection bias in the Aim 3 cohort resulting in an overestimate of the association 
between OUD/Bup and postpartum contraceptive provision.  The linkage rates of maternal-infant 
records reported in prior studies using administrative claims data vary widely from 45%-90% 
and fluctuate depending on data source, inclusion criteria, direction of linkage, and exposure of 
interest [74].  Several studies using the MarketScan database have linked maternal-infant records 
with linkage rates varying from 50%-75% [75-77].  The study with the highest linkage rate used 
the commercial and Medicaid components of the Marketscan database; the authors also reported 
the linkage rate as the percentage of liveborn infants linked to a maternal record which tends to 
yield higher rates than reporting the percent of maternal records linked with a liveborn infant 
[77].    
5.8 Public Health Implications 
Overall, this research contributes to our limited understanding of postpartum 
contraceptive patterns among women who use opioids during pregnancy, providing special 
insight into differences by type and pattern of opioid use among privately insured women.  Our 
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study findings consistently indicated that women with OUD/Bup were less likely to receive 
prescription contraception in the postpartum period than women who did not use opioids. 
Furthermore, the study findings indicate that women with non-chronic and chronic prescription 
opioid use during pregnancy are more likely to be provided postpartum contraception than 
women who do not use opioids, a new finding.  This finding highlights the need to differentiate 
between opioid-use type when developing clinical guidelines and policies that address maternal 
health needs.  The public health implications of this research include tailoring antenatal and 
postpartum care for women with various types of opioid use, decreasing barriers to immediate 
postpartum LARC especially among the privately insured population, and considering and 
incorporating the health status of the infant into clinical guidance for postpartum maternal 
healthcare.       
This research highlighted stark demographic and clinical differences between women 
with OUD/Bup, non-chronic and chronic prescription opioid use during pregnancy.  These 
results, disaggregated by type of opioid use during pregnancy, offer an opportunity for clinicians 
and public health professionals to develop tailored clinical guidance for how best to care for 
these women in the antenatal and postpartum period. It is imperative that contraceptive 
counseling guidelines are non-coercive and collaborative, particularly in the context of a drug-
using population as there is a history of targeting these populations for long-acting or permanent 
forms of contraception using coercive incentives and counseling [78, 79].  A 2019 review by 
Heil et al described several quasi-experimental studies examining the efficacy of co-locating 
drug treatment and family planning services on contraceptive uptake [5, 80-83].  These 
integrated care models appear to hold promise for promoting contraceptive use among women 
with OUD/Bup in a convenient, safe, and non-judgmental atmosphere. 
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The results of two quasi-experimental studies showed significant increases in 
contraceptive uptake for women receiving interventions designed specifically for OUD 
populations.  In a 2016 study, women with OUD in the intervention group were provided with 
the contraceptive method of their choice free-of-charge with immediate on-site initiation plus an 
additional six months of follow-up visits to manage side effects and contraceptive adherence 
[80].  Women in the intervention group universally initiated contraception compared with 29% 
of women in the usual care group; contraceptive continuation was also higher in the intervention 
group over the six-month follow-up period [80].  Findings of a second study, focused on 
postpartum contraception, indicated that using women-centered OUD treatment services during 
pregnancy resulted in higher postpartum visit attendance and postpartum LARC use compared to 
women provided usual OUD treatment [81].   
An integrated program from 2005-2009 provided contraceptive services to women in a 
pediatric clinic located within a drug treatment facility [83].  Women participated in ante- and 
postpartum group education sessions focused on contraception and were able to receive the 
method of their choice free-of-charge.  Although no comparison group was included, 70% of 
women requested postpartum contraception and 68% ultimately received a method [83].  In a 
retrospective chart review, Collier et al did not find significant differences in interpregnancy 
interval or contraceptive uptake between women receiving medication assisted therapy (MAT) 
co-located at an obstetric office compared to those receiving MAT at a community MAT 
program [5].  The authors note, however, that co-location of MAT and obstetric services was not 
available in the immediate postpartum period which likely influenced contraceptive uptake. 
These programs and interventions provide an encouraging avenue for ensuring that pregnant 
women with OUD/Bup can make informed decisions about postpartum contraception and 
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conveniently access their method of choice.  Our research findings demonstrate that more 
interventions are needed to address the disparity in postpartum contraceptive provision for 
women with OUD/Bup.               
Immediate postpartum LARC insertion, defined as LARC insertion prior to hospital 
discharge following delivery, is safe and acceptable among women of reproductive age; yet the 
rates of immediate LARC insertion remain low, especially among privately insured women [30, 
84, 85].  In the current study, immediate postpartum LARC provision was very low, with 
approximately 0.1% of women receiving immediate postpartum LARC, consistent with levels 
observed in other studies of privately insured women [26].  Immediate postpartum LARC 
increases optimal birth spacing, decreases unintended and mistimed pregnancies, and is highly 
cost-effective [84, 86, 87].  Decreasing barriers to postpartum LARC not only benefit the broader 
population of postpartum women, but also may help address the disparity in contraceptive 
provision and timing observed in the current study for women with OUD/Bup.   
In a 2017 study among a nationally representative sample of postpartum women, women 
with non-private insurance were significantly more likely to receive immediate postpartum 
LARC than women with private insurance [30].  The differential rates of immediate postpartum 
LARC use by insurance type are likely due to differences in reimbursement practices.  Starting in 
2012, several state Medicaid programs began reimbursing for the LARC device and insertion 
procedure during the hospital stay for delivery, separately from the bundled labor and delivery 
reimbursement fee [88].  Currently, 37 state Medicaid programs reimburse for immediate 
postpartum LARC insertion [89].  Conversely, very few private insurance companies have 
moved to reimburse for the LARC device or insertion procedure during the hospital stay for 
delivery, although both are universally covered in an outpatient setting.   
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Expanding access to immediate postpartum LARCs through changes to insurance 
reimbursement may help decrease disparities in postpartum contraception for several reasons.  It 
is estimated that up to 40% of women do not receive a postpartum visit, and these rates are even 
higher among the OUD/Bup population, making immediate insertion a convenient and safe 
option for women who choose to use these methods [4, 11, 16, 90].  Among women who intend 
to use LARCs postpartum, studies show that 40%-75% do not end up receiving their method of 
choice [91, 92].  Removing financial and logistical barriers to immediate postpartum LARC 
insertion will help ensure that even when women do not attend a postpartum visit, they have an 
opportunity to obtain LARC if they choose to do so.  Up to 80% of pregnancies to women with 
OUD are unintended and in conjunction with low postpartum visit attendance, increasing access 
to immediate postpartum LARC insertion can help close gaps in contraceptive provision and 
prevent unintended and mistimed pregnancies for all postpartum women [93, 94].   
There is limited research on how the health status of an infant impacts the postpartum 
healthcare seeking behavior of the mother.  The current research found an association between 
infant hospital length of stay and postpartum contraceptive provision among women who used 
opioids during pregnancy, suggesting that women with severely ill infants have lower levels of 
contraceptive provision.  This area is ripe for future research and potential public health 
interventions.  Counseling strategies that encourage uptake of maternal postpartum care services, 
while remaining sensitive to the emotional and psychological needs of mothers and parents with 
severely ill infants, need to be developed.  The results of qualitative and quantitative studies 
demonstrate that women with infants admitted to the NICU are at increased risk for delayed or 
inadequate postpartum care given their concern with their infant’s health [56, 59, 95].   
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Crude estimates from a 2016 study indicated that women with preterm, low birth weight 
infants had a significantly lower postpartum visit attendance compared to women delivering 
term, normal weight infants [16].  There also is some evidence that interventions designed 
specifically for women with severely ill infants may increase postpartum care utilization.  For 
example, the results of a quasi-experimental trial among mothers with infants admitted to the 
NICU showed that an intensive counseling intervention significantly increased postpartum visit 
attendance among the intervention group compared to the control group [96].   Future research 
should focus on developing guidelines, counseling techniques, and interventions that improve 
uptake of postpartum healthcare services among women with critically ill infants.  
5.9 Conclusions 
This study addressed a gap in the research and added to the literature on postpartum 
contraception and substance use.  Women with non-chronic and chronic prescription opioid use 
during pregnancy were consistently more likely to receive postpartum prescription contraception 
at 60 and 365 days postpartum than women who did not use opioids.  On the other hand, women 
with OUD/Bup were significantly less likely to receive contraception, although use showed 
important nuances over the postpartum period.  Women with OUD/Bup were less likely to 
receive contraception within the first 60 days postpartum but after the 60-day mark, their 
likelihood of receiving contraception was like that of women who did not use opioids and had 
also not received contraception within 60 days postpartum.  The study findings highlight the 
need to develop tailored approaches to holistically caring for women during pregnancy and the 
postpartum period who use opioids, depending on the specific manifestation and reasons for 
opioid use.  Our study also found a strong relationship between hospital length of stay for the 
infant and postpartum contraceptive provision among women who use opioids during pregnancy.  
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This finding warrants additional research in an expanded population to better understand the 
relationship between infant illness and postpartum health care for women overall and those who 
use opioids and other substances specifically.        
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Diagnostic, Procedure, and Drug Codes for All Variables Except National 
Drug Codes for Prescription Opioids 
Table 1. Live Births [1] 
Description Code Type Codes 
Level I 










Complicated Cesarean Section DRG 765 
Uncomplicated Cesarean Section DRG 766 
Complicated Vaginal Delivery DRG 774 
Uncomplicated Vaginal Delivery DRG 775 
Uncomplicated vaginal delivery with 
sterilization and/or dilatation & curettage 
DRG 767 
Vaginal delivery with operation room 
procedure except sterilization and/or 
dilatation & curettage 
DRG 768 
Level IV: Selected Delivery-Related Procedures 
Forceps ICD-9-PCS 
ICD-10-PCS 
720, 721, 7221, 7229, 7231, 7239, 
724, 726 
10D07Z3, 0W8NXZZ, 10D07Z4, 
10D07Z5, 10S07ZZ 
Breech Extraction ICD-9-PCS 
ICD-10-PCS 
7251, 7252, 7253, 7254 
10D07Z3, 10D07Z4, 10D07Z5, 
10D07Z6 






















Cesarean Section ICD-9-PCS 
ICD-10-PCS 
740, 741, 742, 744, 7499 
10D00Z0, 10D00Z1, 10D00Z2 
Exclusionary Diagnosis and Procedure Codes 
Hydatidiform Mole ICD-9-CM 630 
224 
 
Description Code Type Codes 
ICD-10-CM O01*, O08* 
Abnormal Products of Conception ICD-9-CM 
ICD-10-CM 
631 
O02*, O07* O08*  
Ectopic Pregnancy ICD-9-CM 
ICD-10-CM 
633 
O00*, O03*, O08*  
Abortion ICD-9-CM 
ICD-10-CM 
632, 634, 635, 636, 637, 638, 639, 
6901, 6951, 7491, 750 
Z332, O04*, O07*, 10A07ZZ, 




V271, V274, V277 
Z371, Z374, Z377 
 
Table 2. Postpartum Contraception [2] 
Contraceptive 
Method 
Codes Data Source 
Female 
Sterilization 





ICD-10: Z30.2, Z98.51, 0UL.74ZZ, 0UL.78ZZ, 0U5.74ZZ, 
0U5.78ZZ, 0UL.74DZ, 0UL.78DZ, 0UL.74CZ, 0UL.70ZZ, 
0UL.73ZZ 0UL.77ZZ, 0UL.70CZ, 0UL.70DZ, 0UL.73CZ, 
0UL.73DZ, 0UL.77DZ,  0UL.78DZ 
CPT: 58600, 58605, 58615, 58611, 58670, 58671, 58565 
HCPCS: A4264 





ICD-10: Z30.430, Z30.433, Z30.431, Z97.5, T83.39XA, 
0UH.97HZ, 0UH.98HZ, 0UH.C7HZ, 0UH.C8HZ  
CPT: 58300 
HCPCS: J7300, J7301, J7302, S4989, Q0090, S4981 










ICD-10: Z30.49, Z30.18 
CPT: 11981, 11983 
HCPCS: J7306, J7307  















NDC: 54569370100, 54569490400, 54569552700, 
54569561600, 54569621900, 54868361300, 54868410000, 
54868410001, 54868525700, 55045350501, 59762453701, 









ICD-10: Z30.011, Z30.41  
HCPCS: S4993 
NDC: 00008111720, 00008111730, 00008251402, 
00008253505, 00008253601, 00008253605, 00052026106, 
00052028306, 00062125100, 00062125115, 00062125120, 
00062133220, 00062141116, 00062141123, 00062171400, 
00062171415, 00062176100, 00062176115, 00062178100, 
00062178115, 00062179600, 00062179615, 00062190120, 
00062190320, 000190700, 00062190715, 00062191000, 
00062191015, 00247052028, 00247069028, 00247069128, 
00247069228, 00247139828, 00247151328, 00247151628, 
00247151728, 00247176404, 00247176421, 00247176521, 
00247198621, 00247198628, 00247200828, 00247201004, 
00247201008, 00247201028, 00247201228, 00247201328, 
00247214728, 00247216928, 00247217028, 00247223028, 
00247223528, 00247226028, 00247226828, 00378655053, 
00378727253, 00378729253, 00430042014, 00430048214, 
00430053014, 00430053550, 00430057014, 00430057045, 
00430058014, 00430058045, 00430058114, 00430058514, 
00430058545, 00555034458, 00555071558, 00555900867, 
00555900942, 00555901058, 00555901258, 00555901467, 
00555901658, 00555901858, 00555902058, 00555902542, 
00555902557, 00555902658, 00555902742, 00555902757, 
00555902858, 00555903270, 00555903458, 00555904358, 
00555904558, 00555904758, 00555904958, 00555905058, 
00555905158, 00555905167, 00555906458, 00555906467, 
00555906558, 00555906658, 00555906667, 00555912366, 
00555913167, 00555913179, 00603359017, 00603359049, 
00603752117, 00603752149, 00603752517, 00603752549, 
00603754017, 00603754049, 00603760615, 00603760648, 
00603760715, 00603760748, 00603760817, 00603760917, 
00603762517, 00603762549, 00603763417, 00603763449, 
00603764017, 00603764217, 00603766317, 00603766517, 








Codes Data Source 
24090096184, 35356001468, 35356001568, 35356002168, 
35356025528, 35356037028, 43386062030, 45802084054, 
50419040201, 50419040203, 50419040303, 50419040503, 
50419040701, 50419040703, 50419041112, 50419041128, 
50419043306, 50419043312, 50452025115, 50458017115, 
50458017615, 50458017815, 50458019115, 50458019411, 
50458019416, 50458019615, 50458019715, 50458025115, 
51285005866, 51285007997, 51285008070, 51285008198, 
51285008297, 51285008370, 51285008498, 51285008787, 
51285009158, 51285009287, 51285011458, 51285043165, 
51285054628, 51285076993, 51285094288, 51285094388, 
52544014331, 52544017572, 52544020431, 52544021028, 
52544021928, 52544022829, 52544023528, 52544023531, 
52544024531, 52544024728, 52544024828, 52544025428, 
52544025928, 52544025988, 52544026528, 52544026531, 
52544026829, 52544026884, 52544027428, 52544027431, 
52544027536, 52544027928, 52544028754, 52544029128, 
52544029231, 52544029241, 52544029528, 52544038328, 
52544038428, 52544047536, 52544055028, 52544055228, 
52544055428, 52544062928, 52544063028, 52544063128, 
52544084728, 52544084828, 52544089228, 52544093628, 
52544094028, 52544094928, 52544095021, 52544095121, 
52544095328, 52544095428, 52544095931, 52544096691, 
52544096728, 52544098131, 52544098231, 52959045002, 
54569067900, 54569068500, 54569068501, 54569068900, 
54569068901, 54569143900, 54569384400, 54569422200, 
54569422201, 54569426900, 54569427301, 54569481700, 
54569487800, 54569487801, 54569489000, 54569498400, 
54569499700, 54569499800, 54569516100, 54569534300, 
54569534900, 54569549300, 54569549302, 54569579600, 
54569579700, 54569579800, 54569581600, 54569582600, 
54569603200, 54569612800, 54569614400, 54569614500, 
54569627200, 54569628000, 54569628100, 54868042800, 
54868044300, 54868050200, 54868050700, 54868050801, 
54868050901, 54868051600, 54868151200, 54868156400, 
54868231600, 54868260600, 54868270100, 54868377200, 
54868386300, 54868394800, 54868409300, 54868423900, 
54868436900, 54868453800, 54868459000, 54868460700, 
54868473000, 54868473100, 54868474200, 54868474500, 
54868475400, 54868477600, 54868481400, 54868482800, 
54868485100, 54868486000, 54868491100, 54868502800, 
54868528600, 54868532600, 54868535600, 54868582600, 
54868582800, 54868594200, 55045283902, 55045348506, 





Codes Data Source 
55045378302, 55289024708, 55289088704, 55887005228, 
55887028628, 58016474701, 58016482701, 66993061128, 
66993061528, 68180084313, 68180084413, 68180084613, 
68180084813, 68180085413, 68180087611, 68180087613, 
68180089713, 68180089813, 68180090213, 68462030329, 
68462030529, 68462030929, 68462031629, 68462031829, 
68462038829, 68462039429, 68462055629, 68462056529 





NDC: 00062192001, 00062192015, 00062192024, 





















NDC: 00027013160, 00027013180, 00062330100, 
00062330200, 00062330300, 00062330400, 00062330500, 
00062330600, 00062330700, 00062330800, 00062330900, 
00062331000, 00062331100, 00062331200, 00062331300, 
00062334100, 00062334200, 00062334300, 00062334400, 
00062334500, 00062334600, 00062334700, 00062334800, 
00062334900, 00062335000, 00062335100, 00062335200, 
00062338100, 00062338200, 00062338300, 00062338400, 
00062338500, 00062338600, 00062338700, 00062338800, 
00062338900, 00062364103, 00062364300, 00234005100, 
00234013100, 00234013150, 00234013155, 00234013160, 
00234013165, 00234013170, 00234013175, 00234013180, 
00234013185, 00234013190, 00234013195, 00234013600, 








Codes Data Source 
00234013680, 00234013685, 00234013690, 00234013695, 
00396401065, 00396401070, 00396401075, 00396401080 
  
Table 3. Opioid Use Disorder [3] 
Description Code Type Codes 
Opioid Use Disorder ICD-9-CM 
ICD-10-CM 
30400 30401 30402 30403 30470 
30471 30472 30473 30550 30551 
30552 30553 96500 96501 96502 
96509 
 
F1110 F11120 F11121 F11122 
F11129 F1114 F11150 F11151 
F11159 F11181 F11182 F11188 
F1119 F1120 F1121 F11220 
F11221 F11222 F11229 F1123 
F1124 F11250 F11251 F11259 
F11281 F11282 F11288 F1129 
F1190 F11920 F11921 F11922 
F11929 F1193 F1194 F11950 
F11951 F11959 F11981 F11982 
F11988 F1199 
 
Table 4. Mode of Delivery [4, 5] 
Description Code Type Codes 






66971 64981 64982 
 
740 741 742 744 7499 
 
O82 O7582 
10D00Z0 10D00Z1 10D00Z2 
 
 Table 5. Psychiatric Diagnoses [6-8] 
Psychiatric Diagnoses Code Type Codes 
Depression ICD-9-CM 
ICD-10-CM 
29620 29625 29630 29635 3004 
311 29383 29621 29622 29623 
29624 29626 29631 29632 29633 
29634 29636  
F329 F324 F339 F3341 F341 
F0630 F320 F321 F322 F323 
229 
 
Psychiatric Diagnoses Code Type Codes 




30000 30009 30020 30029 3003 
F419 F418 F409 F40218 F40240 
F40241 F408 F42 




Bipolar Disorder ICD-9-CM 
ICD-10-CM 
29600 29601 29602 29603 29604 
29605 29606 29610 29611 29612 
29613 29614 29615 29616 29640 
29641 29642 29643 29644 29645 
29646 29650 29651 29652 29653 
29654 29655 29656 29660 29661 
29662 29663 29664 29665 29666 
2967 29680 29681 29682 29689 
30113  
F3010 F3011 F3012 F3013 F302 
F303 F304 F3110 F3111 F3112 
F3113 F312 F3173 F3174 F3130 
F3131 F3132 F314 F315 F3175 
F3176 F3160 F3161 F3162 3163 
F3164 F3177 F3178 F319 F308 
F328 F3181 F340 
Schizophrenia ICD-9-CM 
ICD-10-CM 
29500 29501 29502 29503 29504 
29505 29510 29511 29512 29513 
29514 29515 29520 29521 29522 
29523 29524 29525 29530 29531 
29532 29533 29534 29535 29540 
29541 29542 29543 29544 29545 
29550 29551 29552 29553 29554 
29555 29560 29561 29562 29563 
29564 29565 29570 29571 29572 
29573 29574 29575 29580 29581 
29582 29583 29584 29585 29590 
29591 29592 29593 29594 29595 
F2089 F201 F202 F200 F2081 
F205 F259 F209 
 
Table 6. Non-Opioid Substance Use Disorders [8] 
Non-Opioid Substance Use Disorder Code Type Codes 
Alcohol Use Disorder ICD-9-CM 
ICD-10-CM 
2910 2911 2912 2913 2914 2915 
29181 29182 29189 2919 30300 
30301 30302 30303 30390 30391 
30392 30393 30500 30501 30502 
230 
 
Non-Opioid Substance Use Disorder Code Type Codes 
F1010 F10120 F10121 F10129 
F1014 F10150 F10151 F10159 
F10180 F10181 F10182 F10188 
F1019   F1020 F1021 F10220 
F10221 F10229 F10230 F10231 
F10232 F10239 F1024 F10250 
F10251 F10259 F1026 F1027 
F10280 F10281 F10282 F10288 
F1029 F10920 F10921 F10929 
F1094 F10950 F10951 F10959 
F1096 F1097 F10980 F10981 
F10982 F10988 F1099 
Drug-Induced Mental Disorders ICD-9-CM 2920 29211 29212 2922 29281 
29282 29283 29284 29285 29289 
2929 




30410 30411 30412 30413 30540 
30541 30542 30543 
 
F1310 F13120 F13121 F13129 
F1314 F13150 F13151 F13159 
F13180 F13191 F13182 F13188 
F1319 F1320 F1321 F13220 
F13221 F13229 F13230 F13231 
F13232 F13239 F1324 F13250 
F13251 F13259 F1326 F1327 
F13280 F13281 F13282 F13288 
F1329 F1390 F13920 F13921 
F13929 F13930 F13931 F13932 
F13939 F1394 F13950 F13951 
F13959 F1396 F1397 F13980 
F13981 F13982 F13988 F1399  
Cocaine Dependence  ICD-9-CM 
ICD-10-CM 
30420 30421 30422 30423 30560 
30561 30562 30563 
 
F1410 F14120 F14212 F14122 
F14129 F1414 F14150 F14151 
F14159 F14180 F14181 F14182 
F14188 F1419 F1420 F1421 
F14220 F14221 F14222 F14229 
F1423 F1424 F14250 F14251 
F14259 F14280 F14281 F14282 
F14288 F1429 F1490 F14920 
F14921 F14929 F1494 F14950 
231 
 
Non-Opioid Substance Use Disorder Code Type Codes 
F14951 F14959 F14980 F14981 
F14982 F14988 F1499 
Cannabis Dependence ICD-9-CM 
ICD-10-CM 
30430 30431 30432 30433 30520 
30521 30522 30523 
 
F1210 F12120 F12121 F12122 
F121219 F12150 F12151 F12159 
F12180 F12188 F1219 F1220 
F1221 F12220 F12221 F12222 
F12229 F12250 F12251 F12259 
F12280 F12288 F1229 F1290 
F12920 F12921 F12922 F12929 
F12950 F12951 F12959 F12980 
F12988 F1299  




30440 30441 30442 30443 30570 
30571 30572 30573 
 
F1510 F15120 F15121 F15122 
F15129 F1514 F15150 F15151 
F15159 F15180 F15181 F15182 
F15188 1519 F1520 F1521 
F15220 F15221 F15222 F15229 
F1523 F1524 F15250 F15251 
F15259 F15280 F15281 F15282 
F15288 F1529 F1590 F15920 
F15921 F15922 F15929 F1593 
F1594 F15950 F15951 F15959 
15980 F15981 F15982 F15988 
F1599 
Hallucinogen Dependence   ICD-9-CM 
ICD-10-CM 
30450 30451 30452 30453 30530 
30531 30532 30533 
 
F1610 F16120 F16121 F16122 
F16129 F1614 F16150 F16151 
F16159 F16180 F16183 F16188 
F1619 F1620 F1621 F16220 
F16221 F16229 F1624 F16250 
F16251 F16259 F16280 F16283 
F16288 F1629 F1690 F16920 
F16921 F16929 F1694 F16950 
F16951 F16959 F16980 F16983 
F16988 F1699 
Other Specified Drug Dependence ICD-9-CM 
ICD-10-CM 
30460 30461 30462 30463 30580 




Non-Opioid Substance Use Disorder Code Type Codes 
F1810 F18120 F18121 F18129 
F1814 F18150 F18151 F18159 
F1817 F18180 F18188 F1819 
F1820 F1821 F18220 F18221 
F18229 F1824 F18250 F18251 
F18259 F1827 F18280 F18288 
F1829 F1890 F18920 18921 
F18929 F1894 F18950 F18951 
F18959 F1897 F18980 F18988 
F1899 F1910 F19120 F19121 
F19122 F1914 F19150 F19151 
F19159 F1916 F1917 F19180 
F19181 F19182 F19188 F1919 
F1920 F1921 F19220 F19221 
F19222 F19229 F19230 F19231 
F19232 F19239 F1924 F19250 
F19251 F19259 F1926 F1927 
F19280 F19281 F19282 F19288 
F1929 F1990 F19920 F19921 
F19922 F19929 F19930 F19931 
F19932 F19939 F1994 F19950 
F19951 F19959 F1996 F1997 
F19981 F19982 F19988 F1999 
Combinations of Drug Dependence 
Excluding Opioid Type Drug 
ICD-9-CM 
 
30480 30481 30482 30483 
Unspecified Drug Dependence ICD-9-CM 
 
30490 30491 30492 30493 30590 
30591 30592 30593 
Drug Dependence complicating 
pregnancy, childbirth, or puerperium 
ICD-9-CM 
ICD-10-CM 
64830 64831 64832 64833 64834 
 
O99320 O99321 O99322 O99323 
O99324 O99325 
Noxious Influences affecting fetus or 
newborn via placenta or breastmilk 
ICD-9-CM 76075 
Drug withdrawal syndrome in newborn ICD-9-CM 
ICD-10-CM 
7795 
P0441 P961 P962 











Table 7. Chronic Conditions [9-12]  
Chronic Condition Code Type Codes 
Autoimmune Disease ICD-9-CM 
ICD-10-CM 
1303 1361 2420 2830 340 3570 
3581 35800 35801 37940 37941 
37942 37943 37945 37946 37949 
390 3910 3911 3912 3918 3919 
393 4290 4460 4461 4464 4467 
5472 5790 5813 5819 5830 5831 
5832 5833 5834 6940 6942 6943 
6944 6945 6960 6961 7010 7101  
3920 3929 3940 3941 3942 3949 
3950 3951 3952 3959 3960 3961 
3962 3963 3968 3969 3970 3971 
3979 3980 39890 39891 39899 
4220 42290 42291 42292 42293 
42299 44620 44621 44629  
51630 51631 51362 51633 51634 
51635 51636 51637 5171 5172 
5173 5178 5550 5551 5552 5559  
5560 5561 5562 5563 5564 5565 
5566 5568 5569 5800 5804 
58081 58089 5809 5820 5821 
5822 5824 58281 58289 5829 
69460 69461 71430 71431 71432 
71433 85110 85111 85112 85113 
85114 85115 85116 85119 7100 
7103 7104 7140 7141 7142 7200  
 
B5881 M352 D590 D591 G35 
G610 G733 I00 I092 I514 M300  
M303 M3130 M314 K900 N040 
N049 N059 N052 N055 L130 
L122 L401 L100 L101 L102 
L104 L109 L120 L128 L4054 
L4059 L400 L401 L402 L403 
L404 L408 L900 L940 L943 
M340 M341 M349 M3210 
M3390 M3320 M069 M0500 
M0530 M0560 M061 M459 
E0590 E0591 E0500 E0501 
E0510 E0511 E0520 E0521 
E0530 E0531 E0540 E0541 
E0580 E0581 G7000 G7001 
H5700 H5701 H5702 H5703 
H5704 H5709 I010 I011 I012 
I018 I019 I010 I011 I012 I018 
234 
 
Chronic Condition Code Type Codes 
I019 I050 I051 I052 I058 I059 
I060 I061 I062 I068 I069 I080 
I081 I082 I083 I088 I089 I070 
I071 I072 I078 I079 I090 I091 
I092 I0981 I0989 I099 I41 I409 
I400 I401 I408 M310 J84111 
J84112 J84113 J84114 J85115 
J842 J85117 J17 M3481 J99  
K5000 K5010 K5080 K5090 
K5180 K5120 K5130 K5140 
K5150 K5100 K5190 N003 N013 
N009 N08 N008 N032 N033 
N035 N038 N039 N08 N038 
L121 M0800 M083 M0840 
S0190XA S06330A S06332A 
S06333A S06334A S06335A 
S06336A S06337A S06339A 
Chronic Hypertension ICD-9-CM 
ICD-10-CM 
64200 64201 64202 64203 64204 
64210 64211 64212 64213 64214 
64220 64221 64222 64223 64224  
64290 64291 64292 64293 64294 
64270 64271 64272 64273 64274 
4010 4011 4019, 40501 40509 
40511 40519 40591 40599 4160 
45930 45931 45932 45933 45939  
 
O10011 O10012 O10013 O10019 
O1002 O1003 O10111 O10112  
O10113 O10119 O1012 O1013 
O10211 O10212 O10213 O10219 
O1022 O1023 O10311 O10312 
O10313 O10319 O1032 O1033 
O10411 O10412 O10413 O10419 
O1042 O1043 O10911 O10912 
O10913 O10919 O1092 O1093 
O161 O162 O163 O169 0111 
O112 O113 O119 I10 I150 I158 
I270 I87309 I87319 I87329 
I87339 I87399 
Gestational Hypertension ICD-9-CM 
ICD-10-CM 
64230 64231 64232 64233 64234 
64240 64241 64242 64243 64244 
64250 64251 64252 64253 64254 




Chronic Condition Code Type Codes 
O132 O139 01400 O1402 O1403 
O1410 O1412 O1413 O1420 
O1422 O1423 O1490 O1492 
O1493 01500 O1502 O1503 
O151 O152 O159 
Diabetes Miletus  ICD-9-CM 
ICD-10-CM 
25000 25001 25002 25003 25010 
25011 25012 25013 25020 25021 
25022 25023 25030 25031 25032  
25033 25040 25041 25042 25043 
25050 25051 25052 25053 25060 
25061 25062 25063 25070 25071 
25072 25073 25080 25081 25082 
25083 25090 25091 25092 25093 
24900 24901 24910 24911 24920 
24921 24930 24931 24940 24941 
24950 24951 24960 24961 24970 
24971 24980 24981 24990 
24991, 36201 36202 36203 
36204 36205 36206 36207, 
36641, 3572, 64800 64801 64802 
64803 64804  
 
O24011 O24012 O24013 O24019 
O2402 O2403 O24111 O24112  
O24113 O24119 O2412 O2413 
O24311 O24312 O24313 O24319 
O2432 O2433 O24811 O24812 
O24813 O24819 O2482 O2483  
O24911 O24912 O24913 O24919 
O2492 O2493 E0800 E0801 
E0821 E0822 E0829 E0840 
E0841 E0842 E0843 E0844  
E0849 E0851 E0852 E0859 E088 
E089 E08311 E08319 E08321 
E08329 E08331 E08339 E08341 
E08349 E08351 E08359 E0836 
E0839 E08610 E08618 E08620 
E08621 E08622 E08628 E08630 
E08638 E08641 E08649 E0900 
E0901 E0910 E0911 E0921 
E0922 E0929 E0940 E0941 
E0942 E0943 E0944 E0949 
E0951 E0952 E0959 E098 E099 
E09311 E09319 E09321 E09329 
E09331 E09339 E09341 E09349 
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Chronic Condition Code Type Codes 
E09351 E09359 E0936 E0939 
E09610 E09618 E09620 E09621 
E09622 E09628 E09630 E09638 
E09641 E09649 E0965 E0969 
E1010 E1011 E1021 E1022 
E1029 E1040 E1041 E1042 
E1043 E1044 E1049 E1051 
E1052 E1059 E108 E109 E10311 
E10319 E10321 E10329 E10331 
E10339 E10341 E10349 E10351 
E10359 E1036 E1039 E10610 
E10618 E10620 E10621 E10622 
E10628 E10630 E10638 E10641 
E10649 E1065 E1069 E1100 
E1101 E1121 E1122 E1129 
E1140 E1141 E1142 E1143 
E1144 E1149 E1151 E1152 
E1159 E118 E119 E11311 
E11319 E11321 E11329 E11331 
E11339 E11341 E11349 E11351 
E11359 E1136 E1139 E11610 
E11618 E11620 E11621 E11622 
E11628 E11630 E11638 E11641 
E11649 E1165 E1169 E1300 
E1301 E1310 E1311 E1321 
E1322 E1329 E1340 E1341 
E1342 E1343 E1344 E1349 
E1351 E1352 E1359 E138 E139 
E13311 E13319 E13321 E13329 
E13331 E13339 E13341 E13349 
E13351 E13359 E1336 E1339 
E13610 E13618 E13620 E13621 
E13622 E13628 E13630 E13638 
E13641 E13649 E1365 E1369 
Gestational Diabetes ICD-9-CM 
ICD-10-CM 
64880 64881 64882 64883 64884  
 
O24410 O24414 O24419 O24420 




49300 49301 49302 49310 49311 
49312 49320 49321 49322 49381 
49382 49390 49391 49392  
 
J4520 J4521 J4522 J4530 J4531 
J4532 J4540 J4541 J4542 J4550 
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Chronic Condition Code Type Codes 
J4551 J4552 J45901 J45902 
J45909 J45990 J45991 J45998 
Hepatitis C ICD-9-CM 
ICD-10-CM 
07041 07044 07051 07054 0707 
07070 07071 B182 B1711 B1710 
B182 B1920 B1921 
 
Table 8. Pain Conditions [13] 
Pain Condition Code Type Codes 
Back Pain ICD-9-CM 
ICD-10-CM 
72130 72142 72252 72273 72402 
72403 72420 72430 72440 72450  
 
M4306 M4307 M4316 M4317 
M4716 M4726 M4727 M47816 
M47817 M47896 M47897 
M4806 M4807 M5106 M5116 
M5117 M5126 M5127 M5136 
M5137 M5416 M5417 M5430 
M5431 M5432 M5440 M5441 
M5442 M545 M5489 M549  
S39012A S39012D S39012S 
S39023A S39023D S39023S 
S39092A S39092D S39092S 
Headache ICD-9-CM 
ICD-10-CM 
30781 33900 33901 33902 33903 
33904 33905 33909 33910 33911 
33912 33920 33921 33922 3393  
33941 33942 33943 33944 33981 
33982 33983 33984 33985 33989 
3490 7238 7840 3490 3491 3492 
34931 34939 34981 34982 34989 
3499  
 
R51 G971 M5481 G43001 
G43009 G43011 G43019 G43101 
G43109  G43111 G43119G43401 
G43409 G43411 G43419 G43501 
G43509 G43511 G43519 G43601 
G43609 G43611 G43619 G43701 
G43709 G43711 G43719 G43A0 
G43A1 G43B0 G43B1 G43C0 
G43C1 G43D0 G43D1 G43801 
G43809 G43811 G43819 G43821 
G43829 G43831 G43839 G43901 
G43909 G43911 G43919 G44001 
G44009 G44011 G44019 G44021 
238 
 
Pain Condition Code Type Codes 
G44029 G44031 G44039 G44041 
G44049 G44051 G44059 G44091 
G44099 G441 G44201 G44209 
G44211 G44219 G44221 G44229 
G44301 G44309 G44311 G44319 
G44321 G44329 G4440 G4441 
G4451 G4452 G4453 G4459 
G4481 G4482 G4483 G4484 
G4485 G4489 





Arthritis  ICD-9-CM 
ICD-10-CM 
140 7141 7142 71430 71431 
71432 71433 7144 71481 71489 
7149 71500 71504 71509 71510 
71511 71512 71513 71514 71515 
71516 71517 71518 71520 71521 
71522 71523 71524 71525 71526 
71527 71528 71530 71531 71532 
71533 71534 71535 71536 71537 
71538 71580 71589 71590 71591 
71592 71593 71594 71595 71596 
71597 71598 
 
M0500 M05011 M05012 
M05019 M05021 M05022 
M05029 M05031 M05032 
M05039 M05041 M05042 
M05049 M05051 M05052 
M05059 M05061 M05062 
M05069 M05071 M05072 
M05079 M0509 M0510 M05111 
M05112 M05119 M05121 
M05122 M05129 M05131 
M05132 M05139 M05141 
M05142 M05149 M05151 
M05152 M05159 M05161 
M05162 M05169 M05171 
M05172 M05179 M0519 M0520 
M05211 M05212 M05219 
M05221 M05222 M05229 
M05231 M05232 M05239 
M05241 M05242 M05249 
M05251 M05252 M05259 
M05261 M05262 M05269 
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Pain Condition Code Type Codes 
M05271 M05272 M05279 
M0529 M0530 M05311 M05312 
M05319 M05321 M05322 
M05329 M05331 M05332 
M05339 M05341 M05342 
M05349 M05351 M05352 
M05359 M05361 M05362 
M05369 M05371 M05372 
M05379 M0539 M0540 M05411 
M05412 M05419 M05421 
M05422 M05429 M05431 
M05432 M05439 M05441 
M05442 M05449 M05451 
M05452 M05459 M05461 
M05462 M05469 M05471 
M05472 M05479 M0549 M0550 
M05511 M05512 M05519 
M05521 M05522 M05529 
M05531 M05532 M05539 
M05541 M05542 M05549 
M05551 M05552 M05559 
M05561 M05562 M05569 
MO5571 MO5572 MO5579 
MO559 M0560 M05611 M05612 
M05619 MO5621 MO5622 
M05629 M05631 M05632 
M05639 M05641 M05642 
M05649 M05651 M05652 
M05659 M05661 M05662 
M05669 M05671 M05672 
M05679 M0569 M0570 M05711 
M05712 M05719 M05721 
M05722 M05729 M05731 
M05732 M05739 M05741 
M05742 M05749 M05751 
M05752 M05759 M05761 
M05762 M05769 M05771 
M05772 M05779 M0579 M0580 
M05811 M05812 M05819 
M05821 M05822 M05829 
M05831 M05832 M05839 
M05841 M05842 M05849 
M05851 M05852 M05859 
M05861 M05862 M05869 
M05871 M05872 M05879 
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Pain Condition Code Type Codes 
M0589 M059 M0600 M06011 
M06012 M06019 M06021 
M06022 M06029 M06031 
M06032 M06039 M06031 
M06032 M06039 M06041 
M06042 M06049 M06051 
M06052 M06059 M06061 
M06062 M06069 M06071 
M06072 M06079 M0608 M0609 
M061 M0620 M06221 M06212 
M06219 M06221 M06222 
M06229 M06231 M06232 
M06239 M06241 M06242 
M06249 M06251 M06252 
M06259 M06261 M06262 
M06269 M06271 M06272 
M06279 M0628 M0629 M0630 
M06311 M06312 M06319 
M06321 M06322 M06329 
M06331 M06332 M06339 
M06341 M06342 M06349 
M06351 M06352 M06359 
M06361 M06362 M06369 
M06371 M06372 M06379  
M0638 M0639 M064 M0680 
M06811 M06812 M06819 
M06821 M06822 M06829 
M06831 M06832 M06839 
M06841 M06842 M06849 
M06851 M06852 M06859 
M06861 M06862 M06869 
M06871 M06872 M06879 
M0688 M0689 M069 M150 
M151 M152 M153 M154 M158 
M159 M160 M1610 M1611 
M1612 M162 M1630 M1631 
M1632 M164 M1650 M1651 
M1652 M166 M167 M169 M170 
M1710 M1711 M1712 M172 
M1730 M1731 M1732 M174 
M175 M179 M180 M1810 
M1811 M1812 M182 M1830 
M1831 M1832 M184 M1850 
M1851 M1852 M189 M19011 
M19012 M19019 M19021 
241 
 
Pain Condition Code Type Codes 
M19022 M19029 M19031 
M19032 M19039 M19041 
M19041 M19049 M19071 
M19072 M19079 M19111 
M19112 M19119 M19121 
M19122 M19129 M19131 
M19132 M19139 M19141 
M19142 M19149 M19171 
M19172 M19179 M19211 
M19212 M19219 M19221 
M19222 M19229 M19231 
M19232 M19239 M19241 
M19242 M19249 M19271 
M19272 M19279 M1990 M1991 
M1992 M1993 
Neuropathic Pain ICD-9-CM 
ICD-10-CM 
05312 05313 3501 3502 3508 
3509 3530 3531 3532 3533 3534 
3535 3536 3538 3539 3540 3541 
3542 3543 3544 3545 3548 3549 
3550 3551 3552 3553 3554 3556 
35571 35579 3558 3559 3560 
3561 3562 3563 3564 3568 3569 
33720 33721 33722 33729 25060 
25061 25062 25063  
 
G500 G501 G508 G509 G510 
G511 G512 G513 G514 G518 
G519 G520 G521 G522 G523 
G527 G528 G529 G53 G540 
G546 G548 G59 G600 G601 
G602 G603 G608 G609 B0222 
B0223 B0229 G9050 G90511 
G90512 G90513 G90519 G90521 
G90522 G90523 G90529 G9059 
E1340 E1342 E1342 E1343 
E1344 E1349 
 
Table 9. ANC and PNC Codes and Definition [14] 
Description Code Type Codes 
Antenatal Care Visit 
 
Visit Location “medical office” or 
“outpatient hospital location” AND 
diagnosis code OR provider type 
ICD-9-CM 
ICD-10-CM 
O0900 O0901 O0902 O0903 
O0910 O0911 O0912 O0913 
O09211 O09212 O09213 O09219 
O09291 O09292 O09293 O09299 
O0930 O0931 O0932 O0933 
242 
 
Description Code Type Codes 
“obstetrics & gynecology, certified nurse 
midwife, gynecologist, family practice, 
family practice OB/Gyn, certified nurse 
midwife, maternal and fetal medicine, 
nurse practitioner, or perinatology”  
O0940 O0941 O0942 O0943 
O09511 O09512 O09513 O09519 
O09521 O09522 O09523 O09529 
O09611 O09612 O09613 O09619  
O09621 O09622 O09623 O09629 
O0970 O0971 O0972 O0973 
O09811 O09812 O09813 O09819 
O09821 O09822 O09823 O09829 
O09891 O09892 O09893 O09899 
O0990 O0991 O0992 O0993 
O3680X0  
 
Z3400 Z3401 Z3402 Z3403 
Z3480 Z3481 Z3482 Z3483 
Z3490 Z3491 Z3492 Z3493 V220 
V221 V230 V231 V232 V233 
V2341 V2342 V2349 V235 V237 
V2381 V2382 V2384 V2385 
V2386 V2387 V2389 V239 
Postpartum Care Visit 
 
Visit Location “medical office” or 
“outpatient hospital location” AND 
diagnosis code OR provider type 
“obstetrics & gynecology, certified nurse 
midwife, gynecologist, family practice, 
family practice OB/Gyn, certified nurse 
midwife, maternal and fetal medicine, 
nurse practitioner, or perinatology” 
ICD-9-CM 
ICD-10-CM 
V241 V242  
Z391 Z392 
 
Table 10. NAS Diagnosis [3, 15-17] 
Description Code Type Codes 
Neonatal Abstinence Syndrome  ICD-9-CM 
ICD-10-CM 
779.5 76072  
P96.1, P0449 
Conditions Associated with Iatrogenic Neonatal Abstinence Syndrome (Exclusionary Codes) 
Very Low Birthweight ICD-9-CM 
ICD-10-CM 
V2131, V2132 
P07.00, P07.02, P07.01, P07.03 
Intraventricular Hemorrhage ICD-9-CM 
ICD-10-CM 
772.10, 772.12, 772.14, 772.11, 
772.13 
P523, P521, P5222, P520, P5221 




Necrotizing Enterocolitis ICD-9-CM 
ICD-10-CM 
777.51, 777.52, 777.53, 777.50 
P779, P773, P772, P771 
243 
 
Description Code Type Codes 




Bronchopulmonary Dysplasia ICD-9-CM 
ICD-10-CM 
770.7 
P27.0, P27.1, P27.8 
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Appendix B  
Characteristics of Aim 1 Cohort by Provision of Immediate Postpartum 
Prescription Contraception within Three days Postpartum, Row Totals 








LARC MEM  
Total N (%) 1,204,405 
(93.3%) 
86,947 (6.7%) 72,582 (5.6%) 1,331 (0.1%) 13,034 (1.0%) 
Opioid Use      
















92.0% (4,741) 8.0% (414) 6.2% (322) 0.4% (22) 1.4% (70) 
Age, mean years 
(SD) 
30.1 (5.4) 32.8 (5.1) 33.6 (4.7) 28.9 (6.1) 28.8 (5.2) 
Age, Categorical      
<20 98.3% (36,274) 1.6% (608) 0.02% (9) 0.2% (83) 1.4% (516) 
20-24 97.0% 
(154,366) 
3.0% (4,830) 1.4% (2,307) 0.2% (264) 1.4% (2,259) 
25-29 95.3% 
(339,717) 
4.6% (16,582) 3.3% (11,861) 0.1% (352) 1.2% (4,369) 
30-34 93.2% 
(424,558) 
6.8% (30,857) 5.8% (26,309) 0.1% (380) 0.9% (4,168) 
35-39 88.6% 
(202,060) 
11.4% (25,886) 10.6% (24,197) 0.1% (204) 0.6% (1,485) 
40+ 85.3% (47,430) 14.7% (8,184) 14.2% (7,899) 0.1% (48) 0.4% (237) 
HRSA Region      
Region 1 95.4% (53,217) 4.6% (2,565) 3.6% (2,032) 0.1% (53) 0.9% (480) 
















8.4% (14,432) 7.6% (12,951) 0.1% (150) 0.8% (1,331) 
Region 7 93.6% (49,364) 6.4% (3,362) 5.0% (2,619) 0.1% (58) 1.3% (685) 




6.0% (9,367) 4.5% (6,948) 0.1% (202) 1.4% (2,217) 
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LARC MEM  
Region 10 93.6% (48,522) 6.4% (3,309) 4.9% (2,567) 0.1% (51) 1.3% (691) 
Unknown 92.4% (34,830) 7.6% (2,865) 6.6% (2,506) 0.1% (26) 0.9% (333) 
Delivery in State with ≥20% Hispanic Population 
Yes 93.0% 
(353,578) 
7.0% (26,690) 5.9% (22,634) 0.1% (321) 1.0% (3,735) 
No 93.4% 
(850,827) 
6.6% (60,257) 5.5% (49,948) 0.1% (1,010) 1.0% (9,299) 
Delivery in State with ≥20% Black Population 
Yes 91.5% 
(196,453) 
8.5% (18,313) 7.4% (15,886) 0.1% (329) 1.0% (2,098) 
No 93.6% 
(1,007,952) 
6.4% (68,634) 5.5% (49,948) 0.1% (1,010) 1.0% (9,299) 
Delivery in State with ≥15% Population in Poverty 
Yes 91.0% 
(158,883) 
9.0% (15,665) 7.6% (13,306) 0.2% (281) 1.2% (2,078) 
No 93.6% 
(1,045,522) 
6.4% (71,282) 5.3% (59,276) 0.1% (1,050) 1.0% (10,956) 
Delivery in State with ≥35% Women with College Degree or More 
Yes 94.8% 
(123,851) 
5.2% (6,772) 4.3% (5,636) 0.1% (116) 0.8% (1,020) 
No 93.1% 
(1,080,554) 
6.9% (80,175) 5.8% (66,946) 0.1% (1,215) 1.0% (12,014) 
Insurance Plan Type 
PPO 93.3% 
(716,215) 
6.7% (51,300) 5.7% (44,083) 0.1% (708) 0.8% (6,509) 
Comprehensive 93.7% (12,290) 6.3% (832) 5.0% (662) 0.2% (28) 1.1% (142) 
HMP/EPO 92.9% 
(176,389) 
7.1% (13,453) 5.1% (9,748) 0.2% (299) 1.8% (3,406) 
POS 92.8% (87,604) 7.2% (6,840) 6.2% (5,841) 0.1% (112) 0.9% (887) 
CDHP 93.7% (98,755) 6.3% (6,690) 5.5% (5,775) 0.1% (92) 0.8% (823) 
HDHP 94.3% (73,872) 5.7% (4,430) 4.8% (3,773) 0.1% (68) 0.7% (589) 
Unknown 92.0% (39,280) 8.0% (3,402) 6.3% (2,700) 0.1% (24) 1.6% (678) 
Year of Delivery      
2011 92.5% 
(250,180) 
7.5% (20,325) 6.4% (17,284) 0.1% (161) 1.1% (2,880) 
2012 92.9% 
(241,621) 
7.1% (18,562) 6.0% (15,686) 0.1% (199) 1.0% (2,677) 
2013 93.1% 
(180,640) 
6.9% (13,401) 5.7% (11,055) 0.1% (155) 1.1% (2,191) 
2014 93.5% 
(170,431) 
6.5% (11,784) 5.4% (9,910) 0.1% (177) 0.9% (1,697) 
2015 93.9% 
(135,624) 
6.1% (8,843) 5.1% (7,308) 0.1% (179) 0.9% (1,356) 
2016 94.1% 
(128,925) 
5.9% (8,053) 4.8% (6,538) 0.1% (206) 1.0% (1,309) 
2017 94.2% (96,984) 5.8% (5,979) 4.7% (4,801) 0.2% (254) 0.9% (924) 
Delivery Mode      
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LARC MEM  
Vaginal 97.5% 
(811,700) 
2.5% (20,623) 1.3% (10,958) 0.1% (550) 1.1% (9,115) 
Cesarean Section 85.5% 
(392,705) 
14.5% (66,324) 13.4% (61,624) 0.2% (781) 0.8% (3,919) 
Non-Opioid Substance Use Disorder 
Yes 92.8% (16,319) 7.2% (1,265) 5.3% (933) 0.3% (58) 1.6% (274) 
No 93.3% 
(1,188,086) 
6.7% (85,682) 5.6% (71,649) 0.1% (1,273) 1.0% (12,760) 
Psychiatric Disorder, Any 
Yes 92.0% (66,007) 8.0% (5,700) 6.4% (4,609) 0.2% (133) 1.3% (958) 
No 93.3% 
(1,138,398) 
6.7% (81,247) 5.6% (67,973) 0.1% (1,198) 1.0% (12,076) 
Chronic Hypertension 
Yes 89.6% (97,249) 10.4% (11,254) 9.3% (10,052) 0.2% (185) 0.9% (1,017) 
No 93.6% 
(1,107,156) 




7.6% (11,816) 6.5% (10,174) 0.1% (207) 0.9% (1,435) 
No 93.4% 
(1,060,004) 
6.6% (75,131) 5.5% (62,408) 0.1% (1,124) 1.0% (11,599) 
Diabetes Mellitus 
Yes 88.1% (47,601) 11.9% (6,422) 10.9% (5,886) 0.2% (89) 0.8% (447) 
No 93.5% 
(1,156,804) 
6.5% (80,525) 5.4% (66,696) 0.1% (1,242) 1.0% (12,587) 
Gestational 
Diabetes 
     
Yes 90.6% 
(168,730) 
9.4% (17,560) 8.5% (15,820) 0.1% (191) 0.8% (1,549) 
No 93.7% 
(1,035,675) 
6.3% (69,387) 5.1% (56,762) 0.1% (1,140) 1.0% (11,485) 
Asthma       
Yes 92.5% (58,042) 7.5% (4,676) 5.9% (3,678) 0.2% (120) 1.4% (878) 
No 93.3% 
(1,146,363) 
6.7% (82,271) 5.6% (68,904) 0.1% (1,211) 1.0% (12,156) 
Autoimmune 
Disorder 
     
Yes 91.9% (22,777) 8.0% (1,992) 6.9% (1,703) 2.0% (39) 1.0% (250) 
No 93.3% 
(1,181,628) 
6.7% (84,955) 5.6% (70,879) 0.1% (1,292) 1.0% (12,784) 
Hepatitis C      
Yes 91.1% (864) 8.9% (84) 6.6% (63) 1.0% (9) 1.3% (12) 
No 93.3% 
(1,203,541) 
6.7% (86,863) 5.6% (72,519) 0.1% (1,322) 1.0% (13,022) 
Pain-Related 
Conditions 
     
Yes 92.2% (99,073) 7.8% (8,371) 6.6% (7,051) 0.2% (174) 1.1% (1,146) 
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LARC MEM  
No 93.4% 
(1,105,332) 
6.6% (78,576) 5.5% (65,531) 0.1% (1,157) 1.0% (11,888) 
Any ANC      
Yes 93.3% 
(1,165,495) 
6.7% (84,275) 5.6% (70,467) 0.1% (1,298) 1.0% (12,510) 






Crude Estimates of Mean Time to Contraceptive Provision in Women Who 
Were Provided Contraception Within 365 Postpartum, Aim 2 Cohort 
Covariable  Mean Days to Contraceptive 
Provision (95% CI) 
Opioid Use During Pregnancy  
No use 61.92 (61.76-62.08) 
Non-Chronic Prescription Use 59.34 (58.84-59.82) 
Chronic Prescription Use 54.88 (53.23-56.52) 
OUD/BUP 72.32 (69.54-75.10) 
Contraceptive Method Type  
Any Method 61.66 (61.49-61.69) 
Sterilization 13.26 (12.98-13.54) 
LARC 76.58 (76.30-76.86) 
MEM 66.19 (65.99-66.39) 
Age at Delivery  
>20 75.51 (74.64-76.38) 
20-24 69.32 (68.90-69.74) 
25-29 61.49 (61.23-61.76) 
30-34 60.82 (60.56-61.08) 
35-39 55.82 (55.41-56.23) 
40+ 50.54 (49,60-51.49) 
HRSA Region  
Region 1 66.49 (65.74-67.25) 
Region 2 72.85 (72.12-73.57) 
Region 3 62.86 (62.32-63.41) 
Region 4 59.91 (59.59-60.22) 
Region 5 62.59 (62.23-62.94) 
Region 6 58.23 (57.84-58.63) 
Region 7 61.21 (60.50-61.93) 
Region 8 58.31 (57.56-59.05) 
Region 9 63.61 (63.14-64.09) 
Region 10 57.94 (57.25-58.63) 
Unknown 56.88 (56.09-57.68) 
Delivery in State with ≥20% 
Hispanic Population 
 
No 61.49 (61.31-61.67) 
Yes 62.02 (61.73-62.31) 
Delivery in State with ≥20% 
Black Population 
 
No 62.03 (61.86-62.20) 
Yes 59.82 (59.46-60.19) 
Delivery in State with ≥15% 




Covariable  Mean Days to Contraceptive 
Provision (95% CI) 
No 62.32 (62.15-62.49) 
Yes 57.79 (57.41-58.17) 
Delivery in State with ≥35% 
Women with College Degree or 
More 
 
No 61.15 (60.98-61.31) 
Yes 66.49 (65.97-67.01) 
Insurance Plan Type  
PPO 61.59 (61.39-61.79) 
Comprehensive 65.40 (63.71-67.10) 
HMO/EPO 61.37 (60.97-61.77) 
POS/POS + Capitation 63.16 (62.59-63.73) 
CDHP 62.49 (61.93-63.04) 
HDHP 62.08 (61.41-62.74) 
Unknown 56.68 (55.89-57.47) 
Year of Delivery  
2011 64.11 (63.78-64.45)  
2012 61.30 (60.98-61.63) 
2013 60.88 (60.51-61.25) 
2014 58.94 (58.57-59.30) 
2015 62.37 (61.92-62081) 
2016 61.31 (60.86-61.77) 
Delivery Mode  
Vaginal 67.58 (67.39-67.78) 
Cesarean Section 52.11 (51.86-52.35) 
Non-Opioid Substance Use 
Disorder 
 
No 61.55 (61.39-61.70) 
Yes 67.97 (66.56-69.37) 
Psychiatric Disorder, Any  
No 61.59 (61.43-61.75) 
Yes 62.50 (61.85-63.15) 
Chronic Hypertension  
No 62.21 (61.96-62.28) 
Yes 56.76 (56.26-57.26) 
Gestational Hypertension  
No 61.87 (61.71-62.04) 
Yes 60.09 (59.67-60.50) 
Diabetes Mellitus  
No 61.91 (61.75-62.06) 
Yes 55.61 (54.85-56.37)  
Gestational Diabetes  
No 62.26 (62.10-62.43) 
Yes 57.97 (57.57-58.38) 
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Covariable  Mean Days to Contraceptive 
Provision (95% CI) 
Asthma  
No 61.65 (61.49-61.81) 
Yes 61.47 (60.79-62.15) 
Autoimmune Disease  
No 61.66 (61.50-61.81) 
Yes 60.89 (59.75-62.04) 
Pain Condition  
No 61.68 (61.52-61.84) 
Yes 61.18 (60.63-61.74) 
Hepatitis C  
No 61.64 (61.49-61.79) 
Yes 63.37 (57.31-69.42) 
Any ANC  
No 61.54 (60.66-62.42) 






Log-Rank Test Results from Kaplan-Meier Curves for all Categorical 







Opioid Use   <0.001 
No Opioid Use During 
Pregnancy 
565,692 577,757.79  
Non-Chronic 
Prescription Opioid Use 
63,919 53,233.95  
Chronic Prescription 
Opioid Use 




2,694 2,593.74  
Maternal Age   <0.001 
<20 22,568 18,157.12  
20-24 90,532 76,488.87  
25-29 188,342 171,622.94  
30-34 217,639 227,000.84  
35-39 98,331 115,539.71  
40+ 20,606 29,208.52  
HRSA Region   <0.001 
Region 1 26,338 29,447.33  
Region 2 36,463 53,325.61  
Region 3 52,701 56,667.58  
Region 4 148,128 127,883.83  
Region 5 115,354 120,113.98  
Region 6 91,566 79,752.13  
Region 7 27,975 25,049.80  
Region 8 22,059 19,843.31  
Region 9 70,571 81,916.13  
Region 10 26,795 24,815.36  
Unknown 20,068 19,202.94  
Delivery in State with 
≥20% Hispanic 
Population 
  <0.001 
No 455,849 446,810.45  
Yes 182,169 191,207.55  
Delivery in State with 
≥20% Black Population 
  <0.001 
No 524,912 540,840.40  









Delivery in State with 
≥15% Population in 
Poverty 
  <0.001 
No 542,370 560,323.29  
Yes 95,640 77,694.71  
Delivery in State with 
≥35% Women with 
College Degree or More 
  <0.001 
No 578,879 569,776.34  
Yes 59,139 68,241.66  
Insurance Plan Type   <0.001 
PPO 384,466 382,861.98  
Comprehensive 5,888 5,919.29  
HMO/EPO 95,078 95,795.80  
POS/POS + Capitation 47,917 46,486.33  
CDHP 49,572 48,675.79  
HDHP 33,747 36,788.53  
Unknown 21,350 21,490.28  
Year of Delivery    
2011 146,132 144,079.32  
2012 141,283 139,792.35  
2013 106,313 102,928.90  
2014 98,155 98,306.95  
2015 76,174 78,264.73  
2016 69,961 74,645.75  
Delivery Mode   <0.001 
Vaginal 393,075 427,846.46  
Cesarean Section 244,943 210,171.54  
Non-Opioid Substance 
Use Disorder 
  <0.001 
No 628743       629641.68  
Yes 9275         8376.32  
Psychiatric Disorder, 
Any 
  <0.001 
No 600388       603932.25  
Yes 37630        34085.75  
Chronic Hypertension   <0.001 
No 580,660 587,620.01  
Yes 57,358 50,397.99  
Gestational 
Hypertension 
  <0.001 
No 555,961 563,193.68  
Yes 82,057 74,824.32  









No 611,154 611,487.64  
Yes 26,864 26,530.36  
Gestational Diabetes   0.01 
No 545,390 544,668.86  
Yes 92,628 93,349.14  
Asthma   <0.001 
No 605,638 608,515.55  
Yes 32,380 29,502.45  
Autoimmune Disease   0.24 
No 626,126 626,000.99  
Yes 11,892 12,017.01  
Pain Condition   <0.001 
No 581,171 590,419.12  
Yes 50,847 47,598.88  
Hepatitis C   0.49 
No 637,600 637,585.87  
Yes 418 432.13  
Any ANC   <0.001 
No 19,429 22,419.30  






Aim 2 Kaplan-Meier Curve Graphs and Log-Log Plots 
 
Figure 1. Opioid Use During Pregnancy Kaplan-Meier Survival Curve Estimates 
 





Figure 3. HRSA Region Kaplan-Meier Survival Curve Estimates  
 
 







Figure 5. Delivery in State with ≥20% Black Population Kaplan-Meier Survival Curve Estimates 
 
 







Figure 7. Delivery in State with ≥35% Women with College Degree or More Kaplan-Meier 
Survival Curve Estimates 
 
 






Figure 9. Insurance Plan Type Kaplan-Meier Survival Curve Estimates 
 
 







Figure 11. Any Psychiatric Diagnosis Kaplan-Meier Survival Curve Estimates 
 
 







Figure 13. Autoimmune Disease Kaplan-Meier Survival Curve Estimates 
 
 







Figure 15. Gestational Diabetes Kaplan-Meier Survival Curve Estimates 
 
 







Figure 17. Gestational Hypertension Kaplan-Meier Survival Curve Estimates 
 
 







Figure 19. Pain Conditions Kaplan-Meier Survival Curve Estimates  
 
 













Figure 22. Opioid Use During Pregnancy Log-Log Plot 
 
 







Figure 24. HRSA Region Log-Log Plot 
 
 







Figure 26. Delivery in State with ≥20% Black Population Log-Log Plot 
 
 







Figure 28. Delivery in State with ≥35% Women with College Degree or More Log-Log Plot 
 
 







Figure 30. Insurance Plan Type Log-Log Plot 
 
 







Figure 32. Psychiatric Diagnosis Log-Log Plot 
 
 







Figure 34. Autoimmune Disease Log-Log Plot 
 
 







Figure 36. Gestational Diabetes Log-Log Plot 
 
 







Figure 38. Gestational Hypertension Log-Log Plot 
 
 







Figure 40. Pain Conditions Log-Log Plot 
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literature 
● Responsible for conducting literature reviews for all 11 countries and writing reports for 
each, documenting trends over the past decade pertaining to maternal, child, and infant 
health, health infrastructure, and special populations such as refugees 
 
Teaching Assistant Experience                             September 2013-December 2019 
● Undergraduate class: “Population, Health, and Development” taught by Professor Stan 
Becker, Head Teaching Assistant 
● Graduate class: “Women’s Health Policy” taught by Professor Donna Strobino & Assistant 
Professor Charvonne Holliday 
● Graduate class: “Fundamentals of Program Evaluation” taught by Professor Kristin Mmari 
● Graduate class: “Maternal and Child Health Legislation and Programs” taught by Professors 
Cynthia Minkovitz and Sara Riese 
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● Graduate class: “Population Dynamics” taught by Professors Henry Mosley, ME Hughes, 
Donna Strobino, and Li Liu 
● Graduate class: “Health Survey Research Methods” taught by Professor Susan Sherman  
● Graduate class: “Clinical Issues in Maternal and Newborn Health” taught by Professors 
Pamela Donohue and Donna Strobino 
● Graduate class: “Critiquing the Research Literature in Maternal, Neonatal, and Reproductive 
Health” taught by Professor Donna Strobino  




● Advanced knowledge of Excel, Word, Powerpoint, Stata16, EndNote 
 
 
 
 
 
 
 
 
 
 
 
 
 
